background	NN	ROOT
:	:	punct

assignee	NN	nsubj
of	IN	prep
patent	NNS	pobj
direct	VBN	acl
at	IN	prep
drug	NN	pobj
use	VBN	acl
to	TO	aux
treat	VB	xcomp
patient	NNS	dobj
with	IN	prep
relapse	VBG	pcomp
form	NNS	dobj
of	IN	prep
multiple	JJ	amod
sclerosis	NN	pobj
and	CC	cc
related	JJ	amod
entity	NNS	conj
bring	VBD	ROOT
action	NNS	dobj
against	IN	prep
generic	JJ	amod
drug	NN	compound
manufacturer	NNS	pobj
,	,	punct
assert	VBG	advcl
patent	NN	compound
infringement	NN	compound
claim	NNS	dobj
.	.	punct

follow	VBG	prep
claim	NN	compound
construction	NN	compound
order	NN	pobj
,	,	punct
2016	CD	nummod
WL	NNP	appos
873062	CD	nummod
,	,	punct
and	CC	cc
follow	VBG	conj
consolidated	JJ	amod
bench	NN	compound
trial	NN	dobj
,	,	punct
the	DT	det
United	NNP	compound
States	NNP	compound
District	NNP	compound
Court	NNP	nsubj
for	IN	prep
the	DT	det
District	NNP	pobj
of	IN	prep
Delaware	NNP	pobj
in	IN	prep
No.	SYM	compound
1:14-cv-01171-gms	CD	pobj
,	,	punct
1:14-cv-01172-gms	CD	conj
,	,	punct
1:14-cv-01278-gms	CD	conj
,	,	punct
1:14-cv-01419-gms	CD	conj
,	,	punct
1:15-cv-00124-GMS	NNP	conj
,	,	punct
and	CC	cc
1:15-cv-00306-gms	CD	conj
,	,	punct
Gregory	NNP	compound
M.	NNP	compound
Sleet	NNP	conj
,	,	punct
J.	NNP	appos
,	,	punct
2017	CD	nummod
WL	NNP	appos
401943	CD	nummod
,	,	punct
find	VBD	ROOT
that	IN	mark
asserted	JJ	amod
claim	NNS	nsubj
of	IN	prep
patent	NNS	pobj
be	VBD	ccomp
invalid	JJ	acomp
as	RB	prep
obvious	JJ	amod
.	.	punct

assignee	NN	nsubj
appeal	VBD	ROOT
.	.	punct

 	_SP	

holding	NNS	ROOT
:	:	punct

the	DT	det
Court	NNP	nsubj
of	IN	prep
Appeals	NNPS	pobj
,	,	punct
Reyna	NNP	npadvmod
,	,	punct
Circuit	NNP	compound
Judge	NNP	appos
,	,	punct
hold	VBD	ccomp
that	IN	mark
:	:	punct

 	_SP	
"	``	punct
sufficiency	NN	nmod
"	''	punct
term	NNS	nsubj
in	IN	prep
patent	NNS	pobj
be	VBD	auxpass
non	JJ	subtok
-	JJ	subtok
limiting	JJ	ccomp
;	:	punct

 	_SP	
district	NN	compound
court	NN	poss
's	POS	case
conclusion	NN	nsubj
that	IN	mark
dose	VBG	amod
regiman	NNS	nsubj
disclose	VBN	acl
in	IN	prep
patent	NN	pobj
be	VBD	csubj
obvious	JJ	acomp
be	VBD	ROOT
not	RB	neg
clearly	RB	advmod
erroneous	JJ	acomp
;	:	punct

 	_SP	
district	NN	compound
court	NN	poss
's	POS	case
conclusion	NN	nsubj
that	IN	mark
limitation	NNS	nsubj
in	IN	prep
patent	NN	pobj
regard	VBG	prep
"	``	punct
improve	VBN	amod
tolerability	NN	pobj
"	''	punct
be	VBD	acl
obvious	JJ	acomp
be	VBD	conj
not	RB	neg
clearly	RB	advmod
erroneous	JJ	acomp
;	:	punct
and	CC	cc

 	_SP	
district	NN	compound
court	NN	poss
's	POS	case
conclusion	NN	nsubj
that	IN	det
limitation	NN	nsubj
in	IN	prep
patent	NN	pobj
regard	VBG	prep
"	``	punct
reduced	JJ	amod
severity	NN	pobj
"	''	punct
be	VBD	acl
obvious	JJ	acomp
be	VBD	conj
not	RB	neg
clearly	RB	advmod
erroneous	JJ	acomp
.	.	punct

 	_SP	

Plaintiffs	NNP	compound
-	HYPH	punct
Appellants	NNP	nmod
Teva	NNP	compound
Pharmaceuticals	NNPS	nmod
USA	NNP	nmod
,	,	punct
Inc.	NNP	nsubj
,	,	punct
Teva	NNP	compound
Pharmaceutical	NNP	compound
Industries	NNPS	conj
,	,	punct
Ltd.	NNP	amod
,	,	punct
Teva	NNP	compound
Neuroscience	NNP	conj
,	,	punct
Inc.	NNP	conj
,	,	punct
and	CC	cc
Yeda	NNP	nmod
Research	NNP	nmod
and	CC	cc
Development	NNP	conj
Co.	NNP	conj
,	,	punct
Ltd.	NNP	amod
,	,	punct
appeal	VB	ROOT
the	DT	det
decision	NN	dobj
of	IN	prep
the	DT	det
United	NNP	compound
States	NNP	compound
District	NNP	compound
Court	NNP	pobj
for	IN	prep
the	DT	det
District	NNP	nmod
of	IN	prep
Delaware	NNP	pobj
invalidate	VBG	pobj
all	DT	det
asserted	JJ	amod
claim	NNS	dobj
of	IN	prep
patent	NNS	pobj
direct	VBN	acl
to	IN	prep
COPAXONE	NNP	nmod
(r)	SYM	nmod
40mg	JJ	amod
/	SYM	punct
ml	NN	pobj
,	,	punct
a	DT	det
product	NN	appos
market	VBN	acl
for	IN	prep
treatment	NN	pobj
of	IN	prep
patient	NNS	pobj
with	IN	prep
relapse	VBG	pcomp
form	NNS	dobj
of	IN	prep
multiple	JJ	amod
sclerosis	NN	pobj
.	.	punct

Because	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
correctly	RB	advmod
hold	VBD	advcl
the	DT	det
assert	VBN	amod
claim	NNS	nsubj
invalid	JJ	ccomp
as	RB	prep
obvious	JJ	amod
under	IN	quantmod
35	CD	nummod
U.S.C.	NNP	npadvmod
¡±	CD	dobj
103	CD	nummod
,	,	punct
-PRON-	PRP	nsubj
affirm.1	VBP	ROOT

 	_SP	

i.	NN	compound
Patents	NNP	nsubj
at	IN	prep
Issue	NNP	pobj

 	_SP	
Yeda	NNP	compound
Research	NNP	appos
&	CC	cc
Development	NNP	compound
Co.	NNP	conj
,	,	punct
Ltd.	NNP	amod
be	VBZ	ROOT
the	DT	det
assignee	NN	attr
of	IN	prep
U.S.	NNP	compound
Patent	NNP	compound
No.	SYM	pobj
8,232,250	CD	nummod
,	,	punct
8,399,413	CD	appos
,	,	punct
8,969,302	CD	appos
,	,	punct
and	CC	cc
9,155,776	CD	conj
(	-LRB-	punct
the	DT	det
'	``	punct
250	CD	appos
,	,	punct
'	''	punct
413	CD	prep
,	,	punct
'	''	punct
302	CD	npadvmod
,	,	punct
and	CC	cc
'	``	punct
776	CD	nummod
patent	NN	conj
,	,	punct
respectively	RB	advmod
)	-RRB-	punct
,	,	punct
all	DT	dep
entitle	VBN	acl
"	``	punct
Low	NNP	compound
Frequency	NNP	compound
Glatiramer	NNP	compound
Acetate	NNP	compound
Therapy	NNP	oprd
"	''	punct
.	.	punct

the	DT	det
patent	NNS	nsubj
,	,	punct
collectively	RB	advmod
refer	VBD	acl
to	IN	prep
as	IN	prep
the	DT	det
"	``	punct
Copaxone	NNP	compound
patent	NNS	pobj
,	,	punct
"	''	punct
share	VBP	ROOT
a	DT	det
common	JJ	amod
specification	NN	dobj
and	CC	cc
claim	NN	conj
priority	NN	dobj
to	IN	prep
the	DT	det
same	JJ	amod
two	CD	nummod
provisional	JJ	amod
application	NNS	pobj
.	.	punct

J.A.	NNP	ROOT
57	CD	nummod
-	SYM	punct
69	CD	prep
.	.	punct

the	DT	det
early	JJS	amod
priority	NN	compound
date	NN	nsubj
of	IN	prep
the	DT	det
Copaxone	NNP	compound
patent	NNS	pobj
be	VBZ	ROOT
August	NNP	attr
20	CD	nummod
,	,	punct
2009	CD	nummod
.	.	punct

J.A.	NNP	ROOT
23	CD	nummod
.	.	punct

 	_SP	

the	DT	det
Copaxone	NNP	compound
patent	NNS	nsubj
describe	VBP	ROOT
and	CC	cc
claim	VBP	conj
COPAXONE	NNP	nmod
(r)	SYM	nmod
40mg	JJ	amod
/	SYM	punct
ml	NN	dobj
,	,	punct
a	DT	det
treatment	NN	appos
for	IN	prep
relapse	VBG	npadvmod
-	HYPH	punct
remit	VBG	amod
multiple	JJ	amod
sclerosis	NN	pobj
(	-LRB-	punct
"	``	punct
RRMS	NNP	appos
"	''	punct
)	-RRB-	punct
.	.	punct

RRMS	NNP	nsubj
be	VBZ	ROOT
a	DT	det
form	NN	attr
of	IN	prep
multiple	JJ	amod
sclerosis	NN	pobj
,	,	punct
an	DT	det
autoimmune	JJ	compound
disorder	NN	appos
that	WDT	nsubj
cause	VBZ	relcl
the	DT	det
body	NN	poss
's	POS	case
immune	JJ	amod
system	NN	dobj
to	TO	aux
attack	VB	advcl
the	DT	det
central	JJ	amod
nervous	JJ	amod
system	NN	dobj
.	.	punct

RRMS	NNP	nsubjpass
be	VBZ	auxpass
characterize	VBN	ROOT
by	IN	agent
unpredictable	JJ	amod
relapse	NNS	pobj
follow	VBN	acl
by	IN	agent
period	NNS	pobj
of	IN	prep
remission	NN	pobj
with	IN	prep
no	DT	det
new	JJ	amod
sign	NNS	pobj
of	IN	prep
disease	NN	compound
activity	NN	pobj
.	.	punct

 	_SP	

the	DT	det
active	JJ	amod
ingredient	NN	nsubj
in	IN	prep
COPAXONE	NNP	nmod
(r)	SYM	nmod
40mg	JJ	nmod
/	SYM	punct
ml	NN	pobj
be	VBZ	ROOT
glatiramer	NN	npadvmod
acetate	JJ	acomp
(	-LRB-	punct
"	``	punct
GA	NNP	appos
"	''	punct
)	-RRB-	punct
,	,	punct
a	DT	det
synthetic	JJ	amod
mixture	NN	appos
of	IN	prep
polypeptide	NNS	pobj
.	.	punct

GA	NNP	nsubjpass
be	VBZ	auxpass
also	RB	advmod
know	VBN	ROOT
as	IN	prep
"	``	punct
copolymer	NN	pobj
1	CD	nummod
"	''	punct
or	CC	cc
"	``	punct
cop	VB	subtok
.	.	conj
1	CD	nummod
"	''	punct
.	.	punct
COPAXONE	NNP	npadvmod
(r)	SYM	punct

40mg	JJ	amod
/	SYM	punct
mL	NNP	nsubjpass
be	VBZ	auxpass
supply	VBN	ROOT
as	IN	prep
a	DT	det
single	JJ	amod
-	HYPH	punct
dose	NN	pobj
prefille	VBN	amod
syringe	NN	npadvmod
.	.	punct

broadly	RB	advmod
,	,	punct
the	DT	det
treatment	NN	nsubj
consist	VBZ	ROOT
of	IN	prep
the	DT	det
injection	NN	pobj
of	IN	prep
40	CD	nummod
mg	NN	pobj
of	IN	prep
GA	NNP	pobj
three	CD	nummod
time	NNS	npadvmod
a	DT	det
week	NN	npadvmod
,	,	punct
abbreviate	VBN	amod
"	``	punct
40	CD	nummod
mg	NN	nmod
GA	NNP	compound
3x	NNP	nmod
/	SYM	punct
week	NN	npadvmod
"	''	punct
.	.	punct

relevant	JJ	advcl
to	IN	prep
this	DT	det
appeal	NN	pobj
,	,	punct
side	NN	compound
effect	NNS	nsubj
of	IN	prep
GA	NNP	compound
injection	NNS	pobj
include	VBP	ROOT
injection	NN	compound
-	HYPH	punct
site	NN	compound
reaction	NNS	dobj
(	-LRB-	punct
"	``	punct
isr	NNS	appos
"	''	punct
)	-RRB-	punct
and	CC	cc
immediate	JJ	amod
post	JJ	subtok
-	JJ	subtok
injection	JJ	amod
reaction	NNS	conj
(	-LRB-	punct
"	``	punct
ipir	NNS	appos
"	''	punct
)	-RRB-	punct
.	.	punct

isr	NNS	nsubj
be	VBP	ROOT
physical	JJ	amod
symptom	NNS	attr
at	IN	prep
the	DT	det
injection	NN	compound
site	NN	pobj
,	,	punct
such	JJ	amod
as	IN	prep
swell	VBG	pobj
or	CC	cc
itchiness	NN	conj
.	.	punct

ipir	NNS	nsubj
be	VBP	ROOT
reaction	NNS	attr
immediately	RB	advmod
follow	VBG	acl
an	DT	det
injection	NN	dobj
,	,	punct
such	JJ	amod
as	IN	prep
flush	NNS	pobj
,	,	punct
sweat	VBG	conj
,	,	punct
or	CC	cc
palpitation	NNS	conj
.	.	punct

 	_SP	

prior	RB	advmod
to	IN	prep
COPAXONE	NNP	nmod
(r)	SYM	nmod
40mg	JJ	amod
/	SYM	punct
ml	NN	pobj
,	,	punct
in	IN	pobj
1996	CD	pobj
the	DT	det
Food	NNP	nmod
and	CC	cc
Drug	NNP	conj
Administration	NNP	nsubj
(	-LRB-	punct
"	``	punct
FDA	NNP	appos
"	''	punct
)	-RRB-	punct
approve	VBD	ROOT
COPAXONE	NNP	nmod
(r)	SYM	nmod
20mg	NN	nmod
/	SYM	punct
ml	NN	dobj
,	,	punct
a	DT	det
regimen	NN	appos
consist	VBG	acl
of	IN	prep
the	DT	det
daily	JJ	amod
injection	NN	pobj
of	IN	prep
20	CD	nummod
mg	NN	compound
GA	NNP	pobj
.	.	punct

daily	JJ	compound
GA	NNP	compound
injection	NNS	nsubjpass
be	VBD	auxpass
know	VBN	ROOT
to	TO	aux
subject	VB	xcomp
patient	NNS	dobj
to	TO	aux
discomfort	VB	advcl
,	,	punct
include	VBG	prep
side	NN	compound
effect	NNS	pobj
in	IN	prep
the	DT	det
form	NN	pobj
of	IN	prep
isr	NNS	pobj
and	CC	cc
IPIRs	NNPS	conj
.	.	punct

J.A.	NNP	ROOT
20692	CD	nummod
.	.	punct

 	_SP	

For	IN	prep
analyze	VBG	pcomp
the	DT	det
obviousness	NN	dobj
of	IN	prep
the	DT	det
Copaxone	NNP	compound
patent	NNS	pobj
in	IN	prep
this	DT	det
case	NN	pobj
,	,	punct
a	DT	det
key	JJ	amod
limitation	NN	nsubj
of	IN	prep
the	DT	det
assert	VBN	amod
claim	NNS	pobj
be	VBZ	ROOT
the	DT	det
administration	NN	attr
of	IN	prep
a	DT	det
40	CD	nummod
mg	NN	compound
GA	NNP	compound
dose	NN	pobj
in	IN	prep
three	CD	nummod
subcutaneous	JJ	amod
injection	NNS	pobj
over	IN	prep
seven	CD	nummod
day	NNS	pobj
.	.	punct

claim	NN	nsubj
1	CD	nummod
of	IN	prep
the	DT	det
'	``	punct
250	CD	nummod
patent	NN	pobj
be	VBZ	ROOT
representative	JJ	acomp
:	:	punct

 	_SP	

1	CD	ROOT
.	.	punct

a	DT	det
method	NN	ROOT
of	IN	prep
alleviate	VBG	pcomp
a	DT	det
symptom	NN	dobj
of	IN	prep
relapse	VBG	npadvmod
-	HYPH	punct
remit	VBG	amod
multiple	JJ	amod
sclerosis	NN	pobj
in	IN	prep
a	DT	det
human	JJ	amod
patient	NN	compound
suffering	NN	pobj
from	IN	prep
relapse	VBG	npadvmod
-	HYPH	punct
remit	VBG	amod
multiple	JJ	amod
sclerosis	NN	pobj
or	CC	cc
a	DT	det
patient	NN	conj
who	WP	nsubj
have	VBZ	aux
experience	VBN	relcl
a	DT	det
first	JJ	amod
clinical	JJ	amod
episode	NN	dobj
and	CC	cc
be	VBZ	conj
determined	JJ	acomp
to	TO	aux
be	VB	xcomp
at	IN	prep
high	JJ	amod
risk	NN	pobj
of	IN	prep
develop	VBG	pcomp
clinically	RB	advmod
definite	JJ	amod
multiple	JJ	amod
sclerosis	NN	nsubj
comprising	NN	ccomp
administer	VBG	xcomp
to	IN	prep
the	DT	det
human	JJ	amod
patient	NN	pobj
a	DT	det
therapeutically	RB	advmod
effective	JJ	amod
regiman	NNS	dobj
of	IN	prep
three	CD	nummod
subcutaneous	JJ	amod
injection	NNS	pobj
of	IN	prep
a	DT	det
40	CD	nummod
mg	NN	compound
dose	NN	pobj
of	IN	prep
glatiramer	NN	pobj
acetate	VBP	amod
over	IN	prep
a	DT	det
period	NN	pobj
of	IN	prep
seven	CD	nummod
day	NNS	pobj
with	IN	prep
at	RB	advmod
least	RBS	advmod
one	CD	nummod
day	NN	pobj
between	IN	prep
every	DT	det
subcutaneous	JJ	amod
injection	NN	pobj
,	,	punct
the	DT	det
regiman	NNS	nsubj
be	VBG	acl
sufficient	JJ	acomp
to	TO	aux
alleviate	VB	xcomp
the	DT	det
symptom	NN	dobj
of	IN	prep
the	DT	det
patient	NN	pobj
.	.	punct

 	_SP	
'	POS	punct
250	CD	nummod
patent	NN	compound
col.	NN	appos
16	CD	nummod
will	NN	intj
.	.	punct

35	CD	ROOT
-	SYM	punct
45	CD	prep
.	.	punct

 	_SP	

apart	RB	advmod
from	IN	prep
claim	NN	pobj
1	CD	nsubj
of	IN	prep
the	DT	det
'	``	punct
302	CD	compound
patent,2	IN	pobj
all	DT	appos
assert	VBN	acl
in	IN	advmod
-	HYPH	punct
dependent	JJ	amod
claim	NNS	nsubj
require	VBP	ROOT
at	RB	advmod
least	RBS	advmod
one	CD	nummod
day	NN	npadvmod
between	IN	prep
dos	NNS	pobj
.	.	punct
'	''	punct
250	CD	nummod
patent	NN	compound
col.	NN	ccomp
16	CD	nummod
will	NN	intj
.	.	punct

35	CD	ROOT
-	SYM	punct
45	CD	prep
,	,	punct
col.	NN	prep

col.	NN	ROOT

;	:	ROOT
'	''	punct
413	CD	nummod
patent	NN	npadvmod
col.	NN	pobj
16	CD	nummod
will	NN	intj
.	.	punct

26	CD	nummod
-	SYM	punct
36	CD	prep
,	,	punct
col.	NN	ROOT
18	CD	nummod

will	NN	ROOT
.	.	punct

14	CD	meta
-	SYM	punct
28	CD	prep
;	:	punct
'	''	punct
302	CD	nummod
patent	NN	compound
col.	NN	ROOT
17	CD	nummod
will	NN	intj
.	.	punct

4	CD	ccomp
-	SYM	punct
12	CD	prep
;	:	punct
'	''	punct
776	CD	nummod
patent	NN	npadvmod
col.	NN	ROOT
16	CD	nummod
will	NN	intj
.	.	punct

35	CD	ROOT
-	SYM	punct
50	CD	prep
,	,	punct
col.	NN	prep

col.	JJ	ROOT
,	,	punct
col.	NN	npadvmod
17	CD	nummod
will	NN	intj
.	.	punct

37	CD	ROOT
-	SYM	punct
54	CD	prep
,	,	punct
col.	NN	prep

col.	NN	ROOT
.	.	punct

certain	JJ	amod
dependent	JJ	amod
claim	NNS	ROOT
of	IN	prep
the	DT	det
'	``	punct
250	CD	pobj
,	,	punct
'	''	punct
413	CD	appos
,	,	punct
and	CC	cc
'	``	punct
776	CD	nummod
patent	NNS	nsubj
further	RB	advmod
require	VB	conj
improve	VBN	amod
tolerability	NN	dobj
and/or	CC	cc
reduce	VBN	amod
frequency	NN	conj
of	IN	prep
injection	NN	compound
reaction	NNS	pobj
in	IN	prep
the	DT	det
claim	VBN	amod
regimen	NN	pobj
as	IN	mark
compare	VBN	advcl
to	IN	prep
a	DT	det
20	CD	nummod
mg	NN	nmod
GA	NNP	nmod
daily	JJ	amod
regimen	NN	pobj
.	.	punct

see	VB	ROOT
,	,	punct
e.g.	RB	advmod
,	,	punct
'	''	punct
250	CD	nummod
patent	NN	pobj
col.	NN	npadvmod
17	CD	nummod
will	NN	intj
.	.	punct

21	CD	nummod
-	SYM	punct
24	CD	prep
,	,	punct
col.	NN	ROOT
18	CD	nummod

will	NN	ROOT
.	.	punct

7	CD	meta
-	SYM	punct
15	CD	prep
;	:	punct
'	''	punct
413	CD	nummod
patent	NN	compound
col.	NN	ROOT
16	CD	nummod
will	NN	intj
.	.	punct

51	CD	ccomp
-	SYM	punct
54	CD	prep
;	:	punct
'	''	punct
776	CD	nummod
patent	NN	npadvmod
col.	NN	ROOT
16	CD	nummod
will	NN	intj
.	.	punct

51	CD	ROOT
-	SYM	punct
54	CD	prep
,	,	punct
col	NN	prep
17	CD	pobj

l.	NN	subtok
65-	LS	amod
col.	NN	ROOT
.	.	punct

 	_SP	

the	DT	mark
'	``	punct
776	CD	nummod
patent	NN	nsubj
contain	VBZ	ROOT
additional	JJ	amod
limitation	NNS	dobj
,	,	punct
namely	RB	advmod
,	,	punct
the	DT	det
requirement	NN	appos
that	WDT	mark
the	DT	det
40	CD	nummod
mg	NN	compound
GA	NNP	compound
3x	NNP	nmod
/	SYM	punct
week	NN	compound
regimen	NN	nsubj
"	''	punct
reduce	VB	relcl
[	-LRB-	punct
]	-RRB-	punct
severity	NN	appos
of	IN	prep
injection	NN	compound
site	NN	compound
reaction	NNS	pobj
"	''	punct
compare	VBN	prep
to	IN	prep
a	DT	det
20	CD	nummod
mg	NN	nmod
daily	JJ	amod
regiman	NNS	pobj
,	,	punct
as	IN	mark
see	VBN	advcl
in	IN	prep
claim	NN	pobj
1	CD	npadvmod
:	:	punct

 	_SP	

1	CD	ROOT
.	.	punct

a	DT	det
method	NN	ROOT
of	IN	prep
treat	VBG	pcomp
a	DT	det
human	JJ	amod
patient	NN	compound
suffering	NN	dobj
from	IN	prep
a	DT	det
relapse	VBG	amod
form	NN	pobj
of	IN	prep
multiple	JJ	amod
sclerosis	NN	pobj
,	,	punct
while	IN	mark
induce	VBG	advcl
reduced	JJ	amod
severity	NN	dobj
of	IN	prep
injection	NN	compound
site	NN	compound
reaction	NNS	pobj
in	IN	prep
the	DT	det
human	JJ	amod
patient	NN	pobj
relative	NN	advmod
to	IN	prep
administration	NN	pobj
of	IN	prep
20	CD	nummod
mg	NN	pobj
of	IN	prep
glatiramer	NN	compound
acetate	VBP	pobj
s.c	NNP	pobj
.	.	punct

daily	RB	advmod
,	,	punct
the	DT	det
method	NN	nsubj
consist	VBG	acl
of	IN	prep
one	CD	nummod
subcutaneous	JJ	amod
injection	NN	pobj
of	IN	prep
1	CD	nummod
ml	NN	pobj
of	IN	prep
a	DT	det
pharmaceutical	JJ	amod
composition	NN	pobj
comprise	VBG	acl
40	CD	nummod
mg	NN	dobj
of	IN	prep
glatiramer	NN	pobj
acetate	VBP	advcl
on	IN	prep
only	RB	advmod
each	DT	pobj
of	IN	prep
three	CD	nummod
day	NNS	pobj
during	IN	prep
each	DT	det
week	NN	pobj
of	IN	prep
treatment	NN	pobj
with	IN	prep
at	RB	advmod
least	RBS	advmod
one	CD	nummod
day	NN	pobj
without	IN	prep
a	DT	det
subcutaneous	JJ	amod
injection	NN	pobj
of	IN	prep
the	DT	det
pharmaceutical	JJ	amod
composition	NN	pobj
between	IN	prep
each	DT	det
day	NN	pobj
on	IN	prep
which	WDT	pobj
there	EX	expl
be	VBZ	relcl
a	DT	det
subcutaneous	JJ	amod
injection	NN	attr
,	,	punct
wherein	WRB	advmod
the	DT	det
pharmaceutical	JJ	compound
composition	NN	nsubj
be	VBZ	ccomp
in	IN	prep
a	DT	det
prefille	VBN	amod
syringe	NN	pobj
,	,	punct
and	CC	cc
wherein	WRB	advmod
the	DT	det
pharmaceutical	JJ	compound
composition	NN	nsubj
further	RB	advmod
comprise	VBZ	conj
mannitol	NN	dobj
and	CC	cc
have	VBZ	conj
a	DT	det
pH	NNS	dobj
in	IN	prep
the	DT	det
range	NN	pobj
5.5	CD	dobj
to	IN	prep
7.0	CD	pobj
,	,	punct
so	IN	mark
as	IN	mark
to	TO	aux
thereby	RB	advmod
treat	VB	advcl
the	DT	det
human	JJ	amod
patient	NN	dobj
with	IN	prep
reduced	JJ	amod
severity	NN	pobj
of	IN	prep
injection	NN	compound
site	NN	compound
reaction	NNS	pobj
relative	JJ	advmod
to	IN	prep
administration	NN	pobj
of	IN	prep
20	CD	nummod
mg	NN	pobj
of	IN	prep
glatiramer	NN	compound
acetate	VBP	amod
s.c	NNP	pobj
.	.	punct
daily	RB	advmod
.	.	punct

 	_SP	
'	POS	punct
776	CD	nummod
patent	NN	compound
col.	NN	ROOT
16	CD	nummod
will	NN	intj
.	.	punct

35	CD	nummod
-	SYM	punct
50	CD	prep
(	-LRB-	punct
emphasis	NN	nsubj
add	VBN	ROOT
)	-RRB-	punct
.	.	punct

 	_SP	

II	NNP	ROOT
.	.	punct

Prior	NNP	compound
Art	NNP	compound
References	NNPS	ROOT

 	_SP	

the	DT	det
first	JJ	amod
clinical	JJ	amod
trial	NN	nsubj
for	IN	prep
use	VBG	pcomp
GA	NNP	dobj
to	TO	aux
treat	VB	xcomp
multiple	JJ	amod
sclerosis	NN	dobj
take	VBD	ROOT
place	NN	dobj
in	IN	prep
1987	CD	pobj
by	IN	agent
Dr.	NNP	compound
Bornstein	NNP	compound
et	NNP	compound
al	NNP	pobj
.	.	punct
(	-LRB-	punct
"	``	punct
Bornstein"),3	NNP	dobj
which	WDT	nsubjpass
be	VBD	auxpass
follow	VBN	relcl
by	IN	agent
a	DT	det
Teva	NNP	nmod
Phase	NNP	nmod
iii	CD	nmod
clinical	JJ	amod
trial	NN	pobj
in	IN	prep
1995	CD	pobj
.	.	punct
both	CC	preconj
Bornstein	NNP	nsubj
and	CC	cc
the	DT	det
Phase	NNP	compound
III	NNP	compound
trial	NN	conj
test	VBD	advcl
20	CD	nummod
mg	NN	compound
GA	NNP	dobj
daily	RB	advmod
.	.	punct
J.A.	NNP	npadvmod
20378	CD	nummod
-	SYM	punct
84	CD	prep
,	,	punct
20464	CD	nummod
-	SYM	punct
20782	CD	prep
.	.	punct
Since	IN	mark
GA	NNP	nsubjpass
be	VBD	auxpass
develop	VBN	advcl
in	IN	prep
an	DT	det
expedited	JJ	amod
manner	NN	pobj
under	IN	prep
orphan	NN	compound
drug	NN	compound
status	NN	pobj
in	IN	prep
the	DT	det
United	NNP	compound
States	NNP	pobj
at	IN	prep
a	DT	det
time	NN	pobj
when	WRB	advmod
no	DT	det
other	JJ	amod
disease	NN	nsubj
modify	VBG	acl
multiple	JJ	amod
sclerosis	NN	compound
treatment	NNS	dobj
be	VBD	relcl
available	JJ	acomp
,	,	punct
the	DT	det
20mg	JJ	amod
/	SYM	punct
day	NN	compound
dose	NN	nsubjpass
be	VBD	auxpass
select	VBN	advcl
without	IN	prep
perform	VBG	pcomp
conventional	JJ	amod
optimal	JJ	compound
-	HYPH	punct
dose	NN	compound
-	HYPH	punct
find	VBG	amod
study	NNS	dobj
.	.	punct
J.A.	NNP	npadvmod
24967	CD	nummod
.	.	punct

 	_SP	
the	DT	det
Bornstein	NNP	compound
study	NN	nsubj
show	VBD	ccomp
that	IN	mark
GA	NNP	nsubj
administer	VBD	ccomp
subcutaneously	RB	advmod
for	IN	prep
two	CD	nummod
year	NNS	pobj
at	IN	prep
a	DT	det
daily	JJ	amod
dose	NN	pobj
of	IN	prep
20	CD	nummod
mg	NN	pobj
"	''	punct
produce	VBD	advcl
clinically	RB	advmod
important	JJ	amod
and	CC	cc
statistically	RB	advmod
significant	JJ	conj
beneficial	JJ	amod
effect	NNS	dobj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
20383	CD	nummod
.	.	punct

participant	NNS	nsubj
in	IN	prep
both	DT	det
Bornstein	NNP	pobj
and	CC	cc
the	DT	det
Phase	NNP	compound
III	NNP	compound
trial	NN	conj
report	VBD	ROOT
isr	NNS	dobj
and	CC	cc
IPIRs	NNPS	conj
as	IN	prep
side	NN	compound
effect	NNS	pobj
.	.	punct

J.A.	NNP	ROOT
20383	CD	nummod
,	,	punct
20480	CD	npadvmod
.	.	punct

the	DT	det
Phase	NNP	compound
III	NNP	compound
trial	NN	nsubj
note	VBD	ROOT
"	``	punct
adverse	JJ	amod
experience	NN	dobj
"	''	punct
as	IN	prep
the	DT	det
main	JJ	amod
reason	NN	pobj
contribute	VBG	acl
to	IN	prep
patient	JJ	amod
dropout	NN	pobj
,	,	punct
and	CC	cc
"	``	punct
the	DT	det
most	RBS	advmod
common	JJ	amod
adverse	JJ	amod
event	NN	nsubj
associate	VBN	acl
with	IN	prep
dropout	NN	pobj
be	VBD	conj
injection	NN	compound
site	NN	compound
reaction	NN	attr
"	''	punct
.	.	punct

J.A.	NNP	ROOT
20480	CD	nummod
.	.	punct

a	DT	det
Phase	NNP	compound
III	NNP	compound
trial	NN	compound
reviewer	NN	nsubj
make	VBD	ROOT
recommendation	NNS	dobj
for	IN	prep
future	JJ	amod
researcher	NNS	pobj
to	TO	aux
explore	VB	advcl
dose	NN	nmod
-	HYPH	punct
response	NN	nmod
and	CC	cc
dose	NN	npadvmod
-	HYPH	punct
range	VBG	conj
study	NNS	dobj
,	,	punct
ask	VBG	advcl
"	``	punct
be	VBZ	ccomp
20	CD	nummod
mg	NN	nsubj
the	DT	det
optimum	JJ	amod
dose	NN	attr
?	.	punct

be	VBP	ROOT
daily	JJ	amod
injection	NNS	nsubj
necessary	JJ	acomp
?	.	punct
"	''	punct
J.A.	NNP	npadvmod
20502	CD	nummod
.	.	punct

 	_SP	

In	IN	prep
1996	CD	pobj
,	,	punct
follow	VBG	prep
both	DT	preconj
Bornstein	NNP	dobj
and	CC	cc
the	DT	det
Phase	NNP	nmod
iii	CD	nmod
clinical	JJ	amod
trial	NN	conj
,	,	punct
FDA	NNP	nsubj
approve	VBD	ROOT
Teva	NNP	poss
's	POS	case
New	NNP	compound
Drug	NNP	compound
Application	NNP	dobj
(	-LRB-	punct
"	``	punct
NDA	NNP	appos
"	''	punct
)	-RRB-	punct
for	IN	prep
COPAXONE	NNP	compound
(r)	SYM	pobj

20	CD	nummod
mg	NN	npadvmod
,	,	punct
20	CD	nummod
mg	NN	compound
GA	NNP	nsubj
inject	VBD	ROOT
daily	RB	advmod
.	.	punct

In	IN	prep
-PRON-	PRP$	poss
1996	CD	nummod
Summary	NNP	compound
Basis	NNP	pobj
of	IN	prep
Approval	NNP	pobj
(	-LRB-	punct
"	``	punct
SBOA	NNP	pobj
"	''	punct
)	-RRB-	punct
,	,	punct
FDA	NNP	nsubj
recommend	VBD	ROOT
that	IN	mark
Teva	NNP	nsubj
"	``	punct
evaluate	VB	ccomp
the	DT	det
necessity	NN	dobj
of	IN	prep
daily	JJ	amod
[	-LRB-	punct
GA	NNP	nmod
]	-RRB-	punct
injection	NNS	pobj
as	IN	mark
oppose	VBN	amod
to	IN	prep
more	JJR	advmod
infrequent	NN	amod
intermit	NN	compound
-	HYPH	punct
tent	NN	compound
administration	NN	pobj
of	IN	prep
the	DT	det
drug	NN	pobj
"	''	punct
because	IN	mark
the	DT	det
daily	JJ	amod
dosing	JJ	amod
regiman	NNS	nsubj
"	''	punct
seem	VBZ	advcl
like	IN	mark
-PRON-	PRP	nsubj
would	MD	aux
subject	VB	advcl
the	DT	det
patient	NN	dobj
to	IN	prep
an	DT	det
excessive	JJ	amod
amount	NN	pobj
of	IN	prep
discomfort	NN	pobj
if	IN	mark
-PRON-	PRP	nsubj
be	VBZ	advcl
not	RB	neg
necessary	JJ	acomp
to	TO	aux
maintain	VB	xcomp
efficacy	NN	dobj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
20692	CD	nummod
.	.	punct

 	_SP	

a	DT	det
2002	CD	nummod
study	NN	nsubj
by	IN	prep
Flechter	NNP	compound
et	NNP	compound
al.4	NNP	pobj
(	-LRB-	punct
"	``	punct
Flechter	NNP	appos
"	''	punct
)	-RRB-	punct
evaluate	VBD	ROOT
the	DT	det
treatment	NN	dobj
of	IN	prep
RRMS	NNP	pobj
with	IN	prep
20	CD	nummod
mg	NN	nsubj
of	IN	prep
GA	NNP	pobj
administer	VBD	conj
every	DT	det
other	JJ	amod
day	NN	npadvmod
.	.	punct

J.A.	NNP	ROOT
20436	CD	nummod
-	SYM	punct
40	CD	prep
.	.	punct

Flechter	NNP	nsubj
conclude	VBD	ROOT
that	IN	mark
"	``	punct
alternate	JJ	amod
-	HYPH	punct
day	NN	compound
treatment	NN	nsubj
with	IN	prep
Copolymer	NNP	pobj
1	CD	nummod
be	VBZ	ccomp
safe	JJ	acomp
,	,	punct
well	RB	advmod
tolerate	VBN	conj
,	,	punct
and	CC	cc
probably	RB	advmod
as	RB	advmod
effective	JJ	conj
as	IN	prep
daily	JJ	amod
Copolymer	NNP	pobj
1	CD	nummod
in	IN	prep
reduce	VBG	pcomp
relapse	JJ	amod
rate	NN	dobj
and	CC	cc
slow	VBG	conj
neurologic	JJ	amod
deterioration	NN	dobj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
20440	CD	nummod
.	.	punct

Flechter	NNP	nsubj
also	RB	advmod
note	VBD	ROOT
that	IN	mark
patient	JJ	amod
dropout	NN	compound
rate	NNS	nsubj
decrease	VBD	ccomp
when	WRB	advmod
GA	NNP	nsubjpass
be	VBD	auxpass
administer	VBN	advcl
every	DT	det
other	JJ	amod
day	NN	npadvmod
as	IN	mark
oppose	VBN	advcl
to	IN	aux
daily	RB	advmod
.	.	punct

J.A.	NNP	npadvmod
20440	CD	nummod
(	-LRB-	punct
"	``	punct
-PRON-	PRP	nsubjpass
should	MD	aux
be	VB	auxpass
stress	VBN	ROOT
that	IN	mark
the	DT	det
dropout	NN	compound
rate	NN	nsubj
be	VBD	ccomp
low	JJR	acomp
in	IN	prep
the	DT	det
alternate	JJ	amod
-	HYPH	punct
day	NN	compound
group	NN	pobj
than	IN	prep
in	IN	prep
the	DT	det
daily	JJ	amod
-	HYPH	punct
injection	NN	compound
regime	NN	pobj
(	-LRB-	punct
39.7	CD	nummod
%	NN	appos
versus	IN	prep
60.3	CD	nummod
%	NN	pobj
,	,	punct
p	LS	det
<	XX	nmod
0.01	CD	appos
)	-RRB-	punct
.	.	punct
"	''	punct
)	-RRB-	punct
.	.	punct

 	_SP	

Cohen,5	NNS	auxpass
publish	VBN	advcl
in	IN	prep
2007	CD	pobj
,	,	punct
be	VBD	ROOT
a	DT	det
"	``	punct
double	JJ	amod
-	HYPH	punct
blind	JJ	amod
,	,	punct
dose	NN	compound
-	HYPH	punct
comparison	NN	compound
study	NN	attr
of	IN	prep
glatiramer	NN	compound
acetate	VBP	pobj
in	IN	prep
relapse	VBG	npadvmod
-	HYPH	punct
remit	VBG	amod
MS	NNP	pobj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
20388	CD	nummod
-	SYM	punct
95	CD	prep
.	.	punct

Cohen	NNP	nsubj
compare	VBD	ROOT
daily	JJ	amod
subcutaneous	JJ	amod
injection	NNS	dobj
of	IN	prep
20	CD	nummod
mg	NN	pobj
and	CC	cc
40	CD	nummod
mg	NN	compound
GA	NNP	compound
dosage	NNS	conj
,	,	punct
and	CC	cc
conclude	VBD	conj
that	IN	mark
the	DT	det
40	CD	nummod
mg	NN	compound
dose	NN	nsubj
may	MD	aux
be	VB	ccomp
"	``	punct
more	RBR	advmod
effective	JJ	acomp
"	''	punct
than	IN	prep
the	DT	det
20	CD	nummod
mg	NN	compound
dose	NN	pobj
"	''	punct
in	IN	prep
reduce	VBG	pcomp
mri	NN	compound
activity	NN	dobj
and	CC	cc
clinical	JJ	amod
relapse	NNS	conj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
20389	CD	nummod
.	.	punct

Cohen	NNP	nsubj
also	RB	advmod
note	VBD	ROOT
that	IN	mark
the	DT	det
onset	NN	nsubj
of	IN	prep
action	NN	pobj
of	IN	prep
the	DT	det
40	CD	nummod
mg	NN	compound
dose	NN	pobj
be	VBZ	ccomp
more	RBR	advmod
rapid	JJ	acomp
compare	VBN	prep
to	IN	prep
20	CD	nummod
mg	NN	pobj
.	.	punct

J.A.	NNP	ROOT
20394	CD	nummod
.	.	punct

isr	NNS	nsubj
be	VBD	ROOT
the	DT	det
most	RBS	advmod
frequent	JJ	amod
adverse	JJ	amod
event	NN	attr
for	IN	prep
both	DT	det
dos	NNS	pobj
,	,	punct
occur	VBG	advcl
at	IN	prep
roughly	RB	advmod
equal	JJ	amod
rate	NNS	pobj
.	.	punct

J.A.	NNP	ROOT
20392	CD	nummod
-	SYM	punct
93	CD	prep
.	.	punct

ipir	NNS	nsubj
occur	VBD	ROOT
more	RBR	advmod
frequently	RB	advmod
in	IN	prep
the	DT	det
40	CD	nummod
mg	NN	compound
group	NN	pobj
than	IN	prep
the	DT	det
20	CD	nummod
mg	NN	compound
group	NN	pobj
.	.	punct

Idaho	NNP	compound
Cohen	NNP	nsubj
thus	RB	advmod
conclude	VBD	ROOT
that	IN	mark
the	DT	det
overall	JJ	amod
safety	NN	nmod
and	CC	cc
side	NN	compound
effect	NN	conj
profile	NN	nsubj
of	IN	prep
the	DT	det
40	CD	nummod
mg	NN	compound
dose	NN	pobj
be	VBD	ccomp
"	``	punct
similar	JJ	acomp
"	''	punct
to	IN	prep
the	DT	det
20	CD	nummod
mg	NN	compound
dose	NN	pobj
,	,	punct
but	CC	cc
"	``	punct
be	VBD	auxpass
associate	VBN	conj
with	IN	prep
a	DT	det
great	JJR	amod
incidence	NN	pobj
of	IN	prep
certain	JJ	amod
adverse	JJ	amod
effect	NNS	pobj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
20394	CD	nummod
.	.	punct

 	_SP	

Teva	NNP	poss
's	POS	case
own	JJ	amod
prior	JJ	amod
art	NN	compound
patent	NN	compound
application	NN	nsubjpass
,	,	punct
International	NNP	compound
Patent	NNP	compound
Application	NNP	compound
No.	SYM	compound
WO	NNP	appos
2007/081975	CD	punct
,	,	punct
Method	NNP	conj
of	IN	prep
treat	VBG	compound
Multiple	NNP	compound
Sclerosis	NNP	pobj
(	-LRB-	punct
"	``	punct
Pinchasi	NNP	appos
"	''	punct
)	-RRB-	punct
,	,	punct
be	VBD	auxpass
publish	VBN	ROOT
shortly	RB	advmod
after	IN	prep
the	DT	det
Cohen	NNP	compound
study	NN	pobj
.	.	punct

J.A.	NNP	ROOT
20925	CD	nummod
-	SYM	punct
56	CD	prep
.	.	punct

Pinchasi	NNP	nsubj
disclose	VBZ	ROOT
a	DT	det
40	CD	nummod
mg	NN	compound
GA	NNP	dobj
,	,	punct
every	DT	det
other	JJ	amod
day	NN	npadvmod
dose	VBG	acl
regiman	NNS	dobj
for	IN	prep
the	DT	det
treatment	NN	pobj
of	IN	prep
RRMS	NNP	pobj
.	.	punct

Pinchasi	NNP	nsubj
cite	VBZ	nsubj
to	IN	prep
the	DT	det
datum	NNS	pobj
from	IN	prep
Cohen	NNP	pobj
to	TO	aux
conclude	VB	advcl
that	IN	mark
"	``	punct
the	DT	det
increase	VBN	amod
efficacy	NN	nsubj
observe	VBN	ccomp
with	IN	prep
40	CD	nummod
mg	NN	amod
/	SYM	punct
day	NN	compound
GA	NNP	pobj
in	IN	prep
reduce	VBG	pcomp
MRI	NNP	npadvmod
-	HYPH	punct
measure	VBN	amod
disease	NN	compound
activity	NN	dobj
and	CC	cc
relapse	JJ	amod
rate	NN	conj
indicate	VBZ	ROOT
that	IN	mark
-PRON-	PRP	nsubj
be	VBZ	ccomp
well	RB	advmod
tolerate	VBN	acomp
and	CC	cc
can	MD	aux
improve	VB	conj
the	DT	det
treatment	NN	dobj
of	IN	prep
RRMS	NNP	compound
patient	NNS	pobj
.	.	punct

the	DT	det
improvement	NN	nsubjpass
in	IN	prep
efficacy	NN	pobj
,	,	punct
however	RB	advmod
,	,	punct
be	VBZ	auxpass
not	RB	neg
accompany	VBN	ROOT
by	IN	agent
a	DT	det
corresponding	JJ	amod
increase	NN	pobj
of	IN	prep
adverse	JJ	amod
reaction	NNS	pobj
which	WDT	nsubjpass
would	MD	aux
be	VB	auxpass
expect	VBN	relcl
upon	IN	prep
a	DT	det
doubling	NN	pobj
of	IN	prep
the	DT	det
administer	VBN	amod
dose	NN	pobj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
20944	CD	nummod
.	.	punct

 	_SP	

the	DT	det
FORTE	NNP	nsubj
study,6	:	punct
publish	VBN	acl
in	IN	prep
2008	CD	pobj
,	,	punct
evaluate	VBD	ROOT
the	DT	det
safety	NN	dobj
,	,	punct
tolerability	NN	conj
,	,	punct
and	CC	cc
efficacy	NN	conj
of	IN	prep
40	CD	nummod
mg	NN	compound
GA	NNP	pobj
compare	VBN	prep
to	IN	prep
20	CD	nummod
mg	NN	compound
GA	NNP	pobj
.	.	punct

J.A.	NNP	ROOT
20411	CD	nummod
,	,	punct
20414	CD	npadvmod
-	SYM	punct
22	CD	prep
.	.	punct

FORTE	NNP	nsubj
conclude	VBD	ROOT
that	IN	mark
both	CC	preconj
the	DT	det
40	CD	nummod
mg	NN	nsubj
and	CC	cc
20	CD	nummod
mg	NN	compound
dos	NNS	conj
"	''	punct
be	VBD	ccomp
equally	RB	advmod
effective	JJ	acomp
in	IN	prep
reduce	VBG	pcomp
clinical	JJ	amod
relapse	NNS	dobj
and	CC	cc
MRI	NNP	compound
activity	NN	conj
,	,	punct
"	''	punct
and	CC	cc
that	IN	mark
the	DT	det
40	CD	nummod
mg	NN	compound
dose	NN	nsubj
have	VBZ	conj
a	DT	det
"	``	punct
safety	NN	compound
profile	NN	dobj
similar	JJ	amod
to	IN	prep
that	DT	pobj
observe	VBN	acl
in	IN	prep
previous	JJ	amod
study	NNS	pobj
of	IN	prep
20	CD	nummod
mg	NN	compound
GA	NNP	pobj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
20411	CD	nummod
.	.	punct

FORTE	NNP	nsubj
also	RB	advmod
confirm	VBD	ROOT
Cohen	NNP	poss
's	POS	case
finding	NN	dobj
that	IN	mark
the	DT	det
40	CD	nummod
mg	NN	compound
dose	NN	nsubj
provide	VBD	acl
an	DT	det
early	JJR	amod
onset	NN	dobj
of	IN	prep
action	NN	pobj
.	.	punct

J.A.	NNP	ROOT
20422	CD	nummod
(	-LRB-	punct
note	VBG	acl
a	DT	det
"	``	punct
trend	NN	dobj
for	IN	prep
an	DT	det
early	JJR	amod
effect	NN	pobj
of	IN	prep
high	JJ	amod
[	-LRB-	punct
40	CD	nummod
mg	NN	nmod
]	-RRB-	punct
dose	NN	pobj
on	IN	prep
MRI	NNP	compound
activity	NN	pobj
"	''	punct
)	-RRB-	punct
.	.	punct

 	_SP	

a	DT	det
2008	CD	nummod
study	NN	nsubj
by	IN	prep
Omar	NNP	compound
Khan	NNP	pobj
and	CC	cc
others7	NNP	conj
(	-LRB-	punct
"	``	punct
Khan	NNP	appos
2008	CD	npadvmod
"	''	punct
)	-RRB-	punct
compare	VBN	ROOT
the	DT	det
effect	NN	dobj
of	IN	prep
daily	JJ	pobj
versus	IN	prep
every	DT	det
other	JJ	amod
day	NN	compound
administration	NN	pobj
of	IN	prep
20	CD	nummod
mg	NN	nmod
GA	NNP	nmod
subcutaneous	JJ	amod
injection	NNS	pobj
for	IN	prep
the	DT	det
treatment	NN	pobj
of	IN	prep
RRMS	NNP	pobj
.	.	punct

J.A.	NNP	ROOT
20883	CD	nummod
.	.	punct

the	DT	det
study	NN	compound
abstract	NN	nsubj
note	VBD	ROOT
that	IN	mark
although	IN	mark
the	DT	det
recommend	VBN	amod
dose	NN	nsubj
for	IN	prep
treat	VBG	pcomp
RRMS	NNP	dobj
be	VBZ	advcl
daily	JJ	advmod
20	CD	nummod
mg	NN	compound
GA	NNP	compound
injection	NNS	attr
,	,	punct
"	''	punct
the	DT	det
optimal	JJ	compound
dose	NN	nsubj
remain	VBZ	ccomp
unknown	JJ	acomp
"	''	punct
and	CC	cc
that	IN	mark
there	EX	expl
be	VBZ	conj
"	``	punct
considerable	JJ	amod
interest	NN	attr
in	IN	prep
alternate	JJ	amod
dosing	JJ	amod
regimen	NNS	pobj
of	IN	prep
GA	NNP	pobj
"	''	punct
because	IN	mark
daily	JJ	amod
injection	NNS	nsubj
"	''	punct
can	MD	aux
be	VB	aux
challenge	VBG	advcl
for	IN	prep
long	JJ	amod
-	HYPH	punct
term	NN	compound
patient	JJ	compound
compliance	NN	pobj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
20883	CD	nummod
.	.	punct

thirty	CD	nummod
patient	NNS	nsubjpass
be	VBD	auxpass
randomly	RB	advmod
assign	VBN	ROOT
to	TO	aux
receive	VB	xcomp
20	CD	nummod
mg	NN	compound
GA	NNP	dobj
dose	VBD	acl
daily	RB	advmod
or	CC	cc
every	DT	det
other	JJ	amod
day	NN	npadvmod
.	.	punct

After	IN	prep
two	CD	nummod
year	NNS	pobj
,	,	punct
there	EX	expl
be	VBD	ROOT
"	``	punct
no	DT	det
difference	NNS	attr
"	''	punct
between	IN	prep
the	DT	det
two	CD	nummod
group	NNS	pobj
in	IN	prep
relapse	JJ	amod
rate	NN	pobj
or	CC	cc
disease	NN	compound
progression	NN	conj
.	.	punct

J.A.	NNP	ROOT
20883	CD	nummod
.	.	punct

additionally	RB	advmod
,	,	punct
after	IN	prep
the	DT	det
first	JJ	amod
two	CD	nummod
year	NNS	pobj
elapse	VBD	acl
,	,	punct
patient	NNS	nsubjpass
in	IN	prep
each	DT	det
group	NN	pobj
be	VBD	auxpass
give	VBN	ROOT
the	DT	det
option	NN	dobj
to	TO	aux
continue	VB	acl
or	CC	cc
switch	VB	conj
group	NNS	dobj
,	,	punct
and	CC	cc
be	VBD	auxpass
monitor	VBN	conj
for	IN	prep
an	DT	det
additional	JJ	amod
two	CD	nummod
year	NNS	pobj
.	.	punct

every	DT	det
patient	NN	nsubj
in	IN	prep
the	DT	det
daily	JJ	amod
group	NN	pobj
opt	VBD	ROOT
to	TO	aux
switch	VB	xcomp
to	IN	prep
every	DT	det
other	JJ	amod
day	NN	compound
administration	NN	pobj
.	.	punct

After	IN	prep
four	CD	nummod
year	NNS	pobj
,	,	punct
there	EX	expl
be	VBD	ROOT
no	DT	det
difference	NN	attr
between	IN	prep
the	DT	det
crossover	NN	compound
group	NN	pobj
and	CC	cc
the	DT	det
group	NN	conj
that	WDT	nsubjpass
be	VBD	auxpass
always	RB	advmod
dose	VBN	relcl
every	DT	det
other	JJ	amod
day	NN	npadvmod
.	.	punct

the	DT	det
Caon	NNP	nsubj
reference,8	VBZ	punct
publish	VBN	advcl
in	IN	prep
2009	CD	pobj
,	,	punct
report	VBZ	ROOT
the	DT	det
same	JJ	amod
datum	NNS	dobj
from	IN	prep
the	DT	det
Khan	NNP	nmod
2008	CD	nummod
study	NN	pobj
,	,	punct
but	CC	cc
further	RB	advmod
note	VBD	conj
that	IN	mark
"	``	punct
injection	NN	nmod
relate	VBN	amod
lipoatrophy	NN	nsubj
be	VBD	ccomp
significantly	RB	advmod
less	JJR	acomp
"	``	punct
in	IN	prep
the	DT	det
every	DT	det
other	JJ	amod
day	NN	compound
group	NN	pobj
.	.	punct

J.A.	NNP	ROOT
20386	CD	nummod
.	.	punct

 	_SP	

III	NNP	ROOT
.	.	punct

state	NN	ROOT
of	IN	prep
the	DT	det
Art	NNP	compound
References	NNPS	pobj

 	_SP	

there	EX	expl
be	VBP	ROOT
two	CD	nummod
additional	JJ	amod
reference	NNS	attr
relevant	JJ	amod
to	IN	prep
this	DT	det
appeal	NN	pobj
,	,	punct
a	DT	det
2009	CD	nummod
study	NN	appos
by	IN	prep
Omar	NNP	compound
Khan9	NNS	pobj
(	-LRB-	punct
"	``	punct
Khan	NNP	appos
2009	CD	npadvmod
"	''	punct
)	-RRB-	punct
and	CC	cc
Teva	NNP	poss
's	POS	case
own	JJ	amod
Glatiramer	NNP	compound
Acetate	NNP	compound
low	JJ	compound
-	HYPH	punct
frequency	NN	compound
Administration	NNP	conj
(	-LRB-	punct
"	``	punct
GALA	NNP	appos
"	''	punct
)	-RRB-	punct

Phase	NNP	compound
III	NNP	compound
trial	NN	nsubj
of	IN	prep
40	CD	nummod
mg	NN	compound
GA	NNP	pobj
administer	VBD	ROOT
three	CD	nummod
time	NNS	npadvmod
per	IN	prep
week	NN	pobj
.	.	punct

J.A.	NNP	ROOT
23904	CD	nummod
-	SYM	punct
05	CD	prep
,	,	punct
J.A.	NNP	appos
8246	CD	nummod
-	HYPH	punct
8417	CD	prep
.	.	punct

Khan	NNP	nsubjpass
2009	CD	nummod
and	CC	cc
GALA	NNP	conj
be	VBD	auxpass
both	DT	dep
publish	VBN	ROOT
after	IN	prep
August	NNP	pobj
20	CD	nummod
,	,	punct
2009	CD	nummod
,	,	punct
the	DT	det
priority	NN	compound
date	NN	appos
of	IN	prep
the	DT	det
assert	VBN	amod
patent	NNS	pobj
,	,	punct
and	CC	cc
thus	RB	advmod
do	VBP	aux
not	RB	neg
qualify	VB	conj
as	RB	prep
statutory	JJ	amod
prior	JJ	amod
art	NN	pobj
.	.	punct

 	_SP	

the	DT	det
district	NN	compound
court	NN	nsubj
admit	VBD	ROOT
the	DT	det
Khan	NNP	nmod
2009	CD	nummod
reference	NN	dobj
for	IN	prep
the	DT	det
limited	JJ	amod
purpose	NN	pobj
of	IN	prep
show	VBG	pcomp
the	DT	det
state	NN	dobj
of	IN	prep
the	DT	det
art	NN	pobj
at	IN	prep
the	DT	det
time	NN	pobj
of	IN	prep
the	DT	det
invention	NN	pobj
.	.	punct

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	compound
Consolidated	NNP	compound
Cases	NNPS	pobj
,	,	punct
No.	SYM	pobj
14	CD	nummod
-	SYM	punct
1171-gms	CD	appos
,	,	punct

2017	CD	nummod
WL	NNP	ROOT
401943	CD	nummod
,	,	punct
at	IN	prep
(	-LRB-	punct
D.	NNP	compound
Delaware	NNP	subtok
January	NNP	pobj
30	CD	nummod
,	,	punct
2017	CD	nummod
)	-RRB-	punct
.	.	punct

Khan	NNP	nsubjpass
2009	CD	nummod
be	VBD	auxpass
publish	VBN	ROOT
three	CD	nummod
week	NNS	npadvmod
after	IN	prep
August	NNP	pobj
20	CD	nummod
,	,	punct
2009	CD	nummod
,	,	punct
the	DT	det
priority	NN	compound
date	NN	appos
of	IN	prep
the	DT	det
Copaxone	NNP	compound
patent	NNS	pobj
,	,	punct
but	CC	cc
the	DT	det
study	NN	nsubj
begin	VBD	conj
two	CD	nummod
year	NNS	npadvmod
earlier	RBR	advmod
.	.	punct

J.A.	NNP	ROOT
23904	CD	nummod
-	SYM	punct
05	CD	prep
.	.	punct

the	DT	det
study	NN	compound
abstract	NN	nsubj
note	VBD	ROOT
that	IN	mark
"	``	punct
there	EX	expl
be	VBZ	ccomp
considerable	JJ	amod
interest	NN	attr
in	IN	prep
study	VBG	pcomp
a	DT	det
more	RBR	advmod
patient	JJ	amod
friendly	JJ	amod
dosing	JJ	amod
regimen	NN	dobj
of	IN	prep
GA	NNP	pobj
that	WDT	nsubj
may	MD	aux
be	VB	relcl
as	RB	advmod
efficacious	JJ	acomp
and	CC	cc
better	RBR	conj
tolerate	VBN	conj
than	IN	prep
daily	JJ	amod
GA	NNP	pobj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
23904	CD	nummod
.	.	punct

follow	VBG	prep
the	DT	det
result	NNS	pobj
of	IN	prep
Khan	NNP	pobj
2008	CD	nummod
,	,	punct
which	WDT	nsubj
show	VBD	relcl
that	IN	mark
alternate	JJ	amod
day	NN	compound
administration	NN	nsubj
of	IN	prep
GA	NNP	pobj
appear	VBZ	ccomp
to	TO	aux
be	VB	xcomp
as	RB	advmod
effective	JJ	acomp
as	IN	prep
daily	JJ	amod
administration	NN	pobj
,	,	punct
Khan	NNP	nsubj
2009	CD	nummod
compare	VBD	ROOT
20	CD	nummod
mg	NN	compound
GA	NNP	nsubj
administer	VBD	ccomp
twice	PDT	predet
a	DT	det
week	NN	npadvmod
to	IN	prep
20	CD	nummod
mg	NN	compound
GA	NNP	pobj
administer	VBD	acl
daily	RB	advmod
in	IN	prep
a	DT	det
pilot	NN	nmod
,	,	punct
prospective	JJ	amod
,	,	punct
randomize	VBN	conj
,	,	punct
and	CC	cc
rater	NN	npadvmod
-	HYPH	punct
blind	VBN	amod
two	CD	nummod
-	HYPH	punct
year	NN	compound
study	NN	pobj
.	.	punct

J.A.	NNP	ROOT
23904	CD	nummod
.	.	punct

 	_SP	

concern	VBG	prep
GALA	NNP	dobj
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
recognize	VBD	ROOT
that	IN	mark
the	DT	det
GALA	NNP	compound
trial	NN	compound
protocol	NN	nsubj
do	VBZ	aux
not	RB	neg
qualify	VB	ccomp
as	RB	prep
prior	JJ	amod
art	NN	pobj
.	.	punct

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	prep
*	NFP	punct
20	CD	pobj
.	.	punct

instead	RB	advmod
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
admit	VBD	ROOT
GALA	NNP	dobj
as	IN	prep
an	DT	det
admission	NN	pobj
by	IN	prep
Teva	NNP	pobj
to	TO	aux
inform	VB	acl
on	IN	prep
the	DT	det
motivation	NNS	pobj
of	IN	prep
those	DT	pobj
have	VBG	acl
ordinary	JJ	amod
skill	NN	dobj
in	IN	prep
the	DT	det
art	NN	pobj
at	IN	prep
the	DT	det
time	NN	pobj
of	IN	prep
the	DT	det
invention	NN	pobj
.	.	punct

In	IN	prep
-PRON-	PRP$	poss
submission	NN	pobj
to	IN	prep
FDA	NNP	pobj
,	,	punct
Teva	NNP	nsubj
explain	VBD	ROOT
that	IN	mark
,	,	punct
after	IN	mark
the	DT	det
FORTE	NNP	compound
study	NN	nsubj
demonstrate	VBD	ccomp
that	IN	mark
the	DT	det
40	CD	nummod
mg	NN	compound
dose	NN	nsubj
be	VBD	ccomp
equally	RB	advmod
effective	JJ	acomp
as	IN	prep
the	DT	det
20	CD	nummod
mg	NN	compound
dose	NN	pobj
,	,	punct
"	''	punct
the	DT	det
natural	JJ	amod
next	JJ	amod
step	NN	nsubj
[	-LRB-	punct
be	VBD	conj
]	-RRB-	punct
to	TO	aux
reduce	VB	xcomp
the	DT	det
dosing	JJ	amod
regimen	NN	dobj
of	IN	prep
GA	NNP	pobj
and	CC	cc
find	VB	conj
the	DT	det
optimal	JJ	amod
regimen	NN	dobj
that	WDT	nsubj
[	-LRB-	punct
would	MD	aux
]	-RRB-	punct
improve	VB	relcl
the	DT	det
convenience	NN	dobj
of	IN	prep
treatment	NN	pobj
and	CC	cc
reduce	VB	conj
the	DT	det
burden	NN	dobj
and	CC	cc
adverse	JJ	conj
event	NNS	conj
associate	VBN	acl
with	IN	prep
daily	JJ	amod
subcutaneous	JJ	amod
injection	NNS	pobj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
8266	CD	nummod
.	.	punct

cite	VBG	advcl
the	DT	det
small	JJ	amod
-	HYPH	punct
scale	NN	compound
study	NNS	dobj
with	IN	prep
20	CD	nummod
mg	NN	compound
GA	NNP	pobj
in	IN	prep
the	DT	det
prior	JJ	amod
art	NN	pobj
,	,	punct
such	JJ	amod
as	IN	prep
Khan	NNP	pobj
2008	CD	nummod
,	,	punct
GALA	NNP	nsubj
note	VBD	ROOT
that	IN	mark
result	NNS	nsubj
"	``	punct
demonstrate	VBN	ccomp
effect	NNS	dobj
in	IN	prep
relapse	JJ	amod
rate	NN	compound
reduction	NN	pobj
which	WDT	nsubj
be	VBD	relcl
comparable	JJ	acomp
to	IN	prep
daily	JJ	amod
injection	NNS	pobj
of	IN	prep
GA	NNP	pobj
20	CD	nummod
mg	NN	npadvmod
,	,	punct
suggest	VBG	advcl
a	DT	det
low	JJR	amod
injection	NN	compound
frequency	NN	nsubjpass
can	MD	aux
be	VB	auxpass
consider	VBN	ccomp
"	''	punct
.	.	punct

J.A.	NNP	ROOT
8266	CD	nummod
,	,	punct
8352	CD	appos
.	.	punct

the	DT	det
GALA	NNP	compound
protocol	NN	nsubj
select	VBD	ROOT
a	DT	det
dosing	JJ	amod
regimen	NN	dobj
of	IN	prep
40	CD	nummod
mg	NN	nmod
GA	NNP	compound
3x	NNP	nmod
/	SYM	punct
week	NN	pobj
,	,	punct
in	IN	prep
part	NN	pobj
because	IN	mark
"	``	punct
the	DT	det
subject	NNS	nsubj
will	MD	aux
receive	VB	advcl
approximately	RB	advmod
the	DT	det
same	JJ	amod
weekly	JJ	amod
dose	NN	dobj
,	,	punct
give	VBN	advcl
by	IN	agent
3	CD	nummod
subcutaneous	JJ	amod
injection	NNS	pobj
instead	RB	advmod
of	IN	cc
with	IN	prep
a	DT	det
daily	JJ	amod
injection	NN	compound
frequency	NN	pobj
of	IN	prep
7	CD	nummod
injection	NNS	pobj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
8266	CD	nummod
.	.	punct

 	_SP	

IV	NNP	ROOT
.	.	punct

proceed	VBG	ROOT
below	RB	advmod

 	_SP	

This	DT	det
appeal	NN	nsubj
arise	VBZ	ROOT
out	IN	prep
of	IN	prep
five	CD	nummod
consolidated	JJ	amod
district	NN	compound
court	NN	compound
case	NNS	pobj
.	.	punct

the	DT	det
Defendants	NNP	compound
-	HYPH	punct
Appellees	NNP	nsubj
in	IN	prep
this	DT	det
case	NN	pobj
be	VBP	ROOT
generic	JJ	amod
drug	NN	compound
manufacturer	NNS	attr
who	WP	nsubj
(	-LRB-	punct
prior	RB	advmod
to	IN	prep
the	DT	det
expiration	NN	pobj
of	IN	prep
the	DT	det
Copaxone	NNP	compound
patent	NNS	pobj
)	-RRB-	punct
submit	VBD	relcl
Abbreviated	NNP	compound
New	NNP	compound
Drug	NNP	compound
Applications	NNPS	dobj
(	-LRB-	punct
"	``	punct
anda	NNS	appos
"	''	punct
)	-RRB-	punct
to	IN	prep
FDA	NNP	pobj
for	IN	prep
approval	NN	pobj
to	TO	aux
engage	VB	acl
in	IN	prep
the	DT	det
manufacture	NN	pobj
and	CC	cc
sale	NN	conj
of	IN	prep
generic	JJ	amod
version	NNS	pobj
of	IN	prep
COPAXONE	NNP	compound
(r)	SYM	pobj

40	CD	nummod
mg	NN	nsubj
administer	VBD	ROOT
3	CD	nummod
time	NNS	npadvmod
per	IN	prep
week	NN	pobj
.	.	punct

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	pobj
*	NFP	punct
1	CD	pobj
-	SYM	punct
10	CD	prep
.	.	punct

appellant	NNS	nsubj
Teva	NNP	compound
Pharmaceuticals	NNPS	nmod
USA	NNP	nmod
,	,	punct
Inc.	NNP	appos
,	,	punct
Teva	NNP	compound
Pharmaceutical	NNP	compound
Industries	NNPS	conj
,	,	punct
Ltd.	NNP	amod
,	,	punct
Teva	NNP	compound
Neuroscience	NNP	conj
,	,	punct
Inc.	NNP	conj
,	,	punct
and	CC	cc
Yeda	NNP	compound
Research	NNP	nmod
and	CC	cc
Development	NNP	conj
Co.	NNP	conj
,	,	punct
Ltd.	NNP	amod
(	-LRB-	punct
collectively	RB	advmod
,	,	punct
"	``	punct
Teva	NNP	appos
"	''	punct
)	-RRB-	punct
sue	VBD	ROOT
Appellees	NNP	dobj
in	IN	prep
the	DT	det
United	NNP	compound
States	NNP	compound
District	NNP	compound
Court	NNP	pobj
for	IN	prep
the	DT	det
District	NNP	pobj
of	IN	prep
Delaware	NNP	pobj
,	,	punct
allege	VBG	advcl
that	IN	mark
-PRON-	PRP$	poss
respective	JJ	amod
ANDA	NNP	compound
filing	NNS	nsubj
infringe	VBD	ccomp
claim	NNS	dobj
1	CD	dep
,	,	punct
5	CD	appos
,	,	punct
13	CD	npadvmod
-	SYM	punct
17	CD	prep
of	IN	prep
the	DT	det
'	``	punct
250	CD	nummod
patent	NN	pobj
,	,	punct
claim	VBZ	npadvmod
1	CD	npadvmod
,	,	punct
7	CD	appos
,	,	punct
15	CD	appos
,	,	punct
and	CC	cc
20	CD	nsubj
of	IN	prep
the	DT	det
'	``	punct
413	CD	nummod
patent	NN	pobj
,	,	punct
claim	VBZ	conj
1	CD	npadvmod
,	,	punct
10	CD	npadvmod
,	,	punct
and	CC	cc
11	CD	conj
of	IN	prep
the	DT	det
'	``	punct
302	CD	nummod
patent	NN	pobj
,	,	punct
and	CC	cc
claim	VBZ	conj
1	CD	npadvmod
,	,	punct
2	CD	npadvmod
,	,	punct
5	CD	npadvmod
,	,	punct
6	CD	npadvmod
,	,	punct
9	CD	npadvmod
,	,	punct
12	CD	npadvmod
,	,	punct
16	CD	conj
,	,	punct
and	CC	cc
17	CD	conj
of	IN	prep
the	DT	det
'	``	punct
776	CD	nummod
patent	NN	pobj
.	.	punct

Idaho	NNP	nsubj

 	_SP	
follow	VBG	prep
a	DT	det
Markman	NNP	compound
hearing	NN	dobj
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
enter	VBD	ROOT
a	DT	det
claim	NN	compound
construction	NN	compound
order	NN	dobj
.	.	punct

In	IN	ROOT
re	VBG	pobj
Copaxone	NNP	pobj

40	CD	nummod
Mg	NNP	ROOT
,	,	punct
No.	SYM	appos
14	CD	nummod
-	SYM	punct
1171-gms	CD	conj
,	,	punct

2016	CD	nummod
WL	NNP	dep
873062	CD	nummod
,	,	punct
at	IN	prep
*	NFP	punct
1	CD	pobj
-	SYM	punct
2	CD	prep
(	-LRB-	punct
March	NNP	npadvmod
7	CD	nummod
,	,	punct
2016	CD	nummod
)	-RRB-	punct
(	-LRB-	punct
"	``	punct
Claim	NNP	compound
construction	NN	compound
order	NN	ROOT
"	''	punct
)	-RRB-	punct
.	.	punct

relevant	JJ	advcl
to	IN	prep
this	DT	det
appeal	NN	pobj
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
construe	VBD	ROOT
the	DT	det
'	``	punct
250	CD	nummod
and	CC	cc
'	``	punct
413	CD	conj
patent	NNS	poss
'	POS	punct
"	``	punct
sufficiency"10	NNP	compound
term	NNS	dobj
and	CC	cc
the	DT	det
'	``	punct
776	CD	nummod
patent	NN	poss
's	POS	case
"	``	punct
reduced	JJ	amod
frequency	NN	conj
of	IN	prep
relapses"11	NNP	pobj
and	CC	cc
"	``	punct
effectiveness"12	NNP	compound
term	NNS	conj
as	IN	prep
non	JJ	subtok
-	JJ	subtok
limiting	JJ	amod
statement	NNS	pobj
of	IN	prep
intend	VBN	amod
effect	NN	pobj
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
&	CC	cc
nn.1	NNP	compound
-	SYM	punct
2	CD	conj
.	.	punct

 	_SP	

the	DT	det
district	NN	compound
court	NN	nsubj
hold	VBD	ROOT
a	DT	det
seven	CD	nummod
-	HYPH	punct
day	NN	compound
bench	NN	compound
trial	NN	dobj
during	IN	prep
which	WDT	pobj
-PRON-	PRP	nsubj
consider	VBD	relcl
the	DT	det
invalidity	NN	dobj
of	IN	prep
the	DT	det
assert	VBN	amod
claim	NNS	pobj
of	IN	prep
the	DT	det
Copaxone	NNP	compound
patent	NNS	pobj
.	.	punct

the	DT	det
district	NN	compound
court	NN	nsubj
find	VBD	ROOT
that	IN	mark
a	DT	det
40	CD	nummod
mg	NN	compound
GA	NNP	compound
dose	NN	nsubjpass
be	VBD	auxpass
explicitly	RB	advmod
disclose	VBN	ccomp
in	IN	prep
reference	NNS	pobj
that	WDT	nsubj
predate	VBP	relcl
the	DT	det
Copaxone	NNP	compound
patent	NNS	dobj
,	,	punct
specifically	RB	advmod
Cohen	NNP	appos
,	,	punct
Pinchasi	NNP	conj
,	,	punct
and	CC	cc
FORTE	NNP	conj
.	.	punct

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	prep
*	NFP	punct
14	CD	pobj
.	.	punct

the	DT	det
court	NN	nsubj
reject	VBD	ROOT
Teva	NNP	poss
's	POS	case
argument	NNS	dobj
that	IN	mark
Cohen	NNP	nsubj
and	CC	cc
FORTE	NNP	conj
teach	VBD	acl
away	RB	advmod
from	IN	prep
a	DT	det
40	CD	nummod
mg	NN	compound
dose	NN	pobj
,	,	punct
and	CC	cc
that	IN	mark
a	DT	det
person	NN	nsubj
of	IN	prep
ordinary	JJ	amod
skill	NN	pobj
in	IN	prep
the	DT	det
art	NN	pobj
(	-LRB-	punct
"	``	punct
POSITA	NNP	appos
"	''	punct
)	-RRB-	punct
would	MD	aux
have	VB	aux
think	VBN	conj
that	IN	mark
20	CD	nummod
mg	NN	nsubj
be	VBD	ccomp
the	DT	det
optimal	JJ	compound
dose	NN	attr
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
*	NFP	punct
14	CD	pobj
-	SYM	punct
15	CD	prep
.	.	punct

the	DT	det
district	NN	compound
court	NN	nsubj
also	RB	advmod
find	VBD	ROOT
that	IN	mark
,	,	punct
as	IN	prep
of	IN	pcomp
the	DT	det
priority	NN	compound
date	NN	pobj
,	,	punct
posita	NNS	nsubj
know	VBD	ccomp
that	IN	mark
daily	JJ	amod
injection	NNS	nsubj
be	VBD	ccomp
difficult	JJ	acomp
to	TO	aux
tolerate	VB	xcomp
base	VBN	prep
on	IN	prep
the	DT	det
1996	CD	nummod
FDA	NNP	compound
SBOA	NNP	pobj
,	,	punct
Flechter	NNP	conj
,	,	punct
and	CC	cc
Khan	NNP	conj
2008	CD	nummod
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
*	NFP	punct
15	CD	pobj
-	SYM	punct
16	CD	prep
.	.	punct

rely	VBG	advcl
in	IN	prep
part	NN	pobj
on	IN	prep
trial	NN	compound
testimony	NN	pobj
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
find	VBD	ROOT
that	IN	mark
posita	NNS	nsubj
be	VBD	ccomp
familiar	JJ	acomp
with	IN	prep
the	DT	det
adverse	JJ	amod
reaction	NNS	pobj
,	,	punct
pain	NN	conj
,	,	punct
and	CC	cc
treatment	NN	compound
adherence	NN	compound
problem	NNS	conj
associate	VBN	acl
with	IN	prep
daily	JJ	amod
injection	NNS	pobj
,	,	punct
and	CC	cc
would	MD	aux
have	VB	aux
be	VBN	auxpass
motivate	VBN	conj
to	TO	aux
pursue	VB	xcomp
less	RBR	advmod
frequent	JJ	amod
dose	VBG	dobj
with	IN	prep
a	DT	det
reasonable	JJ	amod
probability	NN	pobj
of	IN	prep
success	NN	pobj
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
*	NFP	punct
16	CD	pobj
.	.	punct

the	DT	det
district	NN	compound
court	NN	nsubj
find	VBD	ROOT
that	IN	mark
Pinchasi	NNP	nsubj
be	VBZ	ccomp
the	DT	det
close	JJS	amod
prior	JJ	amod
art	NN	attr
because	IN	mark
-PRON-	PRP	nsubj
disclose	VBZ	advcl
a	DT	det
dosing	JJ	amod
regimen	NN	dobj
that	WDT	nsubj
differ	VBZ	relcl
from	IN	prep
the	DT	det
claim	VBN	amod
regiman	NNS	pobj
by	IN	prep
only	RB	advmod
one	CD	nummod
dose	NN	pobj
every	DT	det
two	CD	nummod
week	NNS	npadvmod
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
*	NFP	punct
17	CD	pobj
.	.	punct

 	_SP	

In	IN	prep
light	NN	pobj
of	IN	prep
these	DT	det
factual	JJ	amod
finding	NNS	pobj
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
conclude	VBD	ROOT
that	IN	mark
a	DT	det
40	CD	nummod
mg	NN	nmod
GA	NNP	nmod
3x	NNP	nmod
/	SYM	punct
week	NN	compound
dosage	NN	nsubj
would	MD	aux
be	VB	ccomp
obvious	JJ	acomp
to	TO	aux
try	VB	xcomp
,	,	punct
note	VBG	advcl
that	IN	mark
there	EX	expl
be	VBD	ccomp
only	RB	advmod
two	CD	nummod
test	VBN	amod
dosage	NN	compound
amount	NNS	attr
in	IN	prep
the	DT	det
prior	JJ	amod
art-20	NN	nummod
mg	NN	pobj
and	CC	cc
40mg	JJ	conj
-	:	punct
and	CC	cc
that	IN	mark
researcher	NNS	nsubj
be	VBD	aux
pursue	VBG	conj
less	RBR	advmod
frequent	JJ	amod
dosing	JJ	amod
regimen	NNS	dobj
while	IN	mark
recognize	VBG	advcl
there	EX	expl
be	VBP	ccomp
a	DT	det
limited	JJ	amod
number	NN	attr
of	IN	prep
day	NNS	pobj
in	IN	prep
a	DT	det
week	NN	pobj
on	IN	prep
which	WDT	pobj
to	TO	aux
test	VB	relcl
frequency	NN	dobj
.	.	punct

see	VB	ROOT
-PRON-	PRP	subtok
would	MD	dobj
.	.	punct
at	IN	prep
*	NFP	punct
19	CD	pobj
.	.	punct

the	DT	det
court	NN	nsubj
recognize	VBD	ROOT
that	IN	mark
obvious	JJ	amod
-	HYPH	punct
to	TO	prep
-	HYPH	punct
try	VB	pobj
logic	NN	nsubj
be	VBZ	ccomp
not	RB	neg
always	RB	advmod
appropriate	JJ	acomp
,	,	punct
but	CC	cc
find	VBD	conj
that	IN	mark
"	``	punct
here	RB	advmod
,	,	punct
there	EX	expl
be	VBD	ccomp
market	NN	compound
pressure	NN	attr
to	TO	aux
solve	VB	acl
a	DT	det
know	VBN	amod
problem	NN	dobj
-	:	punct
the	DT	det
fact	NN	attr
that	IN	mark
many	JJ	amod
MS	NNP	compound
patient	NNS	nsubj
could	MD	aux
not	RB	neg
tolerate	VB	acl
daily	JJ	amod
injection	NNS	dobj
-	:	punct
and	CC	cc
there	EX	expl
be	VBD	conj
a	DT	det
finite	JJ	amod
number	NN	attr
of	IN	prep
predictable	JJ	amod
solution	NNS	pobj
that	WDT	mark
a	DT	det
person	NN	nsubj
of	IN	prep
ordinary	JJ	amod
skill	NN	pobj
in	IN	prep
the	DT	det
art	NN	pobj
would	MD	aux
have	VB	acl
good	JJ	amod
reason	NN	dobj
to	TO	aux
pursue	VB	relcl
"	''	punct
.	.	punct

Idaho	NNP	ROOT

the	DT	det
district	NN	compound
court	NN	nsubj
cite	VBD	ROOT
to	IN	prep
Khan	NNP	pobj
2009	CD	nummod
,	,	punct
Teva	NNP	poss
's	POS	case
GALA	NNP	compound
study	NN	dobj
,	,	punct
and	CC	cc
trial	NN	compound
testimony	NN	conj
as	IN	prep
evidence	NN	pobj
of	IN	prep
the	DT	det
motivation	NNS	pobj
of	IN	prep
posita	NNS	pobj
at	IN	prep
the	DT	det
time	NN	pobj
of	IN	prep
the	DT	det
invention	NN	pobj
,	,	punct
and	CC	cc
note	VBD	conj
evidence	NN	dobj
and	CC	cc
testimony	NN	conj
support	VBG	acl
the	DT	det
proposition	NN	dobj
that	IN	mark
a	DT	det
dosing	JJ	amod
schedule	NN	nsubj
base	VBN	acl
on	IN	prep
three	CD	nummod
predetermined	JJ	amod
day	NNS	pobj
each	DT	det
week	NN	npadvmod
be	VBZ	acl
preferable	JJ	acomp
for	IN	prep
patient	NNS	pobj
over	IN	prep
an	DT	det
every	DT	det
other	JJ	amod
day	NN	compound
schedule	NN	pobj
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
*	NFP	punct
20	CD	pobj
.	.	punct

the	DT	det
district	NN	compound
court	NN	nsubj
highlight	VBD	ROOT
testimony	NN	dobj
from	IN	prep
Dr.	NNP	compound
Green	NNP	pobj
that	IN	mark
a	DT	det
regimen	NN	nsubj
of	IN	prep
injection	NNS	pobj
on	IN	prep
three	CD	nummod
pre	JJ	subtok
-	JJ	subtok
determined	JJ	amod
day	NNS	pobj
of	IN	prep
each	DT	det
week	NN	pobj
be	VBZ	ccomp
more	RBR	advmod
convenient	JJ	acomp
for	IN	prep
patient	NNS	pobj
and	CC	cc
have	VBZ	conj
better	RBR	amod
patient	JJ	amod
adherence	NN	dobj
than	IN	prep
an	DT	det
every	DT	det
other	JJ	amod
day	NN	compound
regiman	NNS	pobj
,	,	punct
in	IN	prep
which	WDT	pobj
the	DT	det
day	NNS	nsubj
on	IN	prep
which	WDT	pobj
patient	NNS	nsubj
inject	VBP	relcl
differ	NN	relcl
depend	VBG	prep
on	IN	prep
the	DT	det
week	NN	pobj
.	.	punct

Idaho	NNP	ROOT

the	DT	det
district	NN	compound
court	NN	nsubj
also	RB	advmod
note	VBD	ROOT
a	DT	det
study	NN	dobj
show	VBG	acl
that	IN	mark
Rebif	NNP	compound
(r)	SYM	nsubj
,	,	punct
an	DT	det
injectable	JJ	amod
MS	NNP	compound
treatment	NN	appos
dose	VBD	ccomp
three	CD	nummod
time	NNS	npadvmod
a	DT	det
week	NN	npadvmod
,	,	punct
have	VBZ	aux
increase	VBN	conj
patient	JJ	amod
adherence	NN	dobj
compare	VBN	prep
to	IN	prep
the	DT	det
daily	JJ	amod
20	CD	nummod
mg	NN	compound
GA	NNP	compound
regiman	NNS	pobj
.	.	punct

Idaho	NNP	ROOT

 	_SP	

In	IN	prep
light	NN	pobj
of	IN	prep
additional	JJ	amod
testimony	NN	pobj
that	WDT	mark
a	DT	det
POSITA	NNP	nsubj
would	MD	aux
expect	VB	pobj
the	DT	det
number	NN	nsubj
of	IN	prep
isr	NNS	pobj
to	TO	aux
decrease	VB	ccomp
as	IN	mark
the	DT	det
number	NN	nsubj
of	IN	prep
injection	NNS	pobj
per	IN	prep
week	NN	pobj
decrease	VBD	advcl
,	,	punct
as	RB	advmod
well	RB	advmod
as	IN	cc
disclosure	NNS	conj
in	IN	prep
Flechter	NNP	pobj
,	,	punct
Khan	NNP	npadvmod
2008	CD	nummod
,	,	punct
and	CC	cc
Caon	NNP	conj
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
hold	VBD	ROOT
obvious	JJ	amod
the	DT	det
dependent	JJ	amod
claim	NNS	dobj
of	IN	prep
the	DT	det
'	``	punct
250	CD	pobj
and	CC	cc
'	``	punct
413	CD	nummod
patent	NNS	dobj
require	VBG	acl
that	IN	mark
the	DT	det
40	CD	nummod
mg	NN	nmod
GA	NNP	compound
3x	NNP	nmod
/	SYM	punct
week	NN	compound
regiman	NNS	nsubj
reduce	VB	ccomp
the	DT	det
frequency	NN	dobj
of	IN	prep
isr	NNS	pobj
and	CC	cc
IPIRs	NNPS	conj
as	IN	mark
compare	VBN	prep
to	IN	prep
a	DT	det
20mg	JJ	amod
/	SYM	punct
day	NN	compound
regimen	NN	pobj
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
*	NFP	punct
17	CD	pobj
-	SYM	punct
18	CD	prep
.	.	punct

the	DT	det
district	NN	compound
court	NN	nsubj
also	RB	advmod
find	VBD	ROOT
obvious	JJ	amod
claim	NN	dobj
15	CD	nummod
of	IN	prep
the	DT	det
'	``	punct
250	CD	nummod
patent	NN	pobj
,	,	punct
which	WDT	nsubj
require	VBZ	relcl
the	DT	det
claim	VBN	amod
method	NN	dobj
improve	VB	acl
tolerability	NN	dobj
as	IN	mark
compare	VBN	prep
to	IN	prep
a	DT	det
20mg	JJ	amod
/	SYM	punct
day	NN	compound
regimen	NN	pobj
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
*	NFP	punct
17	CD	pobj
.	.	punct

the	DT	det
court	NN	nsubj
further	RB	advmod
determine	VBD	ROOT
the	DT	det
claim	NNS	dobj
of	IN	prep
the	DT	det
'	``	punct
776	CD	nummod
patent	NN	pobj
to	TO	aux
be	VB	relcl
obvious	JJ	acomp
in	IN	prep
light	NN	pobj
of	IN	prep
Caon	NNP	nmod
and	CC	cc
expert	JJ	conj
evidence	NN	pobj
present	VBD	acl
at	IN	prep
trial	NN	pobj
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
*	NFP	punct
22	CD	pobj
-	SYM	punct
23	CD	prep
.	.	punct

finally	RB	advmod
,	,	punct
the	DT	det
court	NN	nsubj
consider	VBD	ROOT
objective	JJ	amod
indicia	NNS	dobj
of	IN	prep
nonobviousness	NN	pobj
,	,	punct
and	CC	cc
conclude	VBD	conj
that	IN	mark
none	NN	nsubj
of	IN	prep
-PRON-	PRP	pobj
war	NN	npadvmod
-	HYPH	punct
rant	VBD	ccomp
a	DT	det
finding	NN	dobj
of	IN	prep
nonobviousness	NN	pobj
of	IN	prep
the	DT	det
Copaxone	NNP	compound
patent	NNS	pobj
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
*	NFP	punct
25	CD	pobj
.	.	punct

 	_SP	

follow	VBG	prep
-PRON-	PRP$	poss
analysis	NN	pobj
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
hold	VBD	ROOT
all	DT	det
asserted	JJ	amod
claim	NNS	dobj
of	IN	prep
the	DT	det
Copaxone	NNP	compound
patent	NNS	pobj
invalid	JJ	advmod
as	RB	prep
obvious	JJ	amod
under	IN	prep
¡±	NNP	pobj
103	CD	nummod
.	.	punct

Teva	NNP	nsubj
appeal	VBZ	ROOT
the	DT	det
district	NN	compound
court	NN	poss
's	POS	case
claim	NN	compound
construction	NN	dobj
and	CC	cc
obviousness	JJ	conj
decision	NNS	conj
.	.	punct

-PRON-	PRP	nsubj
have	VBP	ROOT
jurisdiction	NN	dobj
pursuant	JJ	advmod
to	IN	prep
28	CD	nummod
U.S.C.	NNP	nmod
¡±	CD	nummod
1295(a)(1	CD	pobj
)	-RRB-	punct
.	.	punct

 	_SP	

i.	NN	nmod
Claim	NNP	compound
Construction	NNP	nmod

 	_SP	
Claim	NNP	compound
construction	NN	nsubj
seek	VBZ	ROOT
to	TO	aux
ascribe	VB	xcomp
the	DT	det
"	``	punct
ordinary	JJ	amod
and	CC	cc
customary	JJ	conj
meaning	NN	dobj
"	''	punct
to	TO	aux
claim	VB	relcl
term	NNS	dobj
as	IN	mark
a	DT	det
person	NN	nsubj
of	IN	prep
ordinary	JJ	amod
skill	NN	pobj
in	IN	prep
the	DT	det
art	NN	pobj
would	MD	aux
have	VB	aux
understand	VBN	advcl
-PRON-	PRP	dobj
at	IN	prep
the	DT	det
time	NN	pobj
of	IN	prep
invention	NN	pobj
.	.	punct

phillip	NNS	ROOT
v.	IN	prep
AWH	NNP	compound
Corp.	NNP	pobj
,	,	punct
415	CD	nummod
f.3d	CD	appos
1303	CD	appos
,	,	punct
1312	CD	npadvmod
-	SYM	punct
14	CD	prep
(	-LRB-	punct
Fed	NNP	appos
.	.	punct
Cir	NNP	subtok
.	.	punct
2005	CD	nummod
)	-RRB-	punct
(	-LRB-	punct
en	IN	prep
banc	NN	appos
)	-RRB-	punct
(	-LRB-	punct
cite	VBG	acl
Vitronics	NNP	compound
Corp.	NNP	dobj
v.	IN	prep
Conceptronic	NNP	nmod
,	,	punct
Inc.	NNP	pobj
,	,	punct
90	CD	nummod
f.3d	CD	appos
1576	CD	nummod
,	,	punct
1582	CD	npadvmod
(	-LRB-	punct
Fed	NNP	appos
.	.	punct
Cir	NNP	subtok
.	.	dobj
1996	CD	nummod
)	-RRB-	punct
)	-RRB-	punct
.	.	punct

where	WRB	advmod
the	DT	det
district	NN	compound
court	NN	poss
's	POS	case
claim	NN	compound
construction	NN	nsubj
rely	VBZ	advcl
only	RB	advmod
on	IN	prep
intrinsic	JJ	amod
evidence	NN	pobj
,	,	punct
as	IN	mark
be	VBZ	advcl
the	DT	det
case	NN	nsubj
here	RB	advmod
,	,	punct
the	DT	det
construction	NN	nsubj
be	VBZ	ROOT
a	DT	det
legal	JJ	amod
determination	NN	attr
review	VBN	acl
de	FW	nmod
novo	NN	dobj
.	.	punct

Poly	NNP	compound
-	HYPH	punct
Am	NNP	subtok
.	.	ROOT
,	,	punct
L.P.	NNP	npadvmod
v.	CC	prep
API	NNP	compound
Indus	NNP	pobj
.	.	punct
,	,	punct
Inc.	NNP	npadvmod
,	,	punct
839	CD	nummod
f.3d	CD	appos
1131	CD	appos
,	,	punct
1135	CD	npadvmod
-	SYM	punct
36	CD	prep
(	-LRB-	punct
Fed	NNP	appos
.	.	punct
Cir	NNP	subtok
.	.	punct
2016	CD	npadvmod
)	-RRB-	punct
(	-LRB-	punct
cite	VBG	acl
Teva	NNP	compound
Pharm.	NNP	compound
USA	NNP	nmod
,	,	punct
Inc.	NNP	dobj
v.	CC	prep
Sandoz	NNP	pobj
,	,	punct
Inc.	NNP	appos
,	,	punct
---	:	punct
U.S.	NNP	npadvmod
----	NFP	punct
,	,	punct
135	CD	nummod
S.Ct	NNP	subtok
.	.	npadvmod
831	CD	appos
,	,	punct
841	CD	npadvmod
,	,	punct
---	NFP	punct
l.ed.2d	NN	npadvmod
----	NFP	punct
(	-LRB-	punct
2015	CD	npadvmod
)	-RRB-	punct
)	-RRB-	punct
.	.	punct

 	_SP	

Teva	NNP	nsubj
contend	VBZ	ROOT
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
erroneously	RB	advmod
construe	VBD	ccomp
certain	JJ	amod
claim	NN	compound
term	NNS	dobj
as	IN	prep
non	JJ	subtok
-	JJ	subtok
limiting	JJ	pobj
and	CC	cc
disregard	VBD	conj
-PRON-	PRP	dobj
for	IN	prep
nonobviousness	NN	compound
purpose	NNS	pobj
.	.	punct

teva	JJ	amod
point	NNS	ROOT
to	IN	prep
the	DT	det
"	``	punct
sufficiency	NN	nmod
"	''	punct
term	NNS	pobj
of	IN	prep
the	DT	det
'	``	punct
250	CD	nummod
and	CC	cc
'	``	punct
413	CD	conj
patent	NNS	pobj
as	IN	prep
be	VBG	aux
limit	VBG	pcomp
.	.	punct

Claim	NNP	nsubj
1	CD	nummod
of	IN	prep
the	DT	det
'	``	punct
250	CD	nummod
patent	NN	compound
recite	NNS	ROOT
"	``	punct
a	DT	det
method	NN	dobj
of	IN	prep
alleviate	VBG	pcomp
a	DT	det
symptom	NN	dobj
of	IN	prep
relapse	VBG	npadvmod
-	HYPH	punct
remit	VBG	amod
multiple	JJ	amod
sclerosis	NN	pobj
...	:	punct
comprise	VBG	advcl
administer	VBG	xcomp
to	IN	prep
the	DT	det
human	JJ	amod
patient	NN	pobj
a	DT	det
therapeutically	RB	advmod
effective	JJ	amod
regiman	NNS	dobj
...	NFP	punct
,	,	punct
the	DT	det
regiman	NNS	nsubj
be	VBG	ccomp
sufficient	JJ	acomp
to	TO	aux
alleviate	VB	xcomp
the	DT	det
symptom	NN	dobj
of	IN	prep
the	DT	det
patient	NN	pobj
"	''	punct
.	.	punct
'	''	punct
250	CD	nummod
patent	NN	compound
col.	NN	dep
16	CD	nummod
will	NN	intj
.	.	punct

35	CD	nummod
-	SYM	punct
45	CD	prep
(	-LRB-	punct
emphasis	NN	nsubj
add	VBN	ROOT
)	-RRB-	punct
.	.	punct

similarly	RB	advmod
,	,	punct
claim	VBZ	ROOT
1	CD	dobj
and	CC	cc
20	CD	conj
of	IN	prep
the	DT	det
'	``	punct
413	CD	nummod
patent	NN	pobj
both	DT	nsubj
recite	JJ	acl
"	``	punct
a	DT	det
method	NN	dobj
...	NFP	punct
comprise	VBG	acl
administer	VBG	xcomp
to	IN	prep
the	DT	det
human	JJ	amod
patient	NN	pobj
a	DT	det
therapeutically	RB	advmod
effective	JJ	amod
dosage	NN	compound
regiman	NNS	dobj
...	NFP	punct
,	,	punct
the	DT	det
regiman	NNS	nsubj
be	VBG	advcl
sufficient	JJ	acomp
to	TO	aux
reduce	VB	xcomp
the	DT	det
frequency	NN	dobj
of	IN	prep
relapse	NNS	pobj
in	IN	prep
the	DT	det
patient	NN	pobj
"	''	punct
.	.	punct
'	''	punct
413	CD	nummod
patent	NN	compound
col.	NN	npadvmod
16	CD	nummod
will	NN	intj
.	.	punct

26	CD	nummod
-	SYM	punct
36	CD	prep
,	,	punct
col.	NN	ROOT
18	CD	nummod

will	NN	ROOT
.	.	punct

14	CD	nummod
-	SYM	punct
27	CD	prep
(	-LRB-	punct
emphasis	NN	nsubj
add	VBN	ROOT
)	-RRB-	punct
.	.	punct

Teva	NNP	nsubj
also	RB	advmod
contest	VBZ	ROOT
the	DT	det
district	NN	compound
court	NN	poss
's	POS	case
construction	NN	dobj
of	IN	prep
the	DT	det
"	``	punct
reduced	JJ	amod
frequency	NN	pobj
of	IN	prep
relapse	NN	amod
"	''	punct
term	NNS	pobj
and	CC	cc
"	``	punct
effectiveness	NN	nmod
"	''	punct
term	NNS	conj
in	IN	prep
the	DT	det
'	``	punct
776	CD	nummod
patent	NN	pobj
as	IN	prep
non	JJ	subtok
-	JJ	subtok
limiting	JJ	pobj
.	.	punct

For	IN	prep
example	NN	pobj
,	,	punct
claim	NN	ROOT
5	CD	dobj
of	IN	prep
the	DT	det
'	``	punct
776	CD	nummod
patent	NN	compound
describe	VBZ	ccomp
"	``	punct
a	DT	det
method	NN	dobj
for	IN	prep
reduce	VBG	pcomp
the	DT	det
frequency	NN	dobj
of	IN	prep
relapse	NNS	pobj
"	''	punct
;	:	punct
claim	VBZ	conj
6	CD	npadvmod
,	,	punct
16	CD	npadvmod
,	,	punct
and	CC	cc
17	CD	nsubj
contain	VBP	conj
similar	JJ	amod
limitation	NNS	dobj
.	.	punct
'	''	punct
776	CD	nummod
patent	NN	compound
col.	NN	conj
16	CD	nummod
will	NN	intj
.	.	punct

61	CD	nummod
-	SYM	punct
65	CD	prep
,	,	punct
col.	NN	ROOT
17	CD	nummod

will	NN	ROOT
.	.	punct

20	CD	nummod
-	SYM	punct
22	CD	prep
,	,	punct
65	CD	npadvmod
-	SYM	punct
66	CD	prep
,	,	punct
col.	NN	ROOT
18	CD	nummod
will	NN	intj
.	.	punct

23	CD	ROOT
-	SYM	punct
25	CD	prep
.	.	punct

Claim	NNP	nsubj
12	CD	nummod
describe	VBZ	ROOT
"	``	punct
a	DT	det
method	NN	dobj
for	IN	prep
improve	VBG	pcomp
the	DT	det
tolerability	NN	dobj
of	IN	prep
glatiramer	NN	nmod
acetate	JJ	amod
treatment	NN	pobj
of	IN	prep
a	DT	det
human	JJ	amod
patient	NN	compound
suffering	NN	pobj
from	IN	prep
a	DT	det
relapse	VBG	amod
form	NN	pobj
of	IN	prep
multiple	JJ	amod
sclerosis	NN	pobj
which	WDT	nsubj
be	VBZ	relcl
as	RB	advmod
effective	JJ	acomp
as	IN	prep
administration	NN	pobj
of	IN	prep
20	CD	nummod
mg	NN	pobj
of	IN	prep
glatiramer	NN	compound
acetate	VBP	pobj
s.c	NNP	pobj
.	.	punct
daily	RB	advmod
,	,	punct
"	''	punct
and	CC	cc
claim	VBZ	conj
16	CD	nummod
and	CC	cc
17	CD	conj
contain	VBP	ccomp
similar	JJ	amod
limitation	NNS	dobj
.	.	punct

Idaho	NNP	nsubj
col.	NNP	ROOT
17	CD	nummod
will	NN	intj
.	.	punct

36	CD	nummod
-	SYM	punct
40	CD	prep
(	-LRB-	punct
emphasis	NN	nsubj
add	VBN	ROOT
)	-RRB-	punct
,	,	punct
col.	NN	npadvmod

col.	NN	ROOT
,	,	punct
col.	NN	prep
18	CD	nummod
will	NN	intj
.	.	punct

23	CD	ROOT
-	SYM	punct
25	CD	prep
.	.	punct

 	_SP	

the	DT	det
district	NN	compound
court	NN	nsubj
construe	VBD	ROOT
these	DT	det
term	NNS	nsubj
to	TO	aux
be	VB	ccomp
non	JJ	subtok
-	JJ	subtok
limiting	JJ	amod
statement	NNS	attr
of	IN	prep
intend	VBN	amod
effect	NN	pobj
,	,	punct
hold	VBG	advcl
that	IN	mark
those	DT	det
term	NNS	nsubj
be	VBP	ccomp
"	``	punct
strikingly	RB	advmod
similar	JJ	acomp
to	IN	prep
those	DT	pobj
in	IN	prep
the	DT	det
patent	NNS	pobj
in	IN	prep

Bristol	NNP	compound
-	HYPH	punct
Myers	NNP	compound
Squibb	NNP	compound
Co.	NNP	subtok
v.	IN	ROOT

Ben	NNP	compound
Venue	NNP	nmod
Laboratories	NNP	nmod
,	,	punct
Inc.	NNP	ROOT
,	,	punct
246	CD	nummod
f.3d	CD	appos
1368	CD	nummod
(	-LRB-	punct
Fed	NNP	appos
.	.	punct
Cir	NNP	subtok
.	.	punct
2001	CD	nummod
)	-RRB-	punct
.	.	punct
"	''	punct
Claim	NNP	compound
Construction	NNP	compound
order	NN	conj
,	,	punct
2016	CD	nummod
WL	NNP	appos
873062	CD	nummod
,	,	punct
at	IN	prep
n.2	NNP	pobj
.	.	punct

In	IN	prep
Bristol	NNP	compound
-	HYPH	punct
Myers	NNP	pobj
,	,	punct
the	DT	det
court	NN	nsubj
hold	VBD	ROOT
that	IN	mark
certain	JJ	amod
term	NNS	nsubj
be	VBD	aux
non	JJ	subtok
-	JJ	subtok
limiting	JJ	ccomp
because	IN	mark
-PRON-	PRP	nsubj
"	''	punct
merely	RB	advmod
express	VBD	advcl
a	DT	det
purpose	NN	dobj
"	''	punct
and	CC	cc
"	``	punct
only	RB	advmod
state	VBD	conj
an	DT	det
intend	VBN	amod
result	NN	dobj
of	IN	prep
the	DT	det
claim	VBN	amod
method	NN	pobj
"	''	punct
.	.	punct

246	CD	nummod
f.3d	CD	ROOT
at	IN	prep
1374	CD	pobj
-	SYM	punct
75	CD	prep
.	.	punct

the	DT	det
court	NN	nsubj
state	VBD	ROOT
that	IN	mark
express	VBP	amod
dosage	NN	compound
amount	NNS	nsubj
be	VBP	ccomp
material	JJ	compound
claim	NN	compound
limitation	NNS	attr
,	,	punct
but	CC	cc
statement	NNS	nsubj
of	IN	prep
intend	VBN	amod
result	NNS	pobj
from	IN	prep
-PRON-	PRP$	poss
administration	NN	pobj
,	,	punct
such	JJ	amod
as	IN	prep
"	``	punct
an	DT	det
antineo	NNS	amod
-	,	punct
plastically	RB	advmod
effective	JJ	amod
amount	NN	pobj
,	,	punct
"	''	punct
"	``	punct
do	VBZ	aux
not	RB	neg
change	VB	conj
those	DT	det
amount	NNS	dobj
or	CC	cc
otherwise	RB	advmod
limit	VB	conj
the	DT	det
claim	NN	dobj
"	''	punct
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
1375	CD	pobj
.	.	punct

claim	JJ	compound
language	NN	nsubjpass
without	IN	prep
any	DT	det
bearing	NN	pobj
on	IN	prep
the	DT	det
claim	VBN	amod
method	NNS	pobj
should	MD	aux
be	VB	auxpass
deem	VBN	ROOT
non	JJ	subtok
-	JJ	subtok
limiting	JJ	oprd
when	WRB	advmod
-PRON-	PRP	nsubj
do	VBZ	aux
not	RB	neg
result	VB	advcl
in	IN	prep
"	``	punct
a	DT	det
manipulative	JJ	amod
difference	NN	pobj
in	IN	prep
the	DT	det
step	NNS	pobj
of	IN	prep
the	DT	det
claim	NN	pobj
"	''	punct
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
1376	CD	pobj
.	.	punct

 	_SP	

-PRON-	PRP	nsubj
see	VBP	ROOT
no	DT	det
meaningful	JJ	amod
difference	NN	dobj
between	IN	prep
the	DT	det
claim	NNS	pobj
in	IN	prep
Bristol	NNP	compound
-	HYPH	punct
Myers	NNP	pobj
and	CC	cc
those	DT	conj
at	IN	prep
issue	NN	pobj
here	RB	advmod
.	.	punct

the	DT	det
phrase	NN	nsubj
"	``	punct
the	DT	det
regiman	NNS	nsubj
be	VBG	acl
sufficient	JJ	acomp
to	TO	aux
reduce	VB	xcomp
the	DT	det
frequency	NN	dobj
of	IN	prep
relapse	NNS	pobj
in	IN	prep
the	DT	det
patient	NN	pobj
"	''	punct
do	VBZ	aux
not	RB	neg
change	VB	ROOT
the	DT	det
express	JJ	amod
dosing	NN	compound
amount	NN	dobj
or	CC	cc
method	NN	conj
already	RB	advmod
disclose	VBN	acl
in	IN	prep
the	DT	det
claim	NNS	pobj
,	,	punct
or	CC	cc
otherwise	RB	advmod
result	VBP	conj
in	IN	prep
a	DT	det
manipulative	JJ	amod
difference	NN	pobj
in	IN	prep
the	DT	det
step	NNS	pobj
of	IN	prep
the	DT	det
claim	NNS	pobj
.	.	punct

the	DT	det
claim	NNS	nsubj
be	VBP	ccomp
clear	JJ	acomp
that	IN	mark
the	DT	det
dosing	NN	nsubj
have	VBZ	ccomp
to	TO	aux
be	VB	xcomp
"	``	punct
therapeutically	RB	advmod
effective	JJ	amod
regiman	NNS	attr
"	''	punct
;	:	punct
the	DT	det
addition	NN	nsubj
of	IN	prep
"	``	punct
the	DT	det
regiman	NNS	nsubj
be	VBG	pcomp
sufficient	JJ	acomp
to	TO	aux
"	``	punct
be	VB	xcomp
therapeutically	RB	advmod
effective	JJ	acomp
be	VBZ	ROOT
superfluous	JJ	acomp
,	,	punct
do	VBZ	aux
not	RB	neg
change	VB	conj
the	DT	det
claim	VBN	amod
method	NN	dobj
or	CC	cc
require	VB	conj
any	DT	det
additional	JJ	amod
require	VBN	amod
structure	NN	dobj
or	CC	cc
condition	NN	conj
for	IN	prep
the	DT	det
claim	NNS	pobj
,	,	punct
and	CC	cc
be	VBZ	conj
therefore	RB	advmod
non	JJ	subtok
-	JJ	subtok
limiting	JJ	acomp
.	.	punct

 	_SP	

Teva	NNP	nsubj
argue	VBZ	ROOT
that	IN	mark
the	DT	det
"	``	punct
'	``	punct
sufficiency	NN	poss
'	POS	punct
term	NNS	nsubjpass
be	VBD	auxpass
add	VBN	ccomp
during	IN	prep
prosecution	NN	pobj
to	TO	aux
overcome	VB	acl
rejection	NNS	dobj
"	''	punct
.	.	punct

appellant	NNS	ROOT
'	POS	case
Opening	NNP	compound
Br	NNP	appos
.	.	punct

74	CD	ROOT
.	.	punct

Teva	NNP	nsubj
overstate	VBZ	ROOT
the	DT	det
intrinsic	JJ	amod
record	NN	dobj
.	.	punct

Claim	NNP	nsubjpass
1	CD	nummod
of	IN	prep
the	DT	det
'	``	punct
250	CD	nummod
patent	NN	pobj
be	VBD	auxpass
amend	VBN	ROOT
to	TO	aux
overcome	VB	advcl
a	DT	det
¡±	CD	compound
112	CD	nummod
rejection	NN	dobj
base	VBN	acl
on	IN	prep
the	DT	det
examiner	NN	poss
's	POS	case
read	NN	pobj
of	IN	prep
the	DT	det
claim	NNS	pobj
prior	RB	advmod
to	IN	aux
amendment	NN	advcl
as	IN	prep
permit	VBG	pcomp
only	RB	advmod
a	DT	det
single	JJ	amod
seven	CD	nummod
-	HYPH	punct
day	NN	compound
period	NN	dobj
of	IN	prep
administration	NN	pobj
,	,	punct
rather	RB	advmod
than	IN	cc
an	DT	det
ongoing	JJ	amod
treatment	NN	compound
regimen	NN	pobj
.	.	punct

see	VB	ROOT
J.A.	NNP	dobj
26417	CD	nummod
-	SYM	punct
18	CD	prep
,	,	punct
26464	CD	npadvmod
-	SYM	punct
65	CD	prep
(	-LRB-	punct
same	JJ	appos
,	,	punct
for	IN	prep
the	DT	det
'	``	punct
413	CD	nummod
patent	NN	pobj
)	-RRB-	punct
.	.	punct

the	DT	det
claim	NN	nsubjpass
be	VBD	auxpass
amend	VBN	ROOT
to	TO	aux
replace	VB	xcomp
the	DT	det
ambiguous	JJ	amod
"	''	punct
therapeutically	RB	advmod
effective	JJ	amod
dose	NN	dobj
"	''	punct
with	IN	prep
"	``	punct
therapeutically	RB	advmod
effective	JJ	amod
regiman	NNS	pobj
of	IN	prep
,	,	punct
"	''	punct
as	IN	mark
follow	VBZ	advcl
:	:	punct

 	_SP	

1	CD	ROOT
.	.	punct
(	-LRB-	punct
currently	RB	advmod
amend	VBN	punct
)	-RRB-	punct

a	DT	det
method	NN	ROOT
of	IN	prep
alleviate	VBG	pcomp
a	DT	det
symptom	NN	dobj
of	IN	prep
relapse	VBG	npadvmod
-	HYPH	punct
remit	VBG	amod
multiple	JJ	amod
sclerosis	NN	pobj
in	IN	prep
a	DT	det
human	JJ	amod
patient	NN	compound
suffering	NN	pobj
from	IN	prep
relapse	VBG	npadvmod
-	HYPH	punct
remit	VBG	amod
multiple	JJ	amod
sclerosis	NN	pobj
or	CC	cc
a	DT	det
patient	NN	conj
who	WP	nsubj
have	VBZ	aux
experience	VBN	relcl
a	DT	det
first	JJ	amod
clinical	JJ	amod
episode	NN	dobj
and	CC	cc
be	VBZ	conj
determined	JJ	acomp
to	TO	aux
be	VB	xcomp
at	IN	prep
high	JJ	amod
risk	NN	pobj
of	IN	prep
develop	VBG	pcomp
clinically	RB	advmod
definite	JJ	amod
multiple	JJ	amod
sclerosis	NN	nsubj
comprising	NN	ccomp
administer	VBG	xcomp
to	IN	prep
the	DT	det
human	JJ	amod
patient	NN	pobj
a	DT	det
therapeutically	RB	advmod
effective	JJ	amod
regiman	NNS	dobj
of	IN	prep
three	CD	nummod
subcutaneous	JJ	amod
injection	NNS	pobj
of	IN	prep
a	DT	det
therapeutically	RB	advmod
effective	JJ	amod
40	CD	nummod
mg	NN	compound
dose	NN	pobj
of	IN	prep
glatiramer	NN	pobj
acetate	VBP	amod
over	IN	prep
a	DT	det
period	NN	pobj
of	IN	prep
seven	CD	nummod
day	NNS	pobj
with	IN	prep
at	RB	advmod
least	RBS	advmod
one	CD	nummod
day	NN	pobj
between	IN	prep
every	DT	det
subcutaneous	JJ	amod
injection	NN	pobj
,	,	punct
the	DT	det
regiman	NNS	nsubj
be	VBG	acl
sufficient	JJ	acomp
so	IN	mark
as	IN	mark
to	TO	aux
thereby	RB	advmod
alleviate	VB	advcl
the	DT	det
symptom	NN	dobj
of	IN	prep
the	DT	det
patient	NN	pobj
.	.	punct

 	_SP	
"	''	punct

As	IN	mark
amend	VBD	advcl
the	DT	det
claim	NNS	dobj
can	MD	aux
not	RB	neg
be	VB	auxpass
reasonably	RB	advmod
construe	VBN	ccomp
to	TO	aux
read	VB	xcomp
on	RP	prep
only	RB	advmod
a	DT	det
single	JJ	amod
seven	CD	nummod
day	NN	compound
period	NN	pobj
of	IN	prep
administration	NN	pobj
,	,	punct
at	IN	advmod
least	JJS	advmod
because	IN	mark
the	DT	det
claim	NNS	nsubj
as	IN	prep
amend	VBN	amod
require	VBP	advcl
a	DT	det
'	``	punct
regimen	NN	dobj
.	.	punct
'	''	punct
"	``	punct
J.A.	NNP	nsubj
26436	CD	nummod
;	:	punct
see	VB	ROOT
also	RB	advmod
J.A.	NNP	nsubj
26483	CD	nummod
(	-LRB-	punct
same	JJ	appos
,	,	punct
for	IN	prep
the	DT	det
'	``	punct
413	CD	nummod
patent	NN	pobj
)	-RRB-	punct
.	.	punct

give	VBN	prep
this	DT	det
evidence	NN	pobj
,	,	punct
the	DT	det
addition	NN	nsubj
of	IN	prep
"	``	punct
a	DT	det
therapeutically	RB	advmod
effective	JJ	amod
regiman	NNS	pobj
"	''	punct
would	MD	aux
have	VB	ROOT
alone	RB	advmod
be	VBN	conj
sufficient	JJ	acomp
to	TO	aux
overcome	VB	xcomp
the	DT	det
rejection	NN	dobj
,	,	punct
and	CC	cc
thus	RB	advmod
-PRON-	PRP	nsubjpass
be	VBP	auxpass
unpersuade	VBN	conj
by	IN	agent
Teva	NNP	poss
's	POS	case
contention	NN	pobj
that	IN	mark
addition	NN	nsubj
of	IN	prep
the	DT	det
"	``	punct
regimen	NN	pobj
be	VBG	acl
sufficient	JJ	acomp
...	:	punct
"	``	punct
term	NN	nsubj
be	VBD	conj
necessary	JJ	acomp
or	CC	cc
relevant	JJ	conj
to	IN	prep
the	DT	det
examiner	NN	poss
's	POS	case
approval	NN	pobj
.	.	punct

accordingly	RB	advmod
,	,	punct
-PRON-	PRP	nsubj
find	VBP	ROOT
no	DT	det
error	NN	dobj
in	IN	prep
the	DT	det
district	NN	compound
court	NN	poss
's	POS	case
construction	NN	pobj
.	.	punct

 	_SP	

II	NNP	ROOT
.	.	punct

obviousness	JJ	ROOT
under	IN	prep
35	CD	pobj
u.s.c.	NN	pobj
¡±	CD	nummod
103	CD	nummod

 	_SP	

under	IN	prep
35	CD	pobj
U.S.C.	NNP	subtok
¡±	NNP	npadvmod
103(a	CD	subtok
)	-RRB-	punct
,	,	punct
a	DT	det
patent	NN	nsubjpass
may	MD	aux
not	RB	neg
be	VB	auxpass
obtain	VBN	ROOT
"	''	punct
if	IN	mark
the	DT	det
difference	NNS	nsubj
between	IN	prep
the	DT	det
subject	JJ	amod
matter	NN	pobj
seek	VBD	advcl
to	TO	aux
be	VB	auxpass
patent	VBN	xcomp
and	CC	cc
the	DT	det
prior	JJ	amod
art	NN	nsubj
be	VBP	conj
such	JJ	acomp
that	IN	mark
the	DT	det
subject	JJ	amod
matter	NN	nsubj
as	IN	prep
a	DT	det
whole	NN	pobj
would	MD	aux
have	VB	aux
be	VBN	ccomp
obvious	JJ	acomp
at	IN	prep
the	DT	det
time	NN	pobj
the	DT	det
invention	NN	nsubjpass
be	VBD	auxpass
make	VBN	relcl
to	IN	prep
a	DT	det
person	NN	pobj
have	VBG	acl
ordinary	JJ	amod
skill	NN	dobj
in	IN	prep
the	DT	det
art	NN	pobj
"	''	punct
.	.	punct

35	CD	nummod
u.s.c.	NN	npadvmod
¡±	NNP	nummod
103(a	CD	ccomp
)	-RRB-	punct
(	-LRB-	punct
2006).13	CD	nummod
Obviousness	NNP	nsubj
be	VBZ	ROOT
a	DT	det
question	NN	attr
of	IN	prep
law	NN	pobj
with	IN	prep
underlie	VBG	amod
factual	JJ	amod
finding	NNS	pobj
relate	VBG	acl
to	IN	prep
the	DT	det
scope	NN	pobj
and	CC	cc
content	NN	conj
of	IN	prep
the	DT	det
prior	JJ	amod
art	NN	pobj
;	:	punct

the	DT	det
difference	NNS	ROOT
between	IN	prep
the	DT	det
claim	NNS	pobj
and	CC	cc
the	DT	det
prior	JJ	amod
art	NN	conj
;	:	punct
the	DT	det
level	NN	conj
of	IN	prep
ordinary	JJ	amod
skill	NN	pobj
in	IN	prep
the	DT	det
pertinent	JJ	amod
art	NN	pobj
;	:	punct
and	CC	cc
any	DT	det
secondary	JJ	amod
consideration	NNS	conj
of	IN	prep
non	JJ	subtok
-	JJ	subtok
obviousness	JJ	pobj
.	.	punct

ZUP	NNP	ROOT
,	,	punct
LLC	NNP	conj
v.	CC	prep

Nash	NNP	compound
Mfg	NNP	subtok
.	NNP	ROOT
,	,	punct
Inc.	NNP	npadvmod
,	,	punct
896	CD	nummod
f.3d	CD	appos
1365	CD	appos
,	,	punct
1371	CD	npadvmod
(	-LRB-	punct
Fed	NNP	appos
.	.	punct
Cir	NNP	subtok
.	.	punct
2018	CD	npadvmod
)	-RRB-	punct
(	-LRB-	punct
cite	VBG	acl
Graham	NNP	dobj
v.	IN	prep
John	NNP	compound
Deere	NNP	compound
Co.	NNP	conj
of	IN	prep
Kansas	NNP	compound
City	NNP	pobj
,	,	punct
383	CD	nummod
U.S.	NNP	appos
1	CD	nummod
,	,	punct
17	CD	npadvmod
-	SYM	punct
18	CD	prep
,	,	punct
86	CD	nummod
S.Ct	NNP	subtok
.	.	npadvmod
684	CD	npadvmod
,	,	punct
15	CD	nummod
l.ed.2d	NN	npadvmod
545	CD	nummod
(	-LRB-	punct
1966	CD	appos
)	-RRB-	punct
)	-RRB-	punct
.	.	punct

the	DT	det
inherent	JJ	amod
teaching	NN	nsubj
of	IN	prep
a	DT	det
prior	JJ	amod
art	NN	compound
reference	NN	pobj
be	VBZ	ROOT
a	DT	det
question	NN	attr
of	IN	prep
fact	NN	pobj
.	.	punct

Par	NNP	compound
Pharm.	NNP	ROOT
,	,	punct
Inc.	NNP	npadvmod
v.	IN	prep
TWI	NNP	nmod
Pharm.	NNP	nmod
,	,	punct
Inc.	NNP	pobj
,	,	punct
773	CD	nummod
F.3d	NNP	appos
1186	CD	nummod
,	,	punct
1194	CD	conj
(	-LRB-	punct
Fed	NNP	appos
.	.	punct
Cir	NNP	subtok
.	.	punct
2014	CD	nummod
)	-RRB-	punct
.	.	punct

 	_SP	

After	IN	prep
a	DT	det
bench	NN	compound
trial	NN	pobj
,	,	punct
-PRON-	PRP	nsubj
review	VBP	ROOT
a	DT	det
district	NN	compound
court	NN	poss
's	POS	case
conclusion	NNS	dobj
of	IN	prep
law	NN	nmod
de	FW	nmod
novo	NN	pobj
and	CC	cc
-PRON-	PRP$	poss
finding	NNS	conj
of	IN	prep
fact	NN	pobj
for	IN	prep
clear	JJ	amod
error	NN	pobj
.	.	punct

Senju	NNP	compound
Pharm.	NNP	subtok
Co.	NNP	dep
v.	IN	prep
Lupin	NNP	compound
Ltd.	NNP	pobj
,	,	punct
780	CD	nummod
f.3d	CD	appos
1337	CD	nummod
,	,	punct
1341	CD	npadvmod
(	-LRB-	punct
Fed	NNP	ROOT
.	.	punct
Cir	NNP	subtok
.	.	punct
2015	CD	nummod
)	-RRB-	punct
.	.	punct

a	DT	det
factual	JJ	amod
finding	NN	nsubj
be	VBZ	ROOT
clearly	RB	advmod
erroneous	JJ	acomp
if	IN	mark
the	DT	det
Court	NNP	nsubjpass
be	VBZ	auxpass
leave	VBN	advcl
with	IN	prep
"	``	punct
the	DT	det
definite	JJ	amod
and	CC	cc
firm	JJ	conj
conviction	NN	pobj
that	IN	mark
a	DT	det
mistake	NN	nsubjpass
have	VBZ	aux
be	VBN	auxpass
commit	VBN	acl
"	''	punct
.	.	punct

United	NNP	compound
States	NNP	ROOT
v.	IN	prep
U.S.	NNP	compound
Gypsum	NNP	compound
Co.	NNP	pobj
,	,	punct
333	CD	nummod
U.S.	NNP	appos
364	CD	nummod
,	,	punct
395	CD	appos
,	,	punct

68	CD	nummod
s.ct	NN	subtok
.	.	ROOT

525	CD	ROOT
,	,	punct
92	CD	nummod
L.Ed	NNS	appos
.	.	punct

746	CD	ROOT
(	-LRB-	punct
1948	CD	appos
)	-RRB-	punct
.	.	punct

 	_SP	

On	IN	prep
appeal	NN	pobj
,	,	punct
Teva	NNP	nsubj
dispute	VBZ	ROOT
that	IN	mark
the	DT	det
40	CD	nummod
mg	NN	nmod
GA	NNP	compound
3x	NNP	nmod
/	SYM	punct
week	NN	compound
dosing	NN	compound
regiman	NNS	nsubj
disclose	VBN	acl
in	IN	prep
the	DT	det
Copaxone	NNP	compound
patent	NNS	pobj
would	MD	aux
have	VB	aux
be	VBN	ccomp
obvious	JJ	acomp
to	IN	prep
a	DT	det
person	NN	pobj
of	IN	prep
skill	NN	pobj
in	IN	prep
the	DT	det
art	NN	pobj
.	.	punct

Teva	NNP	nsubj
also	RB	advmod
appeal	VBZ	ROOT
the	DT	det
invalidation	NN	dobj
of	IN	prep
claim	NN	compound
limitation	NNS	pobj
in	IN	prep
the	DT	det
'	``	punct
250	CD	nummod
and	CC	cc
'	``	punct
413	CD	conj
patent	NNS	pobj
relate	VBG	acl
to	IN	prep
improved	JJ	amod
tolerability	NN	pobj
and	CC	cc
reduce	VBN	amod
frequency	NN	conj
of	IN	prep
adverse	JJ	amod
effect	NNS	pobj
,	,	punct
and	CC	cc
the	DT	det
invalidation	NN	conj
of	IN	prep
the	DT	det
'	``	punct
776	CD	nummod
patent	NN	poss
's	POS	case
claim	NNS	pobj
relate	VBG	acl
to	IN	prep
reduced	JJ	amod
severity	NN	pobj
of	IN	prep
injection	NN	compound
site	NN	compound
reaction	NNS	pobj
.	.	punct

Teva	NNP	nsubj
do	VBZ	aux
not	RB	neg
appeal	VB	ROOT
on	IN	prep
the	DT	det
objective	JJ	amod
indicia	NN	pobj
of	IN	prep
nonobviousness	NN	pobj
.	.	punct

-PRON-	PRP	nsubj
address	VBP	ROOT
each	DT	det
argument	NN	dobj
in	IN	prep
turn	NN	pobj
.	.	punct

 	_SP	

a.	NN	nmod
40	CD	nummod
mg	NN	nmod
GA	NNP	compound
3x	NNP	nmod
/	SYM	punct
week	NN	compound
Dosing	NNP	compound
Regimen	NNP	ROOT

 	_SP	

Teva	NNP	nsubj
contend	VBZ	ROOT
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
err	VBD	ccomp
in	IN	prep
find	VBG	pcomp
the	DT	det
claim	VBN	amod
40	CD	nummod
mg	NN	nmod
GA	NNP	compound
3x	NNP	nmod
/	SYM	punct
week	NN	npadvmod
dosing	NN	amod
regiman	NNS	nsubj
obvious	JJ	ccomp
.	.	punct

specifically	RB	advmod
,	,	punct
Teva	NNP	nsubj
argue	VBZ	ROOT
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
impermissibly	RB	advmod
rely	VBD	ccomp
on	IN	prep
hindsight	NN	pobj
and	CC	cc
an	DT	det
improper	JJ	amod
"	''	punct
obvious	JJ	conj
to	TO	aux
try	VB	advcl
"	''	punct
analysis	NN	dobj
,	,	punct
and	CC	cc
analyze	VBD	conj
the	DT	det
obviousness	NN	dobj
of	IN	prep
individual	JJ	amod
claim	NN	compound
element	NNS	pobj
,	,	punct
rather	RB	advmod
than	IN	cc
the	DT	det
invention	NN	pobj
as	IN	prep
a	DT	det
whole	NN	pobj
.	.	punct

Teva	NNP	nsubj
further	RB	advmod
maintain	VBZ	ROOT
that	IN	mark
the	DT	det
district	NN	compound
court	NN	poss
's	POS	case
decision	NN	nsubj
be	VBZ	ccomp
at	IN	prep
odd	NNS	pobj
with	IN	prep
this	DT	det
court	NN	poss
's	POS	case
decision	NN	pobj
in	IN	prep

In	IN	ROOT
re	IN	pobj
Cyclobenzaprine	NNP	compound
Hydrochloride	NNP	compound
Extended	NNP	compound
-	HYPH	punct
Release	NNP	compound
Capsule	NNP	compound
Patent	NNP	compound
Litigation	NNP	pobj
,	,	punct
676	CD	nummod
f.3d	CD	appos
1063	CD	nummod
(	-LRB-	punct
Fed	NNP	appos
.	.	punct
Cir	NNP	subtok
.	.	punct
2012	CD	nummod
)	-RRB-	punct
.	.	punct

 	_SP	

-PRON-	PRP	nsubj
first	RB	advmod
address	NN	ROOT
Teva	NNP	poss
's	POS	case
contention	NN	dobj
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
engage	VBD	acl
in	IN	prep
an	DT	det
impermissible	JJ	amod
"	''	punct
obvious	JJ	pobj
to	TO	aux
try	VB	xcomp
"	''	punct
analysis	NN	dobj
.	.	punct

In	IN	prep
KSR	NNP	pobj
,	,	punct
the	DT	det
Supreme	NNP	compound
Court	NNP	nsubj
endorse	VBD	ROOT
the	DT	det
use	NN	dobj
of	IN	prep
an	DT	det
"	``	punct
obvious	JJ	pobj
to	TO	aux
try	VB	relcl
"	''	punct
analysis	NN	dobj
in	IN	prep
certain	JJ	amod
case	NNS	pobj
:	:	punct

 	_SP	

when	WRB	advmod
there	EX	expl
be	VBZ	advcl
a	DT	det
design	NN	compound
need	NN	attr
or	CC	cc
market	NN	compound
pressure	NN	conj
to	TO	aux
solve	VB	acl
a	DT	det
problem	NN	dobj
and	CC	cc
there	EX	expl
be	VBP	conj
a	DT	det
finite	JJ	amod
number	NN	attr
of	IN	prep
identify	VBN	amod
,	,	punct
predictable	JJ	amod
solution	NNS	pobj
,	,	punct
a	DT	det
person	NN	nsubj
of	IN	prep
ordinary	JJ	amod
skill	NN	pobj
have	VBZ	ROOT
good	JJ	amod
reason	NN	dobj
to	TO	aux
pursue	VB	relcl
the	DT	det
know	VBN	amod
option	NNS	dobj
within	IN	prep
-PRON-	PRP$	poss
or	CC	cc
-PRON-	PRP$	poss
technical	JJ	amod
grasp	NN	pobj
.	.	punct

If	IN	mark
this	DT	nsubj
lead	VBZ	advcl
to	IN	prep
the	DT	det
anticipate	VBN	amod
success	NN	pobj
,	,	punct
-PRON-	PRP	nsubj
be	VBZ	ROOT
likely	RB	acomp
the	DT	det
product	NN	attr
not	RB	neg
of	IN	prep
innovation	NN	pobj
but	CC	cc
of	IN	conj
ordinary	JJ	amod
skill	NN	pobj
and	CC	cc
common	JJ	amod
sense	NN	conj
.	.	punct

In	IN	prep
that	DT	det
instance	NN	pobj
the	DT	det
fact	NN	nsubj
that	IN	mark
a	DT	det
combination	NN	nsubj
be	VBD	acl
obvious	JJ	acomp
to	TO	aux
try	VB	xcomp
may	MD	aux
show	VB	ROOT
that	IN	mark
-PRON-	PRP	nsubj
be	VBD	ccomp
obvious	JJ	acomp
under	IN	prep
¡±	NNP	pobj
103	CD	nummod
.	.	punct

 	_SP	

KSR	NNP	compound
Int'l	NNP	compound
Co.	NNP	ROOT
v.	CC	prep
Teleflex	NNP	compound
Inc.	NNP	pobj
,	,	punct
550	CD	nummod
U.S.	NNP	appos
398	CD	nummod
,	,	punct
421	CD	nummod
,	,	punct
127	CD	nummod
S.Ct	NNP	subtok
.	.	punct

1727	CD	ROOT
,	,	punct
167	CD	nummod
l.ed.2d	NN	appos
705	CD	nummod
(	-LRB-	punct
2007	CD	npadvmod
)	-RRB-	punct
.	.	punct

 	_SP	

-PRON-	PRP	nsubj
have	VBP	aux
previously	RB	advmod
identify	VBN	ccomp
two	CD	nummod
category	NNS	dobj
of	IN	prep
impermissible	JJ	amod
"	''	punct
obvious	JJ	pobj
to	TO	aux
try	VB	xcomp
"	''	punct
analysis	NNS	dobj
that	WDT	nsubj
run	VBP	relcl
afoul	RB	advmod
of	IN	prep
KSR	NNP	pobj
and	CC	cc
¡±	NNP	dobj
103	CD	nummod
:	:	punct
when	WRB	advmod
what	WP	nsubj
be	VBD	advcl
"	``	punct
obvious	JJ	acomp
to	TO	aux
try	VB	xcomp
"	``	punct
be	VBD	ROOT
(	-LRB-	punct
a	DT	attr
)	-RRB-	punct
to	TO	aux
vary	VB	xcomp
all	DT	det
parameter	NNS	dobj
or	CC	cc
try	VB	conj
every	DT	det
available	JJ	amod
option	NN	dobj
until	IN	mark
one	CD	nummod
succeed	VBZ	nsubj
,	,	punct
where	WRB	advmod
the	DT	det
prior	JJ	amod
art	NN	nsubj
give	VBD	relcl
no	DT	det
indication	NN	dobj
of	IN	prep
critical	JJ	amod
parameter	NNS	pobj
and	CC	cc
no	DT	det
direction	NN	conj
as	IN	prep
to	IN	prep
which	WDT	pobj
of	IN	prep
many	JJ	amod
possibility	NNS	pobj
be	VBZ	advcl
likely	JJ	acomp
to	TO	aux
be	VB	xcomp
successful	JJ	acomp
;	:	punct
or	CC	cc
(	-LRB-	punct
b	LS	meta
)	-RRB-	punct
to	TO	aux
explore	VB	conj
a	DT	det
new	JJ	amod
technology	NN	dobj
or	CC	cc
general	JJ	amod
approach	NN	conj
in	IN	prep
a	DT	det
seemingly	RB	advmod
promising	JJ	amod
field	NN	pobj
of	IN	prep
experimentation	NN	pobj
,	,	punct
where	WRB	advmod
the	DT	det
prior	JJ	amod
art	NN	nsubj
give	VBD	relcl
only	RB	advmod
general	JJ	amod
guidance	NN	dobj
as	IN	prep
to	IN	prep
the	DT	det
particular	JJ	amod
form	NN	pobj
or	CC	cc
method	NN	conj
of	IN	prep
achieve	VBG	pcomp
the	DT	det
claim	VBN	amod
invention	NN	dobj
.	.	punct

see	VB	ROOT

In	IN	prep
re	IN	pobj
Kubin	NNP	pobj
,	,	punct
561	CD	nummod
f.3d	CD	appos
1351	CD	nummod
,	,	punct
1359	CD	appos
(	-LRB-	punct
Fed	NNP	ROOT
.	.	punct
Cir	NNP	subtok
.	.	punct
2009	CD	nummod
)	-RRB-	punct
(	-LRB-	punct
quote	VBG	parataxis
in	RP	prep
re	NN	compound
O'Farrell	NNP	pobj
,	,	punct
853	CD	nummod
f.2d	CD	nummod
894	CD	appos
,	,	punct
903	CD	dobj
(	-LRB-	punct
Fed	NNP	dep
.	.	punct
Cir	NNP	subtok
.	.	pobj
1988	CD	nummod
)	-RRB-	punct
)	-RRB-	punct
.	.	punct

 	_SP	

This	DT	det
case	NN	nsubj
fall	VBZ	ROOT
into	IN	prep
neither	DT	pobj
of	IN	prep
the	DT	det
two	CD	nummod
impermissible	JJ	amod
category	NNS	pobj
.	.	punct

here	RB	advmod
,	,	punct
the	DT	det
prior	JJ	amod
art	NN	nsubj
focus	VBD	ROOT
on	IN	prep
two	CD	nummod
critical	JJ	amod
variable	NNS	pobj
,	,	punct
dose	NN	compound
size	NN	conj
and	CC	cc
injection	NN	compound
frequency	NN	conj
,	,	punct
and	CC	cc
provide	VBD	conj
clear	JJ	amod
direction	NN	dobj
as	IN	prep
to	IN	prep
choice	NNS	pobj
likely	JJ	amod
to	TO	aux
be	VB	xcomp
successful	JJ	acomp
in	IN	prep
reduce	VBG	pcomp
adverse	JJ	amod
side	NN	compound
effect	NNS	dobj
and	CC	cc
increase	VBG	conj
patient	JJ	amod
adherence	NN	dobj
.	.	punct

As	IN	prep
of	IN	prep
the	DT	det
priority	NN	compound
date	NN	pobj
,	,	punct
only	RB	advmod
two	CD	nummod
GA	NNP	compound
dose	NN	compound
size	NNS	nsubjpass
have	VBD	aux
be	VBN	auxpass
show	VBN	ROOT
to	TO	aux
be	VB	xcomp
effective	JJ	acomp
,	,	punct
safe	JJ	conj
,	,	punct
and	CC	cc
well	RB	advmod
-	HYPH	punct
tolerate	VBN	conj
:	:	punct
20	CD	nummod
mg	NN	appos
and	CC	cc
40	CD	nummod
mg	NN	conj
.	.	punct

concern	VBG	prep
frequency	NN	pobj
,	,	punct
the	DT	det
1996	CD	nummod
FDA	NNP	compound
SBOA	NNP	nsubj
,	,	punct
Flechter	NNP	conj
,	,	punct
and	CC	cc
Khan	NNP	conj
2008	CD	nummod
all	DT	appos
encourage	VBD	ccomp
posita	NNS	dobj
to	TO	aux
pursue	VB	xcomp
a	DT	det
less	RBR	advmod
frequent	JJ	dobj
than	IN	prep
daily	JJ	amod
dosing	JJ	amod
regiman	NNS	pobj
;	:	punct
these	DT	det
reference	NNS	nsubj
indicate	VBD	ROOT
that	IN	mark
less	RBR	advmod
frequent	JJ	amod
injection	NNS	nsubj
of	IN	prep
GA	NNP	pobj
be	VBD	ccomp
just	RB	advmod
as	RB	advmod
effective	JJ	acomp
as	IN	prep
daily	JJ	amod
injection	NNS	pobj
,	,	punct
and	CC	cc
less	RBR	advmod
frequent	JJ	amod
injection	NNS	nsubj
improve	VBD	conj
patient	JJ	amod
adherence	NN	dobj
and	CC	cc
reduce	VBD	conj
adverse	JJ	amod
reaction	NNS	dobj
.	.	punct

the	DT	det
district	NN	compound
court	NN	nsubj
also	RB	advmod
properly	RB	advmod
rely	VBD	ROOT
on	IN	prep
Khan	NNP	pobj
2009	CD	nummod
not	RB	neg
as	RB	advmod
statutory	JJ	amod
prior	JJ	amod
art	NN	dobj
,	,	punct
but	CC	cc
for	IN	conj
the	DT	det
fact	NN	pobj
that	IN	mark
posita	NNS	nsubj
be	VBD	acl
interested	JJ	acomp
in	IN	prep
pursue	VBG	pcomp
less	RBR	advmod
frequent	JJ	amod
dosing	JJ	amod
regimen	NNS	dobj
.	.	punct

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	prep
*	NFP	punct
14	CD	pobj
.	.	punct

 	_SP	

give	VBN	prep
this	DT	det
motivation	NN	pobj
,	,	punct
a	DT	det
POSITA	NNP	nsubj
have	VBD	ROOT
only	RB	advmod
a	DT	det
limited	JJ	amod
number	NN	dobj
of	IN	prep
permutation	NNS	pobj
of	IN	prep
dose	NN	pobj
and	CC	cc
frequency	NN	conj
to	TO	aux
explore	VB	relcl
that	DT	nsubjpass
be	VBD	auxpass
not	RB	neg
already	RB	advmod
disclose	VBN	relcl
in	IN	prep
the	DT	det
prior	JJ	amod
art	NN	pobj
.	.	punct

Because	IN	mark
a	DT	det
thrice	NN	npadvmod
-	HYPH	punct
weekly	JJ	amod
40	CD	nummod
mg	NN	compound
injection	NN	nsubj
would	MD	aux
result	VB	advcl
in	IN	prep
a	DT	det
total	JJ	amod
weekly	JJ	amod
dose	NN	pobj
very	RB	advmod
close	RB	amod
to	IN	prep
that	DT	pobj
in	IN	prep
the	DT	det
already	RB	advmod
-	HYPH	punct
approve	VBN	amod
daily	JJ	amod
20	CD	nummod
mg	NN	nmod
injection-120mg	NN	advmod
/	SYM	punct
week	NN	pobj
versus	IN	prep
140mg	NNP	amod
/	SYM	punct
week	NN	pobj
-	:	punct
the	DT	det
district	NN	compound
court	NN	nsubj
find	VBD	ROOT
a	DT	det
POSITA	NNP	nsubj
would	MD	aux
have	VB	aux
have	VBN	ccomp
a	DT	det
reasonable	JJ	amod
expectation	NN	dobj
of	IN	prep
success	NN	pobj
in	IN	prep
pursue	VBG	pcomp
the	DT	det
thrice	NN	npadvmod
-	HYPH	punct
weekly	JJ	amod
dose	NN	compound
frequency	NN	dobj
in	IN	prep
term	NNS	pobj
of	IN	prep
effectiveness	NN	pobj
,	,	punct
patient	JJ	amod
adherence	NN	conj
,	,	punct
and	CC	cc
FDA	NNP	compound
approval	NN	conj
.	.	punct

Idaho	NNS	dep
at	IN	prep
(	-LRB-	punct
quote	VBG	pcomp
Allergan	NNP	dobj
,	,	punct
Inc.	NNP	appos
v.	CC	prep
Sandoz	NNP	compound
Inc.	NNP	pobj
,	,	punct
726	CD	nummod
f.3d	CD	pobj
1286	CD	nummod
,	,	punct
1291	CD	conj
(	-LRB-	punct
Fed	NNP	ROOT
.	.	punct
Cir	NNP	subtok
.	.	punct
2013	CD	nummod
)	-RRB-	punct
(	-LRB-	punct
"	``	punct
the	DT	det
potential	NN	nsubjpass
for	IN	prep
FDA	NNP	compound
approval	NN	pobj
also	RB	advmod
may	MD	aux
properly	RB	advmod
be	VB	auxpass
consider	VBN	parataxis
,	,	punct
as	IN	mark
-PRON-	PRP	nsubj
be	VBD	advcl
here	RB	advmod
,	,	punct
in	IN	prep
determine	VBG	pcomp
whether	IN	mark
one	CD	nsubjpass
of	IN	prep
ordinary	JJ	amod
skill	NN	pobj
would	MD	aux
be	VB	auxpass
motivate	VBN	ccomp
to	TO	aux
develop	VB	xcomp
a	DT	det
drug	NN	compound
product	NN	dobj
and	CC	cc
whether	IN	mark
there	EX	expl
be	VBD	conj
skepticism	NN	attr
regard	VBG	prep
the	DT	det
efficacy	NN	pobj
of	IN	prep
such	PDT	predet
a	DT	det
product	NN	pobj
"	''	punct
.	.	punct
)	-RRB-	punct
)	-RRB-	punct
.	.	punct

the	DT	det
district	NN	compound
court	NN	nsubj
give	VBD	ROOT
appropriate	JJ	amod
weight	NN	dobj
to	IN	dative
the	DT	det
testimony	NN	pobj
of	IN	prep
Dr.	NNP	compound
Green	NNP	pobj
regard	VBG	prep
patient	JJ	amod
compliance	NN	pobj
with	IN	prep
thrice	NN	npadvmod
-	HYPH	punct
weekly	JJ	amod
administration	NNS	pobj
and	CC	cc
the	DT	det
Rebif	NNP	nmod
(r)	SYM	punct
regimen	NN	conj
,	,	punct
note	VBG	advcl
that	IN	mark
"	``	punct
even	RB	advmod
though	IN	mark
Rebif	NNP	nsubj
(r)	SYM	nsubj
be	VBZ	ccomp
a	DT	det
different	JJ	amod
MS	NNP	compound
drug	NN	attr
with	IN	prep
a	DT	det
different	JJ	amod
mechanism	NN	pobj
of	IN	prep
action	NN	pobj
,	,	punct
...	NFP	punct
those	DT	nsubjpass
in	IN	prep
the	DT	det
art	NN	pobj
would	MD	aux
still	RB	advmod
be	VB	auxpass
motivate	VBN	conj
to	TO	aux
try	VB	xcomp
dose	VBG	xcomp
GA	NNP	dobj
three	CD	nummod
time	NNS	npadvmod
a	DT	det
week	NN	npadvmod
base	VBN	prep
on	IN	prep
the	DT	det
high	JJR	amod
rate	NNS	pobj
of	IN	prep
patient	JJ	amod
adherence	NN	pobj
to	IN	prep
the	DT	det
Rebif	NNP	nmod
(r)	SYM	compound
therapy	NN	pobj
"	''	punct
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
*	NFP	punct
20	CD	pobj
.	.	punct

 	_SP	

Teva	NNP	nsubj
fault	VBZ	ROOT
the	DT	det
district	NN	compound
court	NN	dobj
for	IN	prep
"	``	punct
narrow	VBG	pcomp
the	DT	det
universe	NN	dobj
"	''	punct
of	IN	prep
possible	JJ	amod
GA	NNP	compound
regimen	NNS	pobj
and	CC	cc
use	VBG	conj
hindsight	NN	dobj
and	CC	cc
the	DT	det
GALA	NNP	compound
protocol	NN	conj
to	TO	aux
reach	VB	xcomp
-PRON-	PRP$	poss
obviousness	JJ	amod
conclusion	NN	dobj
.	.	punct

appellant	NNS	poss
'	POS	case
Opening	NNP	compound
Br	NNP	ROOT
.	.	punct

42	CD	ROOT
(	-LRB-	punct
argue	VBG	acl
the	DT	det
district	NN	compound
court	NN	nsubj
limit	VBD	ccomp
a	DT	det
POSITA	NNP	dobj
to	TO	prep
"	``	punct
two	CD	nummod
dose	VBG	amod
option	NNS	pobj
(	-LRB-	punct
40	CD	nummod
mg	NN	parataxis
and	CC	cc
20	CD	nummod
mg	NN	conj
)	-RRB-	punct
,	,	punct
two	CD	nummod
regimen	NNS	appos
(	-LRB-	punct
1x	CD	nmod
/	SYM	punct
week	NN	appos
and	CC	cc
3x	CD	nmod
/	SYM	punct
week	NN	conj
)	-RRB-	punct
,	,	punct
and	CC	cc
one	CD	nummod
form	NN	conj
(	-LRB-	punct
injection	NNS	appos
)	-RRB-	punct
"	''	punct
)	-RRB-	punct
.	.	punct

-PRON-	PRP	nsubj
disagree	VBP	ccomp
;	:	punct
the	DT	det
district	NN	compound
court	NN	nsubj
have	VBD	ROOT
ample	JJ	amod
evidence	NN	dobj
besides	IN	prep
hindsight	NN	pobj
and	CC	cc
the	DT	det
disclosure	NNS	conj
in	IN	prep
GALA	NNP	pobj
on	IN	prep
which	WDT	pobj
to	TO	aux
find	VB	relcl
a	DT	det
thrice	NN	npadvmod
-	HYPH	punct
weekly	NN	amod
dosing	JJ	compound
regiman	NNS	dobj
of	IN	prep
40	CD	nummod
mg	NN	compound
GA	NNP	pobj
obvious	JJ	advcl
to	TO	aux
try	VB	xcomp
.	.	punct

see	VB	ROOT

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	prep
*	NFP	punct
17	CD	pobj
-	SYM	punct
22	CD	prep
.	.	punct

Although	IN	mark
the	DT	det
universe	NN	nsubj
of	IN	prep
potential	JJ	amod
GA	NNP	compound
dos	NNS	pobj
be	VBZ	advcl
theoretically	RB	advmod
unlimited	JJ	acomp
,	,	punct
the	DT	det
universe	NN	nsubj
of	IN	prep
dosage	NNS	pobj
in	IN	prep
the	DT	det
prior	JJ	amod
art	NN	pobj
that	WDT	nsubj
have	VBD	relcl
clinical	JJ	amod
support	NN	dobj
for	IN	prep
be	VBG	pcomp
effective	JJ	acomp
and	CC	cc
safe	JJ	conj
consisted	JJ	ROOT
of	IN	prep
only	RB	advmod
two	CD	nummod
dos	NNS	pobj
:	:	punct
20	CD	nummod
mg	NN	appos
and	CC	cc
40	CD	nummod
mg	NN	conj
.	.	punct

even	RB	advmod
if	IN	mark
there	EX	expl
be	VBD	advcl
multiple	JJ	amod
injection	NN	compound
frequency	NNS	attr
not	RB	neg
yet	RB	advmod
test	VBN	ROOT
in	IN	prep
the	DT	det
prior	JJ	amod
art-1x	NNP	pobj
,	,	punct
2x	CD	appos
,	,	punct
3x	CD	appos

a	DT	det
week	NN	npadvmod
etc.-these	NN	nsubj
still	RB	advmod
represent	VBP	ROOT
a	DT	det
limited	JJ	amod
number	NN	dobj
of	IN	prep
discrete	JJ	amod
permutation	NNS	pobj
.	.	punct

 	_SP	

This	DT	nsubj
be	VBZ	ccomp
not	RB	neg
a	DT	det
situation	NN	attr
where	WRB	advmod
the	DT	det
prior	JJ	amod
art	NN	nsubj
give	VBD	relcl
no	DT	det
direction	NN	dobj
in	IN	prep
how	WRB	advmod
to	TO	aux
reach	VB	pcomp
a	DT	det
successful	JJ	amod
result	NN	dobj
;	:	punct
the	DT	det
prior	JJ	amod
art	NN	nsubj
clearly	RB	advmod
indicate	VBD	ROOT
that	IN	mark
less	RBR	advmod
frequent	JJ	amod
dos	NNS	nsubjpass
should	MD	aux
be	VB	auxpass
explore	VBN	ccomp
(	-LRB-	punct
i.e.	FW	advmod
,	,	punct
move	VBG	advcl
away	RB	advmod
from	IN	prep
the	DT	det
daily	NN	pobj
,	,	punct
"	``	punct
7x	CD	nmod
/	SYM	punct
week	NN	nmod
"	''	punct
dose	NN	dobj
towards	IN	prep
less	RBR	advmod
frequent	JJ	amod
dos	NNS	pobj
)	-RRB-	punct
and	CC	cc
that	IN	det
high	JJR	amod
dos	NNS	conj
,	,	punct
while	IN	mark
maintain	VBG	advcl
the	DT	det
same	JJ	amod
weekly	JJ	amod
dose	NN	dobj
(	-LRB-	punct
i.e.	FW	advmod
,	,	punct
move	VBG	advcl
from	IN	prep
20	CD	nummod
mg	NN	pobj
daily	RB	advmod
to	IN	prep
40	CD	nummod
mg	NN	pobj
every	DT	det
other	JJ	amod
day	NN	npadvmod
)	-RRB-	punct
,	,	punct
could	MD	aux
increase	VB	conj
efficacy	NN	dobj
while	IN	mark
not	RB	neg
affect	VBG	advcl
adverse	JJ	amod
reaction	NNS	dobj
.	.	punct

further	RB	advmod
-	HYPH	punct
more	JJR	advmod
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
make	VBD	ROOT
factual	JJ	amod
finding	NNS	dobj
specifically	RB	advmod
in	IN	prep
support	NN	pobj
of	IN	prep
thrice	NN	npadvmod
-	HYPH	punct
weekly	JJ	amod
injection	NNS	pobj
.	.	punct

e.g.	RB	ROOT
,	,	punct
-PRON-	PRP	npadvmod
would	MD	intj
.	.	punct

at	IN	prep
(	-LRB-	punct
total	JJ	amod
weekly	JJ	amod
dose	NN	nsubj
of	IN	prep
40	CD	nummod
mg	NN	nmod
GA	NNP	compound
3x	NNP	nmod
/	SYM	punct
week	NN	pobj
be	VBZ	ROOT
very	RB	advmod
close	JJ	acomp
to	IN	prep
the	DT	det
total	JJ	amod
weekly	JJ	amod
dose	NN	pobj
for	IN	prep
the	DT	det
approve	VBN	amod
daily	JJ	amod
20	CD	nummod
mg	NN	compound
GA	NNP	compound
regiman	NNS	pobj
)	-RRB-	punct
;	:	punct
-PRON-	PRP	nsubjpass
would	MD	intj
.	.	punct
at	IN	prep
(	-LRB-	punct
"	``	punct
a	DT	det
skilled	JJ	amod
artisan	NN	nsubjpass
would	MD	aux
be	VB	auxpass
motivate	VBN	conj
to	TO	aux
try	VB	xcomp
regimen	NNS	dobj
close	RB	amod
in	IN	prep
total	JJ	amod
milligram	NNS	pobj
per	IN	prep
week	NN	pobj
to	IN	prep
the	DT	det
regimen	NNS	pobj
already	RB	advmod
approve	VBN	acl
by	IN	agent
the	DT	det
FDA	NNP	pobj
and	CC	cc
know	VBN	conj
to	TO	aux
be	VB	xcomp
effective	JJ	acomp
"	''	punct
.	.	punct
)	-RRB-	punct
;	:	punct
-PRON-	PRP	nsubj
would	MD	intj
.	.	punct
(	-LRB-	punct
find	VBG	conj
motivation	NN	dobj
to	TO	aux
pursue	VB	acl
a	DT	det
3x	NNP	nmod
/	SYM	punct
week	NN	compound
regiman	NNS	dobj
base	VBN	acl
on	IN	prep
patient	JJ	amod
adherence	NN	compound
rate	NNS	pobj
in	IN	prep
the	DT	det
Rebif	NNP	compound
(r)	SYM	compound
therapy	NN	pobj
)	-RRB-	punct
.	.	punct

and	CC	cc
contrary	JJ	advcl
to	IN	prep
Teva	NNP	poss
's	POS	case
argument	NN	pobj
that	IN	mark
the	DT	det
court	NN	nsubj
assume	VBD	acl
without	IN	prep
support	NN	pobj
that	IN	mark
GA	NNP	nsubjpass
must	MD	aux
be	VB	auxpass
inject	VBN	ccomp
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
do	VBD	aux
not	RB	neg
err	VB	ROOT
in	IN	prep
not	RB	neg
consider	VBG	pcomp
other	JJ	amod
form	NNS	dobj
of	IN	prep
GA	NNP	pobj
.	.	punct

evidence	NN	nsubj
consider	VBN	acl
by	IN	agent
the	DT	det
district	NN	compound
court	NN	pobj
reveal	VBZ	ROOT
that	IN	mark
an	DT	det
oral	JJ	amod
version	NN	nsubjpass
of	IN	prep
Copaxone	NNP	pobj
be	VBD	auxpass
prove	VBN	ccomp
to	TO	aux
be	VB	xcomp
ineffective	JJ	acomp
by	IN	prep
2005	CD	pobj
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
*	NFP	punct
23	CD	pobj
;	:	punct
J.A.	NNP	appos
4016	CD	nummod
.	.	punct

-PRON-	PRP	nsubj
recognize	VBP	ROOT
that	IN	mark
the	DT	det
prior	JJ	amod
art	NN	nsubj
do	VBD	aux
not	RB	neg
conclusively	RB	advmod
teach	VB	ccomp
that	IN	mark
a	DT	det
regimen	NN	nsubj
of	IN	prep
40	CD	nummod
mg	NN	nmod
GA	NNP	compound
3x	NNP	nmod
/	SYM	punct
week	NN	pobj
would	MD	aux
be	VB	ccomp
effective	JJ	acomp
.	.	punct

however	RB	advmod
,	,	punct
"	``	punct
conclusive	JJ	amod
proof	NN	nsubj
of	IN	prep
efficacy	NN	pobj
be	VBZ	ROOT
not	RB	neg
necessary	JJ	acomp
to	TO	aux
show	VB	xcomp
obviousness	JJ	dobj
.	.	punct

all	DT	nsubj
that	WDT	nsubjpass
be	VBZ	auxpass
require	VBN	relcl
be	VBZ	ROOT
a	DT	det
reasonable	JJ	amod
expectation	NN	attr
of	IN	prep
success	NN	pobj
"	''	punct
.	.	punct

Hoffmann	NNP	compound
-	HYPH	punct
La	NNP	compound
Roche	NNP	compound
Inc.	NNP	meta
v.	CC	prep
Apotex	NNP	compound
Inc.	NNP	pobj
,	,	punct
748	CD	nummod
f.3d	CD	appos
1326	CD	nummod
,	,	punct
1329	CD	npadvmod
,	,	punct
1331	CD	npadvmod
(	-LRB-	punct
Fed	NNP	appos
.	.	punct
Cir	NNP	subtok
.	.	punct
2014	CD	nummod
)	-RRB-	punct
;	:	punct
see	VB	ROOT
also	RB	advmod

In	IN	prep
re	IN	compound
O'Farrell	NNP	pobj
,	,	punct
853	CD	nummod
f.2d	CD	appos
at	IN	prep
903	CD	pobj
(	-LRB-	punct
"	``	punct
Obviousness	NNP	nsubj
do	VBZ	aux
not	RB	neg
require	VB	ROOT
absolute	JJ	amod
predictability	NN	dobj
of	IN	prep
success	NN	pobj
"	''	punct
.	.	punct
)	-RRB-	punct
.	.	punct

 	_SP	

nor	CC	cc
do	VBP	aux
-PRON-	PRP	nsubj
find	VB	ROOT
merit	NN	dobj
in	IN	prep
Teva	NNP	poss
's	POS	case
argument	NN	pobj
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
separately	RB	advmod
analyze	VBD	acl
the	DT	det
40	CD	nummod
mg	NN	compound
dose	NN	compound
limitation	NN	dobj
and	CC	cc
the	DT	det
3x	NNPS	nmod
/	SYM	punct
week	NN	compound
limitation	NN	conj
,	,	punct
without	IN	prep
consider	VBG	pcomp
-PRON-	PRP	dobj
together	RB	advmod
"	''	punct
except	IN	prep
to	TO	aux
conclude	VB	pcomp
that	IN	mark
the	DT	det
mash	NN	compound
-	HYPH	punct
up	NN	nsubj
would	MD	aux
be	VB	ccomp
obvious	JJ	acomp
to	TO	aux
try	VB	xcomp
"	''	punct
.	.	punct

appellant	NNS	ROOT
'	POS	case
Opening	NNP	compound
Br	NNP	appos
.	.	punct

55	CD	ROOT
.	.	punct

-PRON-	PRP	nsubj
note	VBP	ROOT
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
spend	VBD	ccomp
considerable	JJ	amod
time	NN	dobj
discuss	VBG	xcomp
why	WRB	advmod
the	DT	det
combination	NN	nsubj
of	IN	prep
a	DT	det
40	CD	nummod
mg	NN	compound
dose	NN	pobj
administer	VBN	ccomp
3x	CD	nmod
/	SYM	punct
week	NN	dobj
would	MD	aux
be	VB	ccomp
obvious	JJ	acomp
to	TO	aux
try	VB	xcomp
.	.	punct

see	VB	ROOT

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	conj
*	NFP	punct
19	CD	pobj
.	.	punct

and	CC	cc
while	IN	mark
"	``	punct
the	DT	det
determination	NN	nsubjpass
of	IN	prep
obviousness	NN	pobj
be	VBZ	auxpass
make	VBN	advcl
with	IN	prep
respect	NN	pobj
to	IN	prep
the	DT	det
subject	JJ	amod
matter	NN	pobj
as	IN	prep
a	DT	det
whole	NN	amod
,	,	punct
not	RB	neg
separate	JJ	amod
piece	NNS	pobj
of	IN	prep
the	DT	det
claim	NN	pobj
,	,	punct
"	``	punct
Sanofi	NNP	compound
-	HYPH	punct
Synthelabo	NNP	pobj
v.	CC	prep
Apotex	NNP	pobj
,	,	punct
Inc.	NNP	appos
,	,	punct
550	CD	nummod
f.3d	CD	appos
1075	CD	nummod
,	,	punct
1086	CD	npadvmod
(	-LRB-	punct
Fed	NNP	appos
.	.	punct
Cir	NNP	subtok
.	.	punct
2008	CD	npadvmod
)	-RRB-	punct
,	,	punct
this	DT	det
court	NN	nsubj
have	VBZ	aux
previously	RB	advmod
employ	VBN	ROOT
the	DT	det
same	JJ	amod
frequency	NN	nmod
-	HYPH	punct
and	CC	cc
-	HYPH	punct
dosage	NN	compound
-	HYPH	punct
amount	NN	conj
approach	NN	dobj
to	IN	prep
obviousness	JJ	pobj
use	VBN	acl
by	IN	agent
the	DT	det
district	NN	compound
court	NN	pobj
here	RB	advmod
.	.	punct

In	IN	prep
Hoffmann	NNP	compound
-	HYPH	punct
La	NNP	compound
Roche	NNP	pobj
,	,	punct
748	CD	nummod
f.3d	CD	appos
at	IN	prep
1329	CD	pobj
,	,	punct
the	DT	det
court	NN	nsubj
consider	VBD	ROOT
whether	IN	mark
-PRON-	PRP	nsubj
would	MD	aux
have	VB	aux
be	VBN	ccomp
obvious	JJ	acomp
at	IN	prep
the	DT	det
time	NN	pobj
of	IN	prep
invention	NN	pobj
to	TO	aux
select	VB	xcomp
a	DT	det
once	RB	advmod
a	DT	det
month	NN	npadvmod
oral	JJ	amod
dose	VBG	amod
regiman	NNS	dobj
of	IN	prep
150	CD	nummod
mg	NN	pobj
of	IN	prep
ibandronate	NN	pobj
to	TO	aux
treat	VB	xcomp
osteoporosis	NN	dobj
.	.	punct

the	DT	det
court	NN	nsubj
first	RB	advmod
discuss	VBD	ROOT
how	WRB	advmod
the	DT	det
prior	JJ	amod
art	NN	nsubj
teach	VBD	ccomp
that	DT	mark
infrequent	NN	compound
dose	VBG	nsubj
,	,	punct
such	JJ	amod
as	IN	prep
monthly	JJ	amod
dosing	NN	pobj
,	,	punct
be	VBD	ccomp
prefer	VBN	acomp
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
1329	CD	pobj
-	SYM	punct
31	CD	prep
.	.	punct

the	DT	det
court	NN	nsubj
then	RB	advmod
separately	RB	advmod
discuss	VBD	ROOT
why	WRB	advmod
a	DT	det
POSITA	NNP	nsubj
would	MD	aux
have	VB	aux
select	VBN	ccomp
a	DT	det
150	CD	nummod
mg	NN	compound
dose	NN	dobj
,	,	punct
before	IN	prep
consider	VBG	pcomp
the	DT	det
limitation	NNS	dobj
together	RB	advmod
and	CC	cc
conclude	VBG	conj
that	IN	mark
"	``	punct
at	IN	prep
the	DT	det
very	RB	advmod
least	JJS	pobj
,	,	punct
the	DT	det
150	CD	nummod
mg	NN	compound
dose	NN	nsubj
be	VBD	ccomp
obvious	JJ	acomp
to	TO	aux
try	VB	xcomp
"	''	punct
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
1331	CD	pobj
-	SYM	punct
33	CD	prep
.	.	punct

Teva	NNP	nsubj
make	VBZ	ROOT
no	DT	det
convincing	JJ	amod
argument	NN	dobj
why	WRB	advmod
a	DT	det
similar	JJ	amod
approach	NN	nsubj
be	VBZ	ccomp
inappropriate	JJ	acomp
here	RB	advmod
.	.	punct

 	_SP	

Teva	NNP	nsubj
make	VBZ	ROOT
numerous	JJ	amod
challenge	NNS	dobj
to	IN	prep
factual	JJ	amod
finding	NNS	pobj
by	IN	prep
the	DT	det
district	NN	compound
court	NN	pobj
,	,	punct
none	NN	npadvmod
of	IN	prep
which	WDT	pobj
-PRON-	PRP	nsubj
find	VBP	relcl
persuasive	JJ	oprd
.	.	punct

For	IN	prep
instance	NN	pobj
,	,	punct
Teva	NNP	nsubj
argue	VBZ	ROOT
that	IN	mark
Cohen	NNP	nsubj
and	CC	cc
FORTE	NNP	conj
teach	VBP	ccomp
away	RB	advmod
from	IN	prep
use	VBG	pcomp
40	CD	nummod
mg	NN	compound
GA	NNP	dobj
.	.	punct

the	DT	det
district	NN	compound
court	NN	nsubj
,	,	punct
however	RB	advmod
,	,	punct
find	VBD	ROOT
that	IN	mark
the	DT	det
decision	NN	nsubj
to	TO	aux
include	VB	acl
40	CD	nummod
mg	NN	dobj
in	IN	prep
the	DT	det
later	JJ	amod
forte	JJ	amod
study	NN	pobj
indicate	VBZ	ccomp
that	IN	mark
Cohen	NNP	nsubj
do	VBD	aux
not	RB	neg
teach	VB	ccomp
away	RB	advmod
from	IN	prep
try	VBG	pcomp
40	CD	nummod
mg	NN	dobj
.	.	punct

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	prep
*	NFP	punct
15	CD	pobj
.	.	punct

the	DT	det
district	NN	compound
court	NN	nsubj
further	RB	advmod
note	VBD	ccomp
although	IN	mark
the	DT	det
FORTE	NNP	compound
study	NN	nsubj
ostensibly	RB	advmod
"	``	punct
fail	VBN	advcl
"	''	punct
at	IN	prep
meet	VBG	pcomp
-PRON-	PRP$	poss
stated	JJ	amod
goal	NN	dobj
of	IN	prep
establish	VBG	pcomp
that	IN	det
40mg	JJ	amod
/	SYM	punct
day	NN	dobj
be	VBD	ccomp
30	CD	nummod
%	NN	npadvmod
more	JJR	advmod
effective	JJ	acomp
than	IN	prep
20mg	JJ	amod
/	SYM	punct
day	NN	pobj
,	,	punct
FORTE	NNP	nsubj
still	RB	advmod
find	VBD	ROOT
that	IN	mark
40	CD	nummod
mg	NN	nsubj
be	VBD	ccomp
equally	RB	advmod
effective	JJ	acomp
with	IN	prep
"	``	punct
no	DT	det
unexpected	JJ	amod
adverse	JJ	amod
effect	NN	pobj
,	,	punct
"	''	punct
and	CC	cc
thus	RB	advmod
do	VBD	aux
not	RB	neg
teach	VB	conj
away	RB	advmod
.	.	punct

Idaho	NNP	ROOT

-PRON-	PRP	nsubj
see	VBP	ROOT
no	DT	det
clear	JJ	amod
error	NN	dobj
in	IN	prep
these	DT	det
finding	NNS	pobj
.	.	punct

see	VB	ROOT
Galderma	NNP	compound
Labs.	NNP	dobj
,	,	punct
L.P.	NNP	appos
v.	CC	prep
Tolmar	NNP	pobj
,	,	punct
Inc.	NNP	appos
,	,	punct
737	CD	nummod
F.3d	NNP	appos
731	CD	nummod
,	,	punct
738	CD	appos
(	-LRB-	punct
Fed	NNP	appos
.	.	punct
Cir	NNP	subtok
.	.	punct
2013	CD	nummod
)	-RRB-	punct
(	-LRB-	punct
"	``	punct
a	DT	det
reference	NN	nsubj
do	VBZ	aux
not	RB	neg
teach	VB	ccomp
away	RB	advmod
,	,	punct
however	RB	advmod
,	,	punct
if	IN	mark
-PRON-	PRP	nsubj
merely	RB	advmod
express	VBZ	advcl
a	DT	det
general	JJ	amod
preference	NN	dobj
for	IN	prep
an	DT	det
alternative	JJ	amod
invention	NN	pobj
but	CC	cc
do	VBZ	aux
not	RB	neg
criticize	VB	conj
,	,	punct
discredit	VB	conj
,	,	punct
or	CC	cc
otherwise	RB	advmod
discourage	VBP	compound
investigation	NN	conj
into	IN	prep
the	DT	det
invention	NN	pobj
claim	VBD	advcl
"	''	punct
.	.	punct
)	-RRB-	punct
.	.	punct

nor	CC	cc
be	VBP	auxpass
-PRON-	PRP	nsubjpass
sway	VBN	ROOT
by	IN	agent
Teva	NNP	poss
's	POS	case
argument	NNS	pobj
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
misread	NN	acl
Khan	NNP	dobj
2008	CD	nummod
and	CC	cc
Caon	NNP	conj
in	IN	prep
suggest	VBG	pcomp
that	IN	mark
patient	NNS	nsubj
in	IN	prep
the	DT	det
20mg	JJ	amod
/	SYM	punct
day	NN	compound
group	NN	pobj
switch	VBD	ccomp
to	IN	prep
20	CD	nummod
mg	NN	pobj
every	DT	det
other	JJ	amod
day	NN	npadvmod
to	TO	aux
reduce	VB	advcl
discomfort	NN	dobj
associate	VBN	acl
with	IN	prep
daily	JJ	amod
injection	NNS	pobj
.	.	punct

the	DT	det
district	NN	compound
court	NN	nsubj
cite	VBD	ROOT
extensive	JJ	amod
testimony	NN	dobj
clearly	RB	advmod
show	VBG	acl
that	IN	mark
posita	NNS	nsubj
"	''	punct
be	VBD	ccomp
familiar	JJ	acomp
with	IN	prep
the	DT	det
adverse	JJ	amod
reaction	NNS	pobj
,	,	punct
pain	NN	conj
,	,	punct
and	CC	cc
treatment	NN	compound
adherence	NN	compound
problem	NNS	conj
associate	VBN	acl
with	IN	prep
daily	JJ	pobj
injections".14	NNP	punct

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	prep
*	NFP	punct
16	CD	pobj
.	.	punct

give	VBN	prep
the	DT	det
evidence	NN	pobj
present	VBD	acl
,	,	punct
the	DT	det
district	NN	compound
court	NN	poss
's	POS	case
finding	NN	nsubj
that	IN	dobj
patient	NNS	nsubj
want	VBD	acl
to	TO	aux
switch	VB	xcomp
to	IN	prep
the	DT	det
every	DT	det
other	JJ	amod
day	NN	pobj
regiman	NNS	dobj
to	TO	aux
reduce	VB	advcl
discomfort	NN	dobj
associate	VBN	acl
with	IN	prep
daily	JJ	amod
injection	NNS	pobj
be	VBZ	ROOT
a	DT	det
reasonable	JJ	amod
conclusion	NN	attr
and	CC	cc
not	RB	neg
clearly	RB	advmod
erroneous	JJ	conj
.	.	punct

 	_SP	

Teva	NNP	nsubj
further	RB	advmod
contend	VBZ	ROOT
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
err	VBD	ccomp
in	IN	prep
rely	VBG	pcomp
on	IN	prep
Flechter	NNP	pobj
for	IN	prep
-PRON-	PRP$	poss
finding	NN	pobj
that	IN	mark
a	DT	det
POSITA	NNP	nsubjpass
would	MD	aux
have	VB	aux
be	VBN	auxpass
motivate	VBN	acl
to	TO	aux
pursue	VB	xcomp
a	DT	det
less	JJR	dobj
than	IN	prep
daily	JJ	advmod
dosing	JJ	amod
regiman	NNS	pobj
.	.	punct

-PRON-	PRP	nsubj
do	VBP	aux
not	RB	neg
reach	VB	ROOT
this	DT	det
argument	NN	dobj
give	VBN	prep
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
correctly	RB	advmod
find	VBD	pcomp
similar	JJ	amod
motivation	NNS	dobj
in	IN	prep
other	JJ	amod
reference	NNS	pobj
,	,	punct
such	JJ	amod
as	IN	prep
the	DT	det
SBOA	NNP	pobj
and	CC	cc
Khan	NNP	conj
2008	CD	nummod
.	.	punct

Teva	NNP	nsubj
also	RB	advmod
take	VBZ	ROOT
issue	NN	dobj
with	IN	prep
the	DT	det
district	NN	compound
court	NN	poss
's	POS	case
use	NN	pobj
of	IN	prep
the	DT	det
Pinchasi	NNP	compound
reference	NN	pobj
.	.	punct

Although	IN	mark
the	DT	det
court	NN	nsubj
note	VBD	advcl
that	IN	mark
"	``	punct
Pinchasi	NNP	nsubj
be	VBZ	ccomp
the	DT	det
close	JJS	amod
prior	JJ	amod
art	NN	attr
,	,	punct
"	``	punct
-PRON-	PRP	subtok
would	MD	dep
.	.	punct
at	IN	prep
*	NFP	punct
17	CD	pobj
,	,	punct
this	DT	det
observation	NN	nsubj
be	VBZ	ccomp
not	RB	neg
improper	JJ	acomp
;	:	punct
court	NNS	nsubjpass
be	VBP	auxpass
require	VBN	ROOT
to	TO	aux
determine	VB	xcomp
"	``	punct
the	DT	det
scope	NN	dobj
and	CC	cc
content	NN	conj
of	IN	prep
prior	JJ	amod
art	NN	pobj
"	''	punct
and	CC	cc
the	DT	det
"	``	punct
difference	NNS	conj
between	IN	prep
prior	JJ	amod
art	NN	pobj
and	CC	cc
claim	NNS	conj
"	''	punct
.	.	punct

PAR	NNP	compound
Pharm.	NNP	ROOT
,	,	punct
773	CD	nummod
f.3d	CD	appos
at	IN	prep
1193	CD	pobj
(	-LRB-	punct
emphasis	NN	nsubj
add	VBN	parataxis
)	-RRB-	punct
.	.	punct

contrary	JJ	advmod
to	IN	prep
Teva	NNP	poss
's	POS	case
assertion	NN	pobj
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
give	VBD	acl
no	DT	det
reason	NN	dobj
why	WRB	advmod
a	DT	det
person	NN	nsubj
of	IN	prep
ordinary	JJ	amod
skill	NN	pobj
would	MD	aux
have	VB	aux
start	VBN	relcl
with	IN	prep
Pinchasi	NNP	pobj
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
in	IN	prep
fact	NN	pobj
address	VBD	ROOT
Pinchasi	NNP	compound
fourth	JJ	advmod
in	IN	prep
-PRON-	PRP$	poss
discussion	NN	pobj
on	IN	prep
the	DT	det
thrice	NN	nmod
weekly	JJ	amod
dosing	JJ	compound
limitation	NN	pobj
,	,	punct
after	IN	prep
the	DT	det
SBOA	NNP	pobj
,	,	punct
Flechter	NNP	conj
,	,	punct
and	CC	cc
Khan	NNP	nmod
2008/caon	NN	nummod
reference	NNS	conj
.	.	punct

see	VB	ROOT

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	prep
*	NFP	punct
15	CD	pobj
-	SYM	punct
17	CD	prep
.	.	punct

Teva	NNP	nsubj
raise	VBZ	ROOT
additional	JJ	amod
argument	NNS	dobj
regard	VBG	prep
factual	JJ	amod
finding	NNS	pobj
make	VBN	acl
by	IN	agent
the	DT	det
district	NN	compound
court	NN	pobj
,	,	punct
none	NN	conj
of	IN	prep
which	WDT	pobj
-PRON-	PRP	nsubj
find	VBP	relcl
persuasive	JJ	oprd
.	.	punct

 	_SP	

finally	RB	advmod
,	,	punct
this	DT	det
court	NN	poss
's	POS	case
decision	NN	nsubj
in	IN	prep
In	IN	pobj
re	NN	compound
Cyclobenzaprine	NNP	pobj
,	,	punct
676	CD	nummod
f.3d	CD	appos
at	IN	prep
1063	CD	pobj
,	,	punct
do	VBZ	aux
not	RB	neg
warrant	VB	ROOT
a	DT	det
different	JJ	amod
outcome	NN	dobj
.	.	punct

Teva	NNP	nsubj
argue	VBZ	ROOT
that	IN	mark
prior	RB	advmod
to	IN	prep
the	DT	det
invention	NN	pobj
,	,	punct
high	JJR	amod
dos	NNS	nsubjpass
of	IN	prep
GA	NNP	pobj
be	VBD	auxpass
not	RB	neg
necessarily	RB	advmod
know	VBN	ccomp
to	TO	aux
be	VB	xcomp
more	RBR	advmod
effective	JJ	acomp
,	,	punct
GA	NNP	nmod
's	POS	case
pharmacokinetic	JJ	amod
and	CC	cc
pharmacodynamic	JJ	conj
(	-LRB-	punct
"	``	punct
pk	NNS	nmod
/	SYM	punct
pd	NN	pobj
"	''	punct
)	-RRB-	punct
profile	NN	nsubj
be	VBD	conj
and	CC	cc
remain	VBZ	conj
unknown	JJ	acomp
,	,	punct
GA	NNP	poss
's	POS	case
mechanism	NN	nsubj
of	IN	prep
action	NN	pobj
be	VBZ	conj
still	RB	advmod
unknown	JJ	acomp
,	,	punct
and	CC	cc
the	DT	det
cause	NN	nsubj
of	IN	prep
patient	NN	poss
's	POS	case
reaction	NNS	pobj
to	IN	prep
injection	NNS	pobj
of	IN	prep
GA	NNP	pobj
be	VBZ	conj
unknown	JJ	acomp
.	.	punct

Teva	NNP	nsubj
contend	VBZ	ROOT
that	IN	mark
the	DT	det
unpredictable	JJ	amod
nature	NN	nsubj
of	IN	prep
GA	NNP	pobj
categorically	RB	advmod
preclude	VBZ	ccomp
the	DT	det
obvious	JJ	amod
-	HYPH	punct
to	TO	aux
-	HYPH	punct
try	VB	amod
analysis	NN	dobj
employ	VBN	acl
by	IN	agent
the	DT	det
district	NN	compound
court	NN	pobj
.	.	punct

appellant	NNS	ROOT
'	POS	case
Opening	NNP	compound
Br	NNP	appos
.	.	punct
50	CD	appos
.	.	punct

 	_SP	

In	IN	prep
Cyclobenzaprine	NNP	pobj
,	,	punct
-PRON-	PRP	nsubj
hold	VBD	ROOT
that	DT	det
bioequivalence	NN	nsubj
alone	RB	advmod
could	MD	aux
not	RB	neg
establish	VB	ccomp
obviousness	JJ	dobj
because	IN	mark
"	``	punct
skilled	JJ	amod
artisan	NNS	nsubj
could	MD	aux
not	RB	neg
predict	VB	advcl
whether	IN	mark
any	DT	det
particular	JJ	amod
PK	NNP	compound
profile	NN	nsubj
,	,	punct
include	VBG	prep
a	DT	det
bioequivalent	JJ	amod
one	NN	pobj
,	,	punct
would	MD	aux
produce	VB	ccomp
a	DT	det
therapeutically	RB	advmod
effective	JJ	amod
formulation	NN	dobj
"	''	punct
.	.	punct

676	CD	nummod
f.3d	CD	ROOT
at	IN	prep
1070	CD	pobj
.	.	punct

the	DT	det
court	NN	nsubj
apply	VBD	ROOT
traditional	JJ	amod
motivation	NN	nmod
and	CC	cc
reasonable	JJ	amod
-	HYPH	punct
expectation	NN	nmod
-	HYPH	punct
of	IN	prep
-	HYPH	punct
success	NN	pobj
analysis	NN	dobj
,	,	punct
reason	VBG	advcl
that	IN	mark
"	``	punct
while	IN	mark
-PRON-	PRP	nsubj
may	MD	aux
have	VB	aux
be	VBN	ccomp
obvious	JJ	acomp
to	TO	aux
experiment	VB	xcomp
with	IN	prep
the	DT	det
use	NN	pobj
of	IN	prep
the	DT	det
same	JJ	amod
PK	NNP	compound
profile	NN	pobj
[	-LRB-	punct
from	IN	prep
an	DT	det
immediate	JJ	amod
-	HYPH	punct
release	NN	compound
formulation	NN	pobj
]	-RRB-	punct
when	WRB	advmod
contemplate	VBG	advcl
an	DT	det
extend	VBN	amod
-	HYPH	punct
release	NN	compound
formulation	NN	dobj
,	,	punct
there	EX	expl
be	VBD	conj
nothing	NN	attr
to	TO	aux
indicate	VB	relcl
that	IN	mark
a	DT	det
skilled	JJ	amod
artisan	NN	nsubj
would	MD	aux
have	VB	aux
have	VBN	ccomp
a	DT	det
reasonable	JJ	amod
expectation	NN	dobj
that	IN	mark
such	PDT	predet
an	DT	det
experiment	NN	nsubj
would	MD	aux
succeed	VB	relcl
in	IN	prep
be	VBG	pcomp
therapeutically	RB	advmod
effective	JJ	acomp
"	''	punct
.	.	punct

Idaho	NNP	ROOT

In	IN	prep
Cyclobenzaprine	NNP	pobj
,	,	punct
there	EX	expl
be	VBD	ROOT
no	DT	det
prior	JJ	amod
art	NN	nmod
clinical	JJ	amod
study	NNS	attr
to	TO	aux
suggest	VB	relcl
what	WP	nsubj
would	MD	aux
be	VB	ccomp
a	DT	det
therapeutically	RB	advmod
effective	JJ	amod
formulation	NN	attr
.	.	punct

 	_SP	

-PRON-	PRP	nsubj
do	VBP	aux
not	RB	neg
read	VB	ROOT
Cyclobenzaprine	NNP	dobj
as	IN	prep
establish	VBG	pcomp
a	DT	det
rig	NN	compound
-	HYPH	punct
id	JJ	compound
rule	NN	dobj
categorically	RB	advmod
preclude	VBG	acl
obviousness	JJ	amod
finding	NNS	dobj
without	IN	prep
pk	NN	nmod
/	SYM	punct
pd	NN	appos
datum	NNS	pobj
.	.	punct

further	RB	advmod
,	,	punct
Cyclobenzaprine	NNP	nsubj
be	VBZ	ccomp
distinguishable	JJ	acomp
in	IN	prep
that	DT	pobj
,	,	punct
there	RB	advmod
,	,	punct
the	DT	det
obviousness	JJ	amod
proof	NN	nsubj
rely	VBD	ROOT
entirely	RB	advmod
on	IN	prep
the	DT	det
bioequivalence	NN	pobj
of	IN	prep
certain	JJ	amod
pharmacokinetic	JJ	amod
profile	NNS	pobj
.	.	punct

bioequivalence	NN	nsubjpass
be	VBZ	auxpass
not	RB	neg
argue	VBN	ccomp
here	RB	advmod
;	:	punct
instead	RB	advmod
,	,	punct
obviousness	JJ	nsubjpass
be	VBZ	auxpass
prove	VBN	ROOT
through	IN	prep
human	JJ	amod
clinical	JJ	amod
study	NNS	pobj
establish	VBG	acl
the	DT	det
safety	NN	dobj
,	,	punct
efficacy	NN	conj
,	,	punct
and	CC	cc
tolerability	NN	conj
of	IN	prep
GA	NNP	pobj
at	IN	prep
dos	NNS	pobj
and	CC	cc
dose	NN	compound
frequency	NNS	conj
similar	JJ	amod
to	IN	prep
the	DT	det
claim	VBN	amod
regimen	NN	pobj
.	.	punct

In	IN	prep
this	DT	det
case	NN	pobj
,	,	punct
the	DT	det
evidence	NN	nsubj
show	VBZ	ROOT
that	IN	mark
pk	NN	nmod
/	SYM	punct
pd	NN	intj
datum	NNS	nsubj
be	VBD	ccomp
largely	RB	advmod
irrelevant	JJ	acomp
to	IN	prep
the	DT	det
invention	NN	pobj
.	.	punct

numerous	JJ	amod
clinical	JJ	amod
study	NNS	nsubj
in	IN	prep
the	DT	det
prior	JJ	amod
art	NN	pobj
describe	VBP	ROOT
GA	NNP	dobj
and	CC	cc
-PRON-	PRP$	poss
effect	NNS	conj
on	IN	prep
the	DT	det
human	JJ	amod
body	NN	pobj
.	.	punct

Although	IN	mark
the	DT	det
precise	JJ	amod
mechanism	NN	nsubjpass
of	IN	prep
GA	NNP	pobj
be	VBZ	auxpass
not	RB	neg
know	VBN	advcl
,	,	punct
-PRON-	PRP	nsubjpass
be	VBZ	auxpass
know	VBN	ccomp
to	TO	aux
be	VB	aux
immunomodulate	VBG	xcomp
-	.	punct
i.e	NN	nummod
.	.	dobj
,	,	punct
-PRON-	PRP	nsubj
change	VBZ	ROOT
the	DT	det
immune	JJ	amod
system	NN	dobj
-	,	punct
and	CC	cc
be	VBZ	conj
not	RB	neg
necessarily	RB	advmod
measurable	JJ	acomp
in	IN	prep
the	DT	det
bloodstream	NN	pobj
and	CC	cc
-PRON-	PRP$	poss
level	NNS	nsubj
be	VBP	conj
not	RB	neg
indicative	JJ	acomp
of	IN	prep
efficacy	NN	pobj
.	.	punct

see	VB	ROOT

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	pobj
*	NFP	punct
21	CD	pobj
-	SYM	punct
22	CD	prep
;	:	punct
J.A.	NNP	pobj
3998	CD	nummod
-	SYM	punct
99	CD	prep
,	,	punct
4886	CD	npadvmod
-	SYM	punct
87	CD	prep
.	.	punct

Testimony	NNP	nsubjpass
be	VBD	auxpass
give	VBN	ROOT
at	IN	prep
trial	NN	pobj
that	IN	mark
pharmacokinetic	JJ	amod
study	NNS	nsubj
for	IN	prep
drug	NNS	pobj
like	IN	prep
GA	NNP	pobj
be	VBP	acl
less	RBR	advmod
appropriate	JJ	acomp
than	IN	prep
for	IN	prep
small	JJ	amod
molecule	NN	compound
drug	NNS	pobj
,	,	punct
such	JJ	amod
as	IN	prep
those	DT	pobj
at	IN	prep
issue	NN	pobj
in	IN	prep
Cyclobenzaprine	NNP	pobj
.	.	punct

J.A.	NNP	ROOT
4886	CD	nummod
-	SYM	punct
87	CD	prep
.	.	punct

GA	NNP	nsubjpass
be	VBD	auxpass
also	RB	advmod
know	VBN	ROOT
to	TO	aux
be	VB	aux
"	``	punct
forgive	VBG	xcomp
,	,	punct
"	''	punct
in	IN	prep
that	DT	det
occasional	JJ	amod
miss	VBN	amod
dos	NNS	pobj
would	MD	aux
not	RB	neg
reduce	VB	advcl
efficacy	NN	dobj
,	,	punct
and	CC	cc
that	DT	det
fact	NN	nsubj
give	VBD	conj
posita	NNS	dative
further	JJ	amod
confidence	NN	dobj
in	IN	prep
eliminate	VBG	pcomp
one	CD	nummod
dose	NN	dobj
every	DT	det
two	CD	nummod
week	NNS	npadvmod
.	.	punct

J.A.	NNP	ROOT
4848	CD	nummod
-	SYM	punct
49	CD	prep
;	:	punct
4884	CD	appos
-	SYM	punct
85	CD	prep
;	:	punct
4732	CD	appos
.	.	punct

high	JJR	amod
dos	NNS	nsubjpass
be	VBD	auxpass
clinically	RB	advmod
show	VBN	ccomp
to	TO	aux
be	VB	xcomp
at	IN	advmod
least	JJS	advmod
as	RB	advmod
effective	JJ	acomp
as	IN	prep
low	JJR	amod
dos	NNS	pobj
;	:	punct
Cohen	NNP	nsubj
show	VBZ	ROOT
,	,	punct
at	IN	prep
the	DT	det
very	RB	advmod
least	JJS	pobj
,	,	punct
that	IN	mark
40	CD	nummod
mg	NN	nsubj
be	VBZ	ccomp
as	RB	advmod
effective	JJ	acomp
and	CC	cc
well	RB	advmod
-	HYPH	punct
tolerate	VBN	conj
as	IN	prep
20	CD	nummod
mg	NN	pobj
,	,	punct
but	CC	cc
with	IN	conj
a	DT	det
more	RBR	advmod
rapid	JJ	amod
onset	NN	pobj
of	IN	prep
action	NN	pobj
.	.	punct

finally	RB	advmod
,	,	punct
Teva	NNP	nsubj
-PRON-	PRP	appos
,	,	punct
in	IN	prep
-PRON-	PRP$	poss
1996	CD	nummod
application	NN	pobj
to	IN	prep
FDA	NNP	pobj
,	,	punct
indicate	VBD	ROOT
that	IN	mark
pharmacokinetic	JJ	amod
study	NNS	nsubj
"	''	punct
would	MD	aux
be	VB	ccomp
of	IN	prep
limited	JJ	amod
value	NN	pobj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
20689	CD	nummod
.	.	punct

 	_SP	

In	IN	prep
light	NN	pobj
of	IN	prep
the	DT	det
foregoing	NN	pobj
,	,	punct
-PRON-	PRP	nsubj
hold	VBP	ROOT
that	IN	mark
the	DT	det
40	CD	nummod
mg	NN	compound
GA	NNP	compound
3x	NNP	nmod
/	SYM	punct
week	NN	compound
regimen	NN	nsubj
be	VBZ	ccomp
obvious	JJ	acomp
in	IN	prep
light	NN	pobj
of	IN	prep
the	DT	det
prior	JJ	amod
art	NN	pobj
,	,	punct
and	CC	cc
find	VB	conj
no	DT	det
clear	JJ	amod
error	NN	dobj
in	IN	prep
the	DT	det
conclusion	NN	pobj
that	IN	mark
a	DT	det
POSITA	NNP	nsubjpass
would	MD	aux
be	VB	auxpass
motivate	VBN	acl
to	TO	aux
combine	VB	xcomp
the	DT	det
40	CD	nummod
mg	NN	compound
GA	NNP	compound
dose	NN	dobj
,	,	punct
which	WDT	nsubj
have	VBD	relcl
prove	VBN	amod
efficacy	NN	dobj
,	,	punct
with	IN	prep
a	DT	det
3x	NNP	nmod
/	SYM	punct
week	NN	compound
frequency	NN	pobj
,	,	punct
which	WDT	nsubj
be	VBD	relcl
desirable	JJ	acomp
because	IN	mark
the	DT	det
prior	JJ	amod
art	NN	nsubj
indicate	VBD	advcl
that	IN	mark
less	RBR	advmod
frequent	JJ	amod
administration	NN	nsubj
increase	VBD	ccomp
patient	JJ	amod
adherence	NN	dobj
while	IN	mark
maintain	VBG	advcl
efficacy	NN	dobj
.	.	punct

 	_SP	

B.	NNP	nmod
Improved	NNP	amod
Tolerability	NNP	nsubj
and	CC	cc
Reduced	NNP	compound
Frequency	NNP	compound
Limitations	NNPS	conj

 	_SP	
Claims	NNP	ROOT
14	CD	nummod
,	,	punct
16	CD	npadvmod
,	,	punct
and	CC	cc
17	CD	nsubj
of	IN	prep
the	DT	det
'	``	punct
250	CD	nummod
patent	NN	pobj
and	CC	cc
claim	NN	conj
7	CD	dobj
of	IN	prep
the	DT	det
'	``	punct
413	CD	nummod
patent	NN	compound
require	VBP	conj
that	IN	mark
the	DT	det
40	CD	nummod
mg	NN	nmod
GA	NNP	compound
3x	NNP	nmod
/	SYM	punct
week	NN	appos
regiman	NNS	nsubj
reduce	VB	ccomp
the	DT	det
frequency	NN	dobj
of	IN	prep
isr	NNS	pobj
and	CC	cc
IPIRs	NNPS	conj
relative	JJ	advmod
to	IN	prep
the	DT	det
daily	JJ	amod
20	CD	nummod
mg	NN	compound
GA	NNP	compound
regiman	NNS	pobj
.	.	punct

Claim	NNP	nsubj
15	CD	nummod
of	IN	prep
the	DT	det
'	``	punct
250	CD	nummod
patent	NN	pobj
,	,	punct
on	IN	prep
which	WDT	nsubj
claim	VBZ	pcomp
16	CD	nsubj
and	CC	cc
17	CD	conj
depend	NN	relcl
,	,	punct
require	VBZ	ROOT
that	IN	mark
the	DT	det
claim	VBN	amod
regiman	NNS	nsubj
improve	VB	ccomp
tolerability	NN	dobj
as	IN	prep
compare	VBN	prep
to	IN	prep
the	DT	det
daily	JJ	amod
20	CD	nummod
mg	NN	compound
regimen	NN	pobj
.	.	punct

 	_SP	

Teva	NNP	nsubj
argue	VBZ	ROOT
that	IN	mark
the	DT	det
prior	JJ	amod
art	NN	nsubj
do	VBD	aux
not	RB	neg
lead	VB	ccomp
posita	NNS	dobj
to	TO	aux
expect	VB	xcomp
improve	VBN	amod
tolerability	NN	dobj
and	CC	cc
reduce	VBN	amod
frequency	NN	conj
of	IN	prep
injection	NN	compound
reaction	NNS	pobj
from	IN	prep
the	DT	det
claim	VBN	amod
regimen	NN	pobj
compare	VBN	prep
to	IN	prep
20	CD	nummod
mg	NN	compound
GA	NNP	pobj
daily	RB	advmod
.	.	punct

-PRON-	PRP	nsubj
disagree	VBP	ROOT
,	,	punct
and	CC	cc
find	VB	conj
no	DT	det
clear	JJ	amod
error	NN	dobj
in	IN	prep
the	DT	det
district	NN	compound
court	NN	poss
's	POS	case
finding	NNS	pobj
regard	VBG	prep
Khan	NNP	pobj
2008	CD	nummod
,	,	punct
Caon	NNP	conj
,	,	punct
and	CC	cc
Flechter	NNP	conj
,	,	punct
all	DT	nsubj
of	IN	prep
which	WDT	pobj
demonstrate	VBP	relcl
that	DT	mark
improve	VBN	amod
tolerability	NN	nsubjpass
and	CC	cc
less	RBR	advmod
frequent	JJ	amod
injection	NN	compound
reaction	NNS	conj
be	VBD	auxpass
expect	VBN	ccomp
from	IN	prep
the	DT	det
claim	VBN	amod
less	RBR	advmod
frequent	JJ	amod
regiman	NNS	pobj
,	,	punct
as	IN	mark
compare	VBN	advcl
to	IN	prep
20	CD	nummod
mg	NN	pobj
daily	RB	advmod
.	.	punct

see	VB	ROOT

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	prep
*	NFP	punct
17	CD	pobj
-	SYM	punct
18	CD	prep
.	.	punct

Caon	NNP	nsubj
,	,	punct
for	IN	prep
example	NN	pobj
,	,	punct
disclose	VBD	ROOT
that	IN	mark
the	DT	det
frequency	NN	nsubj
of	IN	prep
a	DT	det
severe	JJ	amod
injection	NN	compound
-	HYPH	punct
site	NN	compound
reaction	NN	pobj
,	,	punct
lipoatrophy	NN	appos
,	,	punct
be	VBD	ccomp
"	``	punct
significantly	RB	advmod
less	RBR	acomp
"	``	punct
for	IN	prep
the	DT	det
every	DT	amod
-	HYPH	punct
other	JJ	amod
-	HYPH	punct
day	NN	compound
patient	NN	compound
group	NN	pobj
than	IN	prep
for	IN	prep
the	DT	det
daily	JJ	amod
group	NN	pobj
.	.	punct

J.A.	NNP	ROOT
20386	CD	nummod
.	.	punct

Pinchasi	NNP	nsubj
recognize	VBD	ROOT
that	IN	mark
a	DT	det
40	CD	nummod
mg	NN	compound
GA	NNP	compound
dose	NN	nsubj
result	VBD	ccomp
in	IN	prep
increase	VBN	amod
efficacy	NN	pobj
"	''	punct
not	RB	neg
accompany	VBN	advcl
by	IN	agent
a	DT	det
corresponding	JJ	amod
increase	NN	pobj
of	IN	prep
adverse	JJ	amod
reaction	NNS	pobj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
20944	CD	nummod
.	.	punct

the	DT	det
court	NN	nsubj
also	RB	advmod
rely	VBD	ROOT
upon	IN	prep
testimony	NN	pobj
from	IN	prep
Dr.	NNP	compound
Green	NNP	pobj
that	IN	mark
reduce	VBG	csubjpass
the	DT	det
frequency	NN	dobj
of	IN	prep
injection	NNS	pobj
be	VBD	auxpass
expect	VBN	ccomp
to	TO	aux
reduce	VB	xcomp
the	DT	det
number	NN	dobj
of	IN	prep
injection	NN	npadvmod
-	HYPH	punct
relate	VBN	amod
reaction	NNS	pobj
.	.	punct

 	_SP	

Teva	NNP	nsubj
find	VBZ	ROOT
fault	NN	dobj
with	IN	prep
the	DT	det
district	NN	compound
court	NN	poss
's	POS	case
reference	NN	pobj
to	IN	prep
"	``	punct
common	JJ	amod
sense	NN	pobj
"	''	punct
in	IN	prep
-PRON-	PRP$	poss
reliance	NN	pobj
on	IN	prep
Dr.	NNP	compound
Green	NNP	poss
's	POS	case
testimony	NN	pobj
.	.	punct

during	IN	prep
trial	NN	pobj
,	,	punct
Appellees	NNP	poss
'	POS	case
expert	NN	nsubj
Dr.	NNP	compound
Green	NNP	appos
testify	VBD	ROOT
that	IN	mark
a	DT	det
POSITA	NNP	nsubj
would	MD	aux
expect	VB	ccomp
reduce	VBG	xcomp
the	DT	det
frequency	NN	dobj
of	IN	prep
injection	NNS	pobj
to	TO	aux
be	VB	auxpass
associate	VBN	relcl
with	IN	prep
enhance	VBN	amod
overall	JJ	amod
tolerability	NN	pobj
of	IN	prep
the	DT	det
regimen	NN	pobj
.	.	punct

J.A.	NNP	ROOT
4911	CD	nummod
.	.	punct

In	IN	prep
-PRON-	PRP$	poss
post	JJ	subtok
-	JJ	subtok
trial	JJ	amod
briefing	NN	pobj
,	,	punct
Teva	NNP	nsubj
argue	VBD	ROOT
that	IN	mark
Dr.	NNP	compound
Green	NNP	poss
's	POS	case
testimony	NN	nsubj
be	VBD	ccomp
conclusory	JJ	acomp
and	CC	cc
unsupported	JJ	conj
by	IN	agent
the	DT	det
prior	JJ	amod
art	NN	pobj
.	.	punct

the	DT	det
district	NN	compound
court	NN	nsubj
reject	VBD	ROOT
this	DT	det
characterization	NN	dobj
,	,	punct
note	VBG	advcl
that	IN	mark
"	``	punct
-PRON-	PRP	nsubj
be	VBZ	ccomp
simply	RB	advmod
common	JJ	amod
sense	NN	attr
that	IN	mark
if	IN	mark
a	DT	det
patient	NN	amod
experience	VBZ	advcl
adverse	JJ	amod
reaction	NNS	dobj
from	IN	prep
an	DT	det
injection	NN	pobj
,	,	punct
reduce	VBG	csubj
the	DT	det
number	NN	dobj
of	IN	prep
injection	NNS	pobj
-PRON-	PRP	nsubj
receive	VBP	relcl
would	MD	aux
reduce	VB	ccomp
the	DT	det
number	NN	dobj
of	IN	prep
time	NNS	pobj
-PRON-	PRP	nsubj
have	VBP	relcl
a	DT	det
reaction	NN	dobj
"	''	punct
.	.	punct

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	prep
*	NFP	punct
17	CD	pobj
.	.	punct

the	DT	det
district	NN	compound
court	NN	nsubj
go	VBD	ROOT
on	RP	prt
to	TO	aux
identify	VB	advcl
additional	JJ	amod
evidence	NN	dobj
in	IN	prep
the	DT	det
record	NN	pobj
to	TO	aux
support	VB	acl
Dr.	NNP	compound
Green	NNP	poss
's	POS	case
statement	NN	dobj
,	,	punct
include	VBG	prep
evidence	NN	pobj
in	IN	prep
the	DT	det
Khan	NNP	nmod
2008/caon	NN	nummod
and	CC	cc
Flechter	NNP	conj
study	NNS	pobj
,	,	punct
and	CC	cc
testimony	NN	conj
from	IN	prep
Dr.	NNP	compound
Wolinksy	NNP	pobj
,	,	punct
Teva	NNP	poss
's	POS	case
own	JJ	amod
expert	NN	appos
,	,	punct
who	WP	nsubj
testify	VBD	relcl
that	IN	mark
-PRON-	PRP	nsubj
have	VBD	aux
prescribe	VBN	ccomp
COPAXONE	NNP	compound
(r)	SYM	dobj

20	CD	nummod
mg	NN	ROOT
for	IN	prep
use	NN	pobj
every	DT	det
other	JJ	amod
day	NN	npadvmod
,	,	punct
off	IN	nmod
-	HYPH	punct
label	NN	pobj
use	NN	appos
,	,	punct
for	IN	prep
-PRON-	PRP$	poss
patient	NNS	pobj
who	WP	nsubj
be	VBD	aux
"	``	punct
do	VBG	relcl
extremely	RB	advmod
well	RB	advmod
on	IN	prep
the	DT	det
drug	NN	pobj
but	CC	cc
[	-LRB-	punct
be	VBD	aux
]	-RRB-	punct
have	VBG	conj
trouble	NN	dobj
with	IN	prep
injection	NN	compound
site	NN	compound
problem	NNS	pobj
"	''	punct
.	.	punct

Idaho	NNP	ROOT

-PRON-	PRP	nsubj
see	VBP	ROOT
no	DT	det
error	NN	dobj
in	IN	prep
what	WP	nsubj
be	VBZ	pcomp
essentially	RB	advmod
a	DT	det
credibility	NN	compound
determination	NN	attr
,	,	punct
where	WRB	advmod
the	DT	det
district	NN	compound
court	NN	nsubj
credit	VBD	relcl
Dr.	NNP	compound
Green	NNP	poss
's	POS	case
expert	NN	compound
testimony	NN	dobj
,	,	punct
support	VBN	acl
by	IN	agent
other	JJ	amod
evidence	NN	pobj
in	IN	prep
the	DT	det
record	NN	pobj
,	,	punct
that	IN	mark
a	DT	det
reduction	NN	nsubj
in	IN	prep
the	DT	det
number	NN	pobj
of	IN	prep
injection	NNS	pobj
would	MD	aux
result	VB	ccomp
in	IN	prep
less	RBR	advmod
frequent	JJ	amod
reaction	NNS	pobj
.	.	punct

see	VB	ROOT
J.A.	NNP	dobj
4857	CD	nummod
.	.	punct

 	_SP	

Teva	NNP	nsubj
also	RB	advmod
argue	VBZ	ROOT
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
err	VBN	ccomp
by	IN	prep
rely	VBG	pcomp
on	IN	prep
Teva	NNP	poss
's	POS	case
GALA	NNP	compound
proto	NN	pobj
col.	NN	npadvmod

the	DT	det
district	NN	compound
court	NN	nsubj
do	VBD	aux
not	RB	neg
use	VB	ROOT
GALA	NNP	dobj
as	IN	prep
invalidate	VBG	pcomp
prior	JJ	amod
art	NN	dobj
,	,	punct
but	CC	cc
instead	RB	advmod
as	IN	conj
evidence	NN	pobj
of	IN	prep
a	DT	det
POSITA	NNP	poss
's	POS	case
motivation	NNS	pobj
and	CC	cc
expectation	NNS	conj
when	WRB	advmod
read	VBG	advcl
the	DT	det
prior	JJ	amod
art	NN	dobj
at	IN	prep
the	DT	det
time	NN	pobj
of	IN	prep
the	DT	det
invention	NN	pobj
.	.	punct

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	prep
*	NFP	punct
20	CD	pobj
.	.	punct

With	IN	prep
respect	NN	pobj
to	IN	prep
the	DT	det
sufficiency	NN	compound
limitation	NNS	pobj
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
use	VBD	ROOT
GALA	NNP	dobj
only	RB	advmod
for	IN	prep
that	DT	det
limited	JJ	amod
purpose	NN	pobj
,	,	punct
note	VBG	advcl
Teva	NNP	poss
's	POS	case
statement	NN	dobj
to	IN	prep
FDA	NNP	pobj
that	IN	mark
"	``	punct
one	PRP	nsubj
may	MD	aux
certainly	RB	advmod
expect	VB	ccomp
a	DT	det
reduction	NN	dobj
in	IN	prep
the	DT	det
frequency	NN	pobj
of	IN	prep
such	JJ	amod
reaction	NNS	pobj
with	IN	prep
this	DT	det
new	JJ	amod
dose	NN	compound
regiman	NNS	pobj
,	,	punct
further	RB	advmod
enhance	VBG	advcl
subject	JJ	amod
adherence	NN	dobj
to	IN	prep
treatment	NN	pobj
"	''	punct
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
(	-LRB-	punct
emphasis	NN	nsubj
add	VBN	parataxis
)	-RRB-	punct
(	-LRB-	punct
quote	VBG	acl
J.A.	NNP	dobj
8267	CD	nummod
)	-RRB-	punct
.	.	punct

the	DT	det
district	NN	compound
court	NN	poss
's	POS	case
reliance	NN	nsubj
on	IN	prep
GALA	NNP	pobj
merely	RB	advmod
as	IN	prep
confirmation	NN	pobj
of	IN	prep
how	WRB	advmod
a	DT	det
POSITA	NNP	nsubj
would	MD	aux
understand	VB	pcomp
FORTE	NNP	dobj
,	,	punct
which	WDT	nsubj
be	VBZ	relcl
prior	JJ	amod
art	NN	attr
,	,	punct
be	VBZ	ROOT
not	RB	neg
erroneous	JJ	acomp
.	.	punct

 	_SP	

C.	NNP	compound
reduce	VBD	compound
Severity	NNP	compound
Claims	NNPS	ROOT
of	IN	prep
the	DT	det
'	``	punct
776	CD	nummod
patent	NN	pobj

 	_SP	

the	DT	det
asserted	JJ	amod
claim	NNS	ROOT
of	IN	prep
the	DT	det
'	``	punct
776	CD	nummod
patent	NN	nsubj
contain	VBP	pobj
additional	JJ	amod
limitation	NNS	dobj
require	VBG	acl
that	IN	mark
the	DT	det
40	CD	nummod
mg	NN	compound
GA	NNP	compound
3x	NNP	nmod
/	SYM	punct
week	NN	compound
regimen	NN	nsubj
"	''	punct
reduce	VBZ	ccomp
severity	NN	dobj
of	IN	prep
injection	NN	compound
site	NN	compound
reaction	NNS	pobj
"	''	punct
compare	VBN	prep
to	IN	prep
a	DT	det
20	CD	nummod
mg	NN	nmod
daily	JJ	amod
regiman	NNS	pobj
.	.	punct

see	VB	ROOT
,	,	punct
e.g.	RB	advmod
,	,	punct
'	''	punct
776	CD	nummod
patent	NN	npadvmod
col.	NN	dobj
17	CD	nummod
will	NN	intj
.	.	punct

37	CD	ROOT
-	SYM	punct
54	CD	prep
;	:	punct
col.	NN	conj

col.	NN	ROOT
.	.	punct

the	DT	det
party	NNS	nsubj
stipulate	VBD	ROOT
that	IN	mark
"	``	punct
severity	NN	nsubj
"	''	punct
mean	VBZ	ccomp
"	``	punct
the	DT	det
intensity	NN	dobj
of	IN	prep
a	DT	det
patient	NN	poss
's	POS	case
ISRs	NNPS	pobj
and/or	CC	cc
ipir	NNS	conj
"	''	punct
.	.	punct

J.A.	NNP	ROOT
1994	CD	nummod
.	.	punct
"	``	punct

severity	NN	nsubj
"	''	punct
appear	VBZ	ROOT
in	IN	prep
the	DT	det
specification	NN	pobj
of	IN	prep
the	DT	det
'	``	punct
776	CD	nummod
patent	NN	pobj
only	RB	advmod
once	RB	advmod
in	IN	prep
connection	NN	pobj
with	IN	prep
injection	NN	compound
site	NN	compound
reaction	NNS	pobj
,	,	punct
in	IN	prep
the	DT	det
definition	NN	pobj
of	IN	prep
"	``	punct
tolerability	NN	pobj
,	,	punct
"	''	punct
which	WDT	nsubj
mean	VBZ	relcl
"	``	punct
associate	VBN	xcomp
with	IN	prep
the	DT	det
frequency	NN	pobj
and	CC	cc
severity	NN	conj
of	IN	prep
post	JJ	compound
injection	NN	compound
reaction	NNS	pobj
and	CC	cc
injection	NN	compound
site	NN	compound
reaction	NNS	conj
"	''	punct
.	.	punct
'	''	punct
776	CD	nummod
patent	NN	compound
col.	NN	oprd
7	CD	nummod
,	,	punct
will	UH	intj
.	.	punct

37	CD	nummod
-	SYM	punct
42	CD	prep
(	-LRB-	punct
emphasis	NN	nsubj
add	VBN	ROOT
)	-RRB-	punct
.	.	punct
"	''	punct

tolerability	NN	nsubj
influence	VBZ	ROOT
the	DT	det
period	NN	dobj
that	IN	mark
a	DT	det
patient	NN	nsubj
can	MD	aux
follow	VB	relcl
GA	NNP	compound
treatment	NN	dobj
"	''	punct
.	.	punct

Idaho	NNP	ROOT

 	_SP	

After	IN	prep
review	VBG	pcomp
the	DT	det
prior	JJ	amod
art	NN	dobj
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
conclude	VBD	ROOT
that	IN	mark
the	DT	det
'	``	punct
776	CD	nummod
patent	NN	poss
's	POS	case
claim	NNS	nsubj
direct	VBN	acl
to	IN	prep
reduce	VBG	pcomp
the	DT	det
severity	NN	dobj
of	IN	prep
injection	NN	compound
site	NN	compound
reaction	NNS	pobj
would	MD	aux
have	VB	aux
be	VBN	ccomp
obvious	JJ	acomp
.	.	punct

In	IN	ROOT
re	IN	pobj
Copaxone	NNP	pobj
,	,	punct
2017	CD	nummod
WL	NNP	pobj
401943	CD	nummod
,	,	punct
at	IN	conj
*	NFP	punct
22	CD	pobj
.	.	punct

the	DT	det
district	NN	compound
court	NN	nsubj
broadly	RB	advmod
rely	VBD	ROOT
on	IN	prep
two	CD	nummod
different	JJ	amod
type	NNS	pobj
of	IN	prep
evidence	NN	pobj
in	IN	prep
reach	VBG	pcomp
this	DT	det
conclusion	NN	dobj
:	:	punct
evidence	NN	appos
and	CC	cc
testimony	NN	conj
relate	VBG	acl
to	IN	prep
lipoatrophy	NN	pobj
and	CC	cc
evidence	NN	conj
relate	VBG	acl
to	IN	prep
tolerability	NN	pobj
.	.	punct

 	_SP	

concern	VBG	prep
the	DT	det
evidence	NN	pobj
relate	VBG	acl
to	IN	prep
lipoatrophy	NN	pobj
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
point	VBD	ROOT
to	IN	prep
trial	NN	compound
testimony	NN	pobj
establish	VBG	acl
that	DT	det
lipoatrophy	NN	dobj
,	,	punct
the	DT	det
loss	NN	npadvmod
of	IN	prep
subcutaneous	JJ	amod
fat	NN	pobj
at	IN	prep
the	DT	det
injection	NN	compound
site	NN	pobj
,	,	punct
be	VBZ	conj
a	DT	det
severe	JJ	amod
ISR	NNP	attr
,	,	punct
and	CC	cc
Caon	NNP	poss
's	POS	case
disclosure	NN	conj
that	IN	mark
"	``	punct
injection	NN	nmod
relate	VBN	amod
lipoatrophy	NN	nsubj
be	VBD	acl
significantly	RB	advmod
less	JJR	acomp
"	``	punct
on	IN	prep
the	DT	det
20	CD	nummod
mg	NN	pobj
every	DT	det
other	JJ	amod
day	NN	npadvmod
regimen	NN	attr
than	IN	prep
on	IN	prep
the	DT	det
daily	JJ	amod
20	CD	nummod
mg	NN	compound
regimen	NN	pobj
.	.	punct

Idaho	NNP	ROOT

the	DT	det
court	NN	nsubj
also	RB	advmod
rely	VBD	ROOT
on	IN	prep
Teva	NNP	poss
's	POS	case
expert	NN	pobj
Dr.	NNP	compound
Fox	NNP	appos
,	,	punct
who	WP	nsubj
testify	VBD	relcl
that	IN	mark
"	``	punct
if	IN	mark
there	EX	expl
be	VBZ	advcl
a	DT	det
decrease	NN	attr
in	IN	prep
the	DT	det
frequency	NN	pobj
of	IN	prep
lipoatrophy	NN	pobj
,	,	punct
there	EX	expl
would	MD	aux
,	,	punct
by	IN	prep
definition	NN	pobj
,	,	punct
then	RB	advmod
also	RB	advmod
be	VB	ccomp
a	DT	det
decrease	NN	attr
in	IN	prep
the	DT	det
severity	NN	pobj
of	IN	prep
the	DT	det
adverse	JJ	amod
event	NNS	pobj
"	''	punct
.	.	punct

Idaho	NNP	ROOT

-PRON-	PRP	nsubj
agree	VBP	ROOT
with	IN	prep
the	DT	det
district	NN	compound
court	NN	pobj
that	IN	mark
this	DT	det
evidence	NN	nsubj
"	''	punct
provide	VBZ	ccomp
a	DT	det
reasonable	JJ	amod
expectation	NN	dobj
to	IN	prep
those	DT	pobj
skilled	JJ	amod
in	IN	prep
the	DT	det
art	NN	pobj
that	IN	mark
reduce	VBG	csubj
the	DT	det
number	NN	dobj
of	IN	prep
injection	NNS	pobj
per	IN	prep
week	NN	pobj
may	MD	aux
also	RB	advmod
reduce	VB	relcl
the	DT	det
severity	NN	dobj
of	IN	prep
injection	NN	compound
site	NN	compound
reaction	NNS	pobj
"	''	punct
.	.	punct

Idaho	NNP	ROOT

 	_SP	

In	IN	prep
addition	NN	pobj
to	IN	prep
the	DT	det
evidence	NN	pobj
regard	VBG	prep
lipoatrophy	NN	pobj
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
also	RB	advmod
point	VBD	ROOT
to	IN	prep
a	DT	det
press	NN	compound
release	NN	pobj
issue	VBN	acl
by	IN	agent
Teva	NNP	compound
summarize	VBG	amod
FORTE	NNP	pobj
,	,	punct
which	WDT	nsubj
admit	VBD	relcl
that	IN	mark
the	DT	det
40	CD	nummod
mg	NN	compound
dose	NN	nsubj
"	''	punct
maintain	VBD	ccomp
the	DT	det
favorable	JJ	amod
safety	NN	dobj
and	CC	cc
tolerability	NN	compound
profile	NN	conj
of	IN	prep
COPAXONE	NNP	compound
(r)	SYM	pobj

20	CD	nummod
mg	NN	dep
,	,	punct
"	''	punct
and	CC	cc
testimony	NN	conj
from	IN	prep
the	DT	det
name	VBN	amod
inventor	NN	pobj
,	,	punct
Dr.	NNP	compound
Klinger	NNP	npadvmod
,	,	punct
that	IN	mark
"	``	punct
if	IN	mark
a	DT	det
40	CD	nummod
mg	NN	nmod
three	CD	nummod
-	HYPH	punct
time	NNS	nmod
-	HYPH	punct
a	DT	det
-	HYPH	punct
week	NN	npadvmod
regimen	NN	nsubj
improve	VBZ	advcl
patient	JJ	amod
tolerability	NN	dobj
,	,	punct
then	RB	advmod
-PRON-	PRP	nsubj
inherently	RB	advmod
have	VBZ	ROOT
to	TO	aux
reduce	VB	xcomp
the	DT	det
frequency	NN	dobj
and	CC	cc
severity	NN	conj
of	IN	prep
injection	NN	compound
site	NN	compound
reaction	NNS	pobj
"	''	punct
.	.	punct

Idaho	NNS	ROOT
at	IN	prep
*	NFP	punct
23	CD	pobj
.	.	punct

cite	VBG	advcl
Dr.	NNP	compound
Klinger	NNP	poss
's	POS	case
testimony	NN	dobj
,	,	punct
the	DT	det
district	NN	compound
court	NN	nsubj
correctly	RB	advmod
conclude	VBD	ROOT
that	IN	mark
"	``	punct
-PRON-	PRP	nsubj
follow	VBZ	ccomp
that	IN	mark
the	DT	det
FORTE	NNP	compound
study	NN	nsubj
show	VBD	ccomp
that	IN	mark
administer	VBG	csubj
40	CD	nummod
mg	NN	dobj
of	IN	prep
GA	NNP	pobj
daily	RB	advmod
to	IN	prep
patient	NNS	pobj
do	VBD	aux
not	RB	neg
increase	VB	ccomp
the	DT	det
frequency	NN	dobj
or	CC	cc
severity	NN	conj
of	IN	prep
injection	NN	compound
site	NN	compound
reaction	NNS	pobj
"	''	punct
.	.	punct

Idaho	NNP	ROOT

 	_SP	

Teva	NNP	nsubj
contend	VBZ	ROOT
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
erroneously	RB	advmod
conflate	VBD	ccomp
frequency	NN	dobj
with	IN	prep
severity	NN	pobj
,	,	punct
and	CC	cc
that	IN	det
evidence	NN	nsubj
of	IN	prep
reduced	JJ	amod
frequency	NN	pobj
of	IN	prep
isr	NNS	pobj
can	MD	aux
not	RB	neg
prove	VB	conj
reduced	JJ	amod
severity	NN	dobj
of	IN	prep
ISRs	NNPS	pobj
.	.	punct

While	IN	mark
-PRON-	PRP	nsubj
agree	VBP	advcl
that	IN	mark
the	DT	det
two	CD	nummod
concept	NNS	nsubj
be	VBP	ccomp
distinct	JJ	acomp
,	,	punct
-PRON-	PRP	nsubj
conclude	VBP	ROOT
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
do	VBD	aux
not	RB	neg
err	VB	ccomp
.	.	punct

frequency	NN	nsubj
and	CC	cc
severity	NN	conj
of	IN	prep
isr	NNS	pobj
be	VBP	ROOT
not	RB	neg
interchangeable	JJ	acomp
,	,	punct
but	CC	cc
Dr.	NNP	compound
Fox	NNP	poss
's	POS	case
testimony	NN	nsubj
establish	VBD	conj
that	IN	mark
,	,	punct
in	IN	prep
certain	JJ	amod
instance	NNS	pobj
,	,	punct
-PRON-	PRP	nsubjpass
be	VBP	auxpass
relate	VBN	ccomp
:	:	punct

 	_SP	

Q.	NNP	compound
Doctor	NNP	nsubj
,	,	punct
be	VBZ	ROOT
severity	NN	attr
the	DT	det
same	JJ	amod
thing	NN	attr
as	IN	prep
frequency	NN	pobj
?	.	punct

 	_SP	

a.	NN	compound
no	UH	intj
,	,	punct
-PRON-	PRP	nsubj
be	VBP	ROOT
relate	VBN	acomp
,	,	punct
but	CC	cc
-PRON-	PRP	nsubj
be	VBP	conj
separate	JJ	amod
topic	NNS	attr
.	.	punct

 	_SP	

Q.	NNP	ROOT

how	WRB	advmod
do	VBP	aux
-PRON-	PRP	nsubj
relate	VB	ROOT
to	IN	prep
one	NN	pobj
another	DT	det
?	.	punct

 	_SP	

a.	NN	ROOT

there	RB	expl
,	,	punct
as	IN	mark
-PRON-	PRP	nsubj
mention	VBD	advcl
before	RB	advmod
...	NFP	punct
,	,	punct
there	EX	expl
be	VBP	ROOT
some	DT	det
event	NNS	attr
like	IN	prep
lipoatrophy	NN	pobj
that	WDT	nsubjpass
would	MD	aux
be	VB	auxpass
consider	VBN	relcl
to	TO	aux
be	VB	xcomp
more	RBR	advmod
severe	JJ	acomp
.	.	punct

so	RB	advmod
if	IN	mark
there	EX	expl
be	VBZ	advcl
a	DT	det
decrease	NN	attr
in	IN	prep
the	DT	det
frequency	NN	pobj
of	IN	prep
lipoatrophy	NN	pobj
,	,	punct
there	EX	expl
would	MD	aux
,	,	punct
by	IN	prep
definition	NN	pobj
,	,	punct
then	RB	advmod
also	RB	advmod
be	VB	ROOT
a	DT	det
decrease	NN	attr
in	IN	prep
the	DT	det
severity	NN	pobj
of	IN	prep
the	DT	det
adverse	JJ	amod
event	NNS	pobj
.	.	punct

 	_SP	

Q.	NNP	ROOT

so	RB	advmod
do	VBP	aux
-PRON-	PRP	nsubj
consider	VB	ROOT
these	DT	det
two	CD	nummod
concept	NNS	nsubj
to	TO	aux
be	VB	ccomp
mutually	RB	advmod
exclusive	JJ	acomp
?	.	punct

 	_SP	

a.	NN	compound
no	UH	intj
,	,	punct
-PRON-	PRP	nsubj
be	VBP	ROOT
not	RB	neg
.	.	punct

-PRON-	PRP	nsubjpass
be	VBP	auxpass
relate	VBN	ROOT
.	.	punct

 	_SP	

Caon	NNP	nsubj
show	VBD	ROOT
that	IN	mark
reduce	VBG	csubj
the	DT	det
frequency	NN	dobj
of	IN	prep
injection	NNS	pobj
from	IN	prep
daily	RB	pobj
to	IN	prep
every	DT	det
other	JJ	amod
day	NN	pobj
result	VBD	ccomp
in	IN	prep
"	``	punct
significantly	RB	advmod
less	JJR	amod
lipoatrophy	NN	pobj
,	,	punct
"	''	punct
a	DT	det
severe	JJ	amod
ISR	NNP	appos
.	.	punct

This	DT	det
statement	NN	nsubjpass
in	IN	prep
Caon	NNP	pobj
can	MD	aux
be	VB	auxpass
read	VBN	ROOT
as	IN	prep
indicate	VBG	pcomp
either	CC	preconj
that	DT	det
lipoatrophy	NN	nsubj
occur	VBD	ccomp
less	RBR	advmod
frequently	RB	advmod
with	IN	prep
less	RBR	advmod
frequent	JJ	amod
injection	NNS	pobj
-	:	punct
which	WDT	nsubj
,	,	punct
accord	VBG	prep
to	IN	prep
Dr.	NNP	compound
Fox	NNP	poss
's	POS	case
testimony	NN	pobj
,	,	punct
"	''	punct
by	IN	prep
definition	NN	pobj
"	''	punct
mean	VBZ	relcl
reduce	VBN	amod
severity	NN	dobj
-	:	punct
or	CC	cc
the	DT	det
expression	NN	nsubj
of	IN	prep
the	DT	det
lipoatrophy	NN	pobj
-PRON-	PRP	appos
be	VBD	ccomp
less	RBR	advmod
severe	JJ	acomp
.	.	punct

-PRON-	PRP	nsubj
be	VBD	ROOT
not	RB	neg
unreasonable	JJ	acomp
for	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
to	TO	aux
conclude	VB	advcl
from	IN	prep
this	DT	det
evidence	NN	pobj
that	IN	mark
a	DT	det
POSITA	NNP	nsubj
would	MD	aux
think	VB	acl
-PRON-	PRP	nsubj
obvious	JJ	ccomp
that	IN	mark
the	DT	det
40	CD	nummod
mg	NN	nmod
GA	NNP	compound
3x	NNP	nmod
/	SYM	punct
week	NN	compound
regiman	NNS	nsubj
,	,	punct
with	IN	prep
-PRON-	PRP$	poss
less	RBR	advmod
frequent	JJ	amod
injection	NNS	pobj
,	,	punct
would	MD	aux
result	VB	ccomp
in	IN	prep
reduced	JJ	amod
severity	NN	pobj
of	IN	prep
at	RB	advmod
least	RBS	advmod
one	CD	nummod
ISR	NNP	pobj
,	,	punct
lipoatrophy	NN	appos
,	,	punct
particularly	RB	advmod
give	VBN	prep
Dr.	NNP	compound
Fox	NNP	poss
's	POS	case
testimony	NN	pobj
endorse	VBG	acl
the	DT	det
same	JJ	dobj
.	.	punct

see	VB	advcl
Hoffmann	NNP	compound
-	HYPH	punct
La	NNP	compound
Roche	NNP	dobj
,	,	punct
748	CD	nummod
f.3d	CD	appos
at	IN	prep
1331	CD	pobj
(	-LRB-	punct
hold	VBG	csubj
that	IN	mark
prior	JJ	amod
art	NN	compound
reference	NNS	nsubj
need	VBP	ccomp
only	RB	advmod
demonstrate	VB	ROOT
"	``	punct
a	DT	det
reasonable	JJ	amod
expectation	NN	dobj
of	IN	prep
success	NN	pobj
,	,	punct
"	''	punct
not	RB	neg
"	``	punct
conclusive	JJ	amod
proof	NN	dep
of	IN	prep
efficacy	NN	pobj
"	''	punct
)	-RRB-	punct
.	.	punct

 	_SP	

Teva	NNP	nsubj
also	RB	advmod
dispute	VBZ	ROOT
the	DT	det
district	NN	compound
court	NN	poss
's	POS	case
reliance	NN	dobj
on	IN	prep
the	DT	det
forte	JJ	compound
press	NN	compound
release	NN	pobj
.	.	punct

however	RB	advmod
,	,	punct
give	VBN	prep
that	IN	mark
the	DT	det
finding	NNS	nsubj
make	VBN	acl
by	IN	agent
the	DT	det
district	NN	compound
court	NN	pobj
in	IN	prep
reach	VBG	pcomp
-PRON-	PRP$	poss
obviousness	JJ	amod
conclusion	NN	dobj
,	,	punct
base	VBN	acl
on	IN	prep
the	DT	det
other	JJ	amod
evidence	NN	pobj
rely	VBN	acl
on	RP	prt
by	IN	agent
the	DT	det
court	NN	pobj
,	,	punct
be	VBD	pcomp
not	RB	neg
clearly	RB	advmod
erroneous	JJ	acomp
,	,	punct
-PRON-	PRP	nsubj
do	VBP	aux
not	RB	neg
reach	VB	ROOT
this	DT	det
argument	NN	dobj
.	.	punct

 	_SP	

In	IN	prep
light	NN	pobj
of	IN	prep
the	DT	det
foregoing	NN	pobj
,	,	punct
-PRON-	PRP	nsubj
conclude	VBP	ROOT
that	IN	mark
the	DT	det
district	NN	compound
court	NN	nsubj
do	VBD	aux
not	RB	neg
err	VB	ccomp
in	IN	prep
invalidate	VBG	pobj
all	DT	det
assert	VBN	amod
claim	NNS	dobj
of	IN	prep
the	DT	det
Copaxone	NNP	compound
patent	NNS	pobj
as	RB	prep
obvious	JJ	amod
.	.	punct

 	_SP	

no	DT	det
cost	NNS	ROOT
.	.	punct

 	_SP	

all	DT	det
Citations	NNPS	nsubj

 	_SP	
906	CD	nummod
f.3d	CD	appos
1013	CD	appos
,	,	punct
128	CD	nummod
U.S.P.Q.2d	NNP	appos
1301	CD	nummod

 	_SP	
Footnotes	NNP	ROOT

 	_SP	

In	IN	prep
a	DT	det
companion	NN	compound
case	NN	pobj
decide	VBD	acl
today	NN	npadvmod
,	,	punct
Yeda	NNP	compound
Research	NNP	dep
&	CC	cc
Development	NNP	compound
Co.	NNP	conj
v.	CC	prep
Mylan	NNP	compound
Pharmaceuticals	NNPS	compound
Inc.	NNP	pobj
,	,	punct
No.	SYM	npadvmod
17	CD	nummod
-	SYM	punct
1594	CD	nummod
,	,	punct
17	CD	npadvmod
-	SYM	punct
1595	CD	prep
,	,	punct
17	CD	appos
-	SYM	punct
1596	CD	prep
,	,	punct
906	CD	nummod
f.3d	CD	appos
1031	CD	appos
,	,	punct
2018	CD	npadvmod
WL	NNP	appos
4938974	CD	appos
(	-LRB-	punct
Fed	NNP	ROOT
.	.	punct
Cir	NNP	npadvmod
.	.	punct
October	NNP	npadvmod
12	CD	nummod
,	,	punct
2018	CD	nummod
)	-RRB-	punct
,	,	punct

Yeda	NNP	compound
Research	NNP	nsubj
and	CC	cc
Development	NNP	compound
Co.	NNP	conj
appeal	VBD	ROOT
from	IN	prep
the	DT	det
Patent	NNP	compound
Trial	NNP	pobj
and	CC	cc
Appeal	NNP	compound
Board	NNP	conj
's	POS	case
final	JJ	amod
write	VBN	amod
decision	NNS	pobj
find	VBG	acl
all	DT	det
claim	NNS	dobj
of	IN	prep
U.S.	NNP	compound
Patent	NNP	compound
No.	SYM	pobj
8,232,250	CD	nummod
,	,	punct
8,399,413	CD	appos
,	,	punct
and	CC	cc
8,969,302	CD	conj
unpatentable	JJ	amod
as	IN	prep
obvious	JJ	amod
in	IN	prep
three	CD	nummod
related	JJ	amod
inter	JJ	nsubj
parte	NNS	ccomp
review	VBP	compound
proceeding	NNS	dobj
.	.	punct

 	_SP	

claim	NN	nsubj
1	CD	nummod
of	IN	prep
the	DT	det
'	``	punct
302	CD	nummod
patent	NN	pobj
do	VBZ	aux
not	RB	neg
specify	VB	ROOT
any	DT	det
particular	JJ	amod
interval	NN	dobj
between	IN	prep
dos	NNS	pobj
.	.	punct
'	''	punct
302	CD	nummod
patent	NN	nsubj
col.	NN	ccomp
16	CD	nummod
will	NN	intj
.	.	punct

37	CD	ROOT
-	SYM	punct
41	CD	prep
.	.	punct

independent	JJ	nsubj
claim	NN	ROOT
10	CD	nsubj
of	IN	prep
the	DT	det
'	``	punct
302	CD	nummod
patent	NN	pobj
require	VBZ	ccomp
that	IN	mark
the	DT	det
injection	NN	nsubjpass
be	VB	auxpass
administer	VBN	ccomp
"	``	punct
three	CD	nummod
time	NNS	npadvmod
per	IN	prep
week	NN	pobj
with	IN	prep
at	RB	advmod
least	RBS	advmod
one	CD	nummod
day	NN	pobj
between	IN	prep
every	DT	det
subcutaneous	JJ	amod
injection	NN	pobj
"	''	punct
.	.	punct

Idaho	NNP	nsubj
col.	NNP	ROOT
17	CD	nummod
will	NN	intj
.	.	punct

4	CD	ROOT
-	SYM	punct
12	CD	prep
.	.	punct

 	_SP	

Murray	NNP	compound
B.	NNP	compound
Bornstein	NNP	compound
et	NNP	compound
al	NNP	subtok
.	.	ROOT
,	,	punct

a	DT	det
Pilot	NNP	compound
Trial	NNP	ROOT
of	IN	prep
COP	NNP	pobj
1	CD	conj
in	IN	prep
Exacerbating	NNP	compound
-	HYPH	punct
remit	VBG	compound
Multiple	NNP	compound
Sclerosis	NNP	pobj
,	,	punct
317	CD	nummod
New	NNP	compound
Eng	NNP	appos
.	.	punct

J.	NNP	compound
Med	NNP	ROOT
.	.	punct

408	CD	ROOT
,	,	punct
408	CD	nummod
-	SYM	punct
14	CD	prep
(	-LRB-	punct
1987	CD	appos
)	-RRB-	punct
.	.	punct

 	_SP	

Shlomo	NNP	compound
Flechter	NNP	compound
et	NNP	compound
al	NNP	subtok
.	.	ROOT
,	,	punct
Copolymer	NNP	npadvmod
1	CD	nummod
(	-LRB-	punct
Glatiramer	NNP	compound
Acetate	NNP	appos
)	-RRB-	punct
in	IN	prep
relapse	VBG	pcomp
Forms	NNPS	dobj
of	IN	prep
Multiple	NNP	compound
Sclerosis	NNP	pobj
:	:	punct

Open	NNP	compound
Multicenter	NNP	compound
Study	NNP	ROOT
of	IN	prep
Alternate	NNP	compound
-	HYPH	punct
Day	NNP	compound
Administration	NNP	pobj
,	,	punct
25	CD	nummod
Clinical	NNP	compound
Neuropharmacology	NNP	appos
11	CD	nummod
,	,	punct
11	CD	npadvmod
-	SYM	punct
15	CD	prep
(	-LRB-	punct
2002	CD	appos
)	-RRB-	punct
.	.	punct

 	_SP	

J.A.	NNP	compound
Cohen	NNP	compound
et	NNP	compound
al	NNP	subtok
.	.	ROOT
,	,	punct

randomize	VBN	ROOT
,	,	punct
double	JJ	amod
-	HYPH	punct
blind	JJ	conj
,	,	punct
Dose	NNP	compound
-	HYPH	punct
Comparison	NNP	compound
Study	NNP	conj
of	IN	prep
Glatiramer	NNP	compound
Acetate	NNP	pobj
in	IN	prep
Relapsing	NNP	npadvmod
-	HYPH	punct
remit	VBG	compound
MS	NNP	pobj
,	,	punct

68	CD	nummod
neurology	NN	ROOT
939	CD	nummod
,	,	punct
939	CD	npadvmod
-	SYM	punct
44	CD	prep
(	-LRB-	punct
2007	CD	npadvmod
)	-RRB-	punct
.	.	punct

 	_SP	

Giancarlo	NNP	compound
Comi	NNP	ROOT
,	,	punct
Jeffrey	NNP	compound
A.	NNP	compound
Cohen	NNP	conj
,	,	punct
Massimo	NNP	compound
Filippi	NNP	appos
for	IN	prep
the	DT	det
FORTE	NNP	compound
Study	NNP	compound
Group	NNP	pobj
,	,	punct
Results	NNP	conj
from	IN	prep
a	DT	det
Phase	NNP	compound
III	NNP	pobj
,	,	punct

one	CD	nummod
-	HYPH	punct
Year	NNP	ROOT
,	,	punct
Randomized	NNP	npadvmod
,	,	punct
double	JJ	amod
-	HYPH	punct
blind	JJ	conj
,	,	punct
Parallel	NNP	compound
-	HYPH	punct
Group	NNP	conj
,	,	punct

Dose	NNP	compound
-	HYPH	punct
Comparison	NNP	compound
Study	NNP	ROOT
with	IN	prep
Glatiramer	NNP	compound
Acetate	NNP	pobj
in	IN	prep
relapse	VBG	npadvmod
-	HYPH	punct
remit	VBG	compound
Multiple	NNP	compound
Sclerosis	NNP	pobj
,	,	punct
14	CD	nummod
Multiple	NNP	compound
Sclerosis	NNP	compound
S299	NNP	appos
,	,	punct
S299-S301	NNP	npadvmod
(	-LRB-	punct
2008	CD	appos
)	-RRB-	punct
.	.	punct

 	_SP	

Omar	NNP	compound
Khan	NNP	compound
et	NNP	compound
al	NNP	subtok
.	.	ROOT
,	,	punct

Randomized	NNP	ROOT
,	,	punct
Prospective	NNP	conj
,	,	punct
Rater	NNP	compound
-	HYPH	punct
Blinded	NNP	conj
,	,	punct
Four	NNP	nummod
-	HYPH	punct
Year	NNP	conj
,	,	punct
Pilot	NNP	compound
Study	NNP	npadvmod
to	TO	aux
compare	VB	advcl
the	DT	det
Effect	NNP	dobj
of	IN	prep
Daily	NNP	compound
Versus	NNP	pobj

Every	NNP	compound
-	HYPH	punct
Other	NNP	amod
-	HYPH	punct
Day	NNP	compound
Glatiramer	NNP	compound
Acetate	NNP	ROOT
20	CD	nummod
Mg	NNP	compound
Subcutaneous	NNP	compound
Injections	NNPS	appos
in	IN	prep
Relapsing	NNP	npadvmod
-	HYPH	punct
remit	VBG	compound
Multiple	NNP	compound
Sclerosis	NNP	pobj
,	,	punct
14	CD	nummod
Multiple	NNP	compound
Sclerosis	NNP	conj
S296	NNP	appos
,	,	punct
S296	NNP	npadvmod
(	-LRB-	punct
2008	CD	appos
)	-RRB-	punct
.	.	punct

 	_SP	

Christina	NNP	compound
Caon	NNP	compound
et	NNP	compound
al	NNP	subtok
.	.	ROOT
,	,	punct
Randomized	NNP	npadvmod
,	,	punct
Prospective	NNP	conj
,	,	punct
Rater	NNP	compound
-	HYPH	punct
Blinded	NNP	conj
,	,	punct

Four	NNP	nummod
Year	NNP	compound
Pilot	NNP	compound
Study	NNP	nsubj
to	TO	aux
compare	VB	ROOT
the	DT	det
Effect	NNP	dobj
of	IN	prep
Daily	NNP	compound
Versus	NNP	pobj

every	DT	det
Other	NNP	amod
Day	NNP	ROOT

Glatiramer	NNP	compound
Acetate	NNP	ROOT
20	CD	nummod
mg	NN	compound
Subcutaneous	NNP	compound
Injections	NNPS	appos
in	IN	prep
RRMS	NNP	pobj
,	,	punct
72	CD	nummod
neurology	NN	conj
(	-LRB-	punct
Suppl	NNP	appos
.	.	punct
3	LS	nummod
)	-RRB-	punct
A317	NNP	appos
(	-LRB-	punct
2009	CD	appos
)	-RRB-	punct
.	.	punct

 	_SP	

O.	NNP	compound
Khan	NNP	compound
et	NNP	compound
al	NNP	subtok
.	.	ROOT
,	,	punct
Glatiramer	NNP	compound
Acetate	NNP	npadvmod

20	CD	nummod
mg	NN	compound
subcutaneous	JJ	compound
Twice	NNP	compound
-	HYPH	punct
Weekly	NNP	compound
Versus	NNP	compound
Daily	NNP	compound
Injections	NNPS	ROOT
:	:	punct
result	NNS	appos
of	IN	prep
a	DT	det
Pilot	NNP	nmod
,	,	punct
Prospective	NNP	conj
,	,	punct
Randomised	NNP	conj
,	,	punct
and	CC	cc
Rater	NNP	compound
-	HYPH	punct
Blinded	NNP	compound
Clinical	NNP	conj
and	CC	cc
MRI	NNP	compound
2-year	CD	conj
study	NN	pobj
in	IN	prep
Relapsing	NNP	npadvmod
-	HYPH	punct
remit	VBG	compound
Multiple	NNP	compound
Sclerosis	NNP	pobj
,	,	punct
15	CD	nummod
Multiple	NNP	compound
Sclerosis	NNP	compound
S249	NNP	appos
,	,	punct
s249	NN	compound
-	HYPH	punct
50	CD	conj
(	-LRB-	punct
2009	CD	appos
)	-RRB-	punct
.	.	punct

 	_SP	

e.g.	RB	ROOT
,	,	punct
'	''	punct
250	CD	nummod
patent	NN	compound
col.	NN	npadvmod
16	CD	nummod
will	NN	intj
.	.	punct

44	CD	ROOT
-	SYM	punct
45	CD	prep
(	-LRB-	punct
"	``	punct
the	DT	det
regiman	NNS	nsubj
be	VBG	advcl
sufficient	JJ	acomp
to	TO	aux
alleviate	VB	xcomp
the	DT	det
symptom	NN	dobj
of	IN	prep
the	DT	det
patient	NN	pobj
"	''	punct
)	-RRB-	punct
;	:	punct
'	''	punct
413	CD	nummod
patent	NN	compound
col.	NN	conj
16	CD	nummod
will	NN	intj
.	.	punct

35	CD	ROOT
-	SYM	punct
36	CD	prep
(	-LRB-	punct
"	``	punct
the	DT	det
regiman	NNS	nsubj
be	VBG	advcl
sufficient	JJ	acomp
to	TO	aux
reduce	VB	xcomp
the	DT	det
frequency	NN	dobj
of	IN	prep
relapse	NNS	pobj
in	IN	prep
the	DT	det
patient	NN	pobj
"	''	punct
)	-RRB-	punct
.	.	punct

 	_SP	

e.g.	RB	ROOT
,	,	punct
'	''	punct
776	CD	nummod
patent	NN	compound
col.	NN	npadvmod
17	CD	nummod
will	NN	intj
.	.	punct

20	CD	ROOT
-	SYM	punct
22	CD	prep
(	-LRB-	punct
"	``	punct
which	WDT	nsubj
reduce	VBZ	relcl
brain	NN	compound
atrophy	NN	dobj
and	CC	cc
for	IN	prep
reduce	VBG	pcomp
the	DT	det
frequency	NN	dobj
of	IN	prep
relapse	NNS	pobj
by	IN	prep
30	CD	nummod
%	NN	pobj
or	CC	cc
more	JJR	nummod
as	IN	prep
compare	VBN	prep
to	TO	prep
placebo	VB	pobj
in	IN	prep
a	DT	det
human	JJ	amod
population	NN	pobj
"	''	punct
)	-RRB-	punct
.	.	punct

 	_SP	

e.g.	RB	ROOT
,	,	punct
'	''	punct
776	CD	nummod
patent	NN	compound
col.	NN	npadvmod
17	CD	nummod
will	NN	intj
.	.	punct

39	CD	meta
-	SYM	punct
40	CD	prep
(	-LRB-	punct
"	''	punct
which	WDT	nsubj
be	VBZ	ROOT
as	RB	advmod
effective	JJ	acomp
as	IN	prep
administration	NN	pobj
of	IN	prep
20	CD	nummod
mg	NN	pobj
of	IN	prep
glatiramer	NN	nmod
acetate	VBP	amod
s.c	NNP	pobj
.	.	punct
daily	RB	acomp
"	''	punct
)	-RRB-	punct
.	.	punct

 	_SP	

Congress	NNP	nsubj
amend	VBD	ROOT
¡±	CD	nummod
103	CD	dobj
when	WRB	advmod
-PRON-	PRP	nsubj
pass	VBD	advcl
the	DT	det
Leahy	NNP	compound
-	HYPH	punct
Smith	NNP	compound
America	NNP	compound
Invents	NNPS	compound
Act	NNP	dobj
(	-LRB-	punct
AIA	NNP	appos
)	-RRB-	punct
.	.	punct

Pub	NNP	ROOT
.	.	punct

L.	NNP	compound
No.	SYM	ROOT
112	CD	nummod
-	SYM	punct
29	CD	prep
,	,	punct
¡±	CD	punct
3(c	CD	appos
)	-RRB-	punct
,	,	punct
125	CD	nummod
Stat	NNP	subtok
.	.	punct

284	CD	ROOT
,	,	punct
287	CD	nummod
(	-LRB-	punct
2011	CD	npadvmod
)	-RRB-	punct
.	.	punct

Because	IN	mark
the	DT	det
application	NNS	nsubj
that	WDT	nsubj
lead	VBD	relcl
to	IN	prep
the	DT	det
patent	NNS	pobj
at	IN	prep
issue	NN	pobj
have	VBP	aux
never	RB	neg
contain	VBN	ROOT
a	DT	det
claim	NN	dobj
have	VBG	acl
an	DT	det
effective	JJ	amod
filing	NN	compound
date	NN	dobj
on	IN	prep
or	CC	cc
after	IN	conj
March	NNP	pobj
16	CD	nummod
,	,	punct
2013	CD	nummod
(	-LRB-	punct
the	DT	det
effective	JJ	amod
date	NN	npadvmod
of	IN	prep
the	DT	det
statutory	JJ	amod
change	NNS	pobj
enact	VBN	acl
in	IN	prep
2011	CD	pobj
)	-RRB-	punct
,	,	punct
or	CC	cc
a	DT	det
reference	NN	conj
under	IN	prep
35	CD	pobj
u.s.c.	NN	subtok
¡±	NNP	prep

¡±	NNP	dep
120	CD	nummod
,	,	punct
121	CD	appos
,	,	punct
or	CC	cc
365(c	LS	punct
)	-RRB-	punct
to	IN	prep
any	DT	det
patent	NN	pobj
or	CC	cc
application	NN	conj
that	WDT	nsubj
ever	RB	advmod
contain	VBD	relcl
such	PDT	predet
a	DT	det
claim	NN	dobj
,	,	punct
the	DT	det
pre	JJ	subtok
-	JJ	subtok
AIA	NNP	dep
¡±	CD	pobj
103	CD	nummod
apply	VBZ	ROOT
.	.	punct

Idaho	NNP	ROOT
¡±	NNP	dep
3(n)(1	NNP	intj
)	-RRB-	punct
,	,	punct
125	CD	nummod
Stat	NNP	appos
.	.	punct
at	IN	prep
293	CD	pobj
.	.	punct

 	_SP	

see	VB	ccomp
,	,	punct
e.g.	RB	advmod
,	,	punct
J.A.	NNP	pobj
4676	CD	nummod
-	SYM	punct
77	CD	prep
(	-LRB-	punct
Kolodny	NNP	compound
deposition	NN	appos
,	,	punct
describe	VBG	acl
needle	NN	compound
fatigue	NN	dobj
associate	VBN	acl
with	IN	prep
Copaxone	NNP	nmod
20mg	NN	nmod
/	SYM	punct
day	NN	pobj
)	-RRB-	punct
;	:	punct
J.A.	NNP	appos
4869	CD	nummod
(	-LRB-	punct
Dr.	NNP	compound
Green	NNP	appos
,	,	punct
describe	VBG	acl
Khan	NNP	dobj
2008	CD	nummod
:	:	punct
"	``	punct
-PRON-	PRP	nsubj
reveal	VBZ	ROOT
clear	JJ	amod
and	CC	cc
obvious	JJ	conj
patient	JJ	compound
preference	NN	dobj
for	IN	prep
an	DT	det
every	DT	det
-	HYPH	punct
other	JJ	amod
-	HYPH	punct
day	NN	compound
dose	VBG	compound
regiman	NNS	pobj
when	WRB	advmod
compare	VBN	advcl
to	IN	prep
a	DT	det
daily	JJ	amod
dosing	JJ	amod
regiman	NNS	pobj
give	VBN	acl
the	DT	det
option	NN	pobj
"	''	punct
.	.	punct
)	-RRB-	punct

;	:	punct
J.A.	NNP	dep
4857	CD	nummod
(	-LRB-	punct
Dr.	NNP	compound
Green	NNP	nsubjpass
:	:	punct
"	``	punct
As	IN	mark
-PRON-	PRP	nsubj
discuss	VBD	advcl
,	,	punct
most	JJS	nsubj
of	IN	prep
the	DT	det
adverse	JJ	amod
event	NNS	pobj
associate	VBN	acl
with	IN	prep
the	DT	det
use	NN	pobj
of	IN	prep
glatiramer	NN	compound
acetate	VBP	pobj
,	,	punct
and	CC	cc
in	IN	prep
fact	NN	pobj
the	DT	det
most	RBS	advmod
troubling	JJ	amod
set	NN	conj
of	IN	prep
adverse	JJ	amod
event	NNS	pobj
have	VBD	ccomp
to	TO	aux
do	VB	xcomp
with	IN	prep
injection	NN	compound
site	NN	compound
reaction	NNS	pobj
or	CC	cc
immediate	JJ	amod
post	JJ	subtok
-	JJ	subtok
injection	JJ	amod
reaction	NNS	conj
.	.	punct
both	DT	nsubjpass
of	IN	prep
those	DT	pobj
be	VBP	auxpass
tie	VBN	ROOT
to	IN	prep
injection	NNS	pobj
.	.	punct
so	RB	advmod
if	IN	mark
-PRON-	PRP	nsubj
reduce	VBP	advcl
the	DT	det
frequency	NN	dobj
of	IN	prep
injection	NNS	pobj
,	,	punct
well	UH	intj
,	,	punct
-PRON-	PRP	nsubj
be	VBZ	advcl
clearly	RB	advmod
obvious	JJ	acomp
that	IN	mark
-PRON-	PRP	nsubj
would	MD	aux
reduce	VB	ccomp
the	DT	det
frequency	NN	dobj
of	IN	prep
those	DT	det
injection	NN	compound
site	NN	compound
reaction	NNS	pobj
or	CC	cc
immediate	JJ	amod
post	JJ	subtok
-	JJ	subtok
injection	JJ	amod
reaction	NNS	conj
"	''	punct
.	.	punct
)	-RRB-	punct
.	.	punct

 	_SP	

